IL184951A - Maleimide derivatives and pharmaceutical compositions comprising them for treating cell proliferative disorder - Google Patents
Maleimide derivatives and pharmaceutical compositions comprising them for treating cell proliferative disorderInfo
- Publication number
- IL184951A IL184951A IL184951A IL18495107A IL184951A IL 184951 A IL184951 A IL 184951A IL 184951 A IL184951 A IL 184951A IL 18495107 A IL18495107 A IL 18495107A IL 184951 A IL184951 A IL 184951A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- dione
- pyrrolo
- quinolin
- dihydro
- Prior art date
Links
- 230000002062 proliferating effect Effects 0.000 title claims abstract description 100
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 43
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 240
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 184
- -1 pyrroloquinolinyl-pyrrole-2,5-dione compound Chemical class 0.000 claims abstract description 126
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 111
- 201000011510 cancer Diseases 0.000 claims abstract description 96
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 291
- 125000000217 alkyl group Chemical group 0.000 claims description 134
- 208000035475 disorder Diseases 0.000 claims description 95
- 208000026310 Breast neoplasm Diseases 0.000 claims description 85
- 206010006187 Breast cancer Diseases 0.000 claims description 77
- 125000001072 heteroaryl group Chemical group 0.000 claims description 62
- 239000001257 hydrogen Substances 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 57
- 125000003118 aryl group Chemical group 0.000 claims description 48
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 46
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 42
- 210000000481 breast Anatomy 0.000 claims description 30
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 28
- 150000002148 esters Chemical class 0.000 claims description 27
- 230000009467 reduction Effects 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 208000029742 colonic neoplasm Diseases 0.000 claims description 19
- 230000005764 inhibitory process Effects 0.000 claims description 19
- 206010009944 Colon cancer Diseases 0.000 claims description 18
- 229910052794 bromium Inorganic materials 0.000 claims description 18
- 229910052740 iodine Inorganic materials 0.000 claims description 18
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 17
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 17
- 208000020816 lung neoplasm Diseases 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 16
- 201000005202 lung cancer Diseases 0.000 claims description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 15
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 15
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 14
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 14
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 11
- 206010020718 hyperplasia Diseases 0.000 claims description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- 229960004397 cyclophosphamide Drugs 0.000 claims description 10
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 229960002429 proline Drugs 0.000 claims description 10
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- 239000004473 Threonine Substances 0.000 claims description 9
- 229960003767 alanine Drugs 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 229960001230 asparagine Drugs 0.000 claims description 9
- 229960005261 aspartic acid Drugs 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 229960002949 fluorouracil Drugs 0.000 claims description 9
- 229960002989 glutamic acid Drugs 0.000 claims description 9
- 229960002743 glutamine Drugs 0.000 claims description 9
- 229960002885 histidine Drugs 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- 229960003136 leucine Drugs 0.000 claims description 9
- 229960004452 methionine Drugs 0.000 claims description 9
- 229960001153 serine Drugs 0.000 claims description 9
- 229960002898 threonine Drugs 0.000 claims description 9
- 229960004441 tyrosine Drugs 0.000 claims description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 229940024606 amino acid Drugs 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 229960000485 methotrexate Drugs 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 229930182816 L-glutamine Natural products 0.000 claims description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 6
- 229960004295 valine Drugs 0.000 claims description 6
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 5
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- 229930182844 L-isoleucine Natural products 0.000 claims description 5
- 239000004395 L-leucine Substances 0.000 claims description 5
- 235000019454 L-leucine Nutrition 0.000 claims description 5
- 229930195722 L-methionine Natural products 0.000 claims description 5
- 229930182821 L-proline Natural products 0.000 claims description 5
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- 201000005389 breast carcinoma in situ Diseases 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 5
- 229960005277 gemcitabine Drugs 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 5
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- 108010016626 Dipeptides Proteins 0.000 claims description 4
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 4
- 108010069236 Goserelin Proteins 0.000 claims description 4
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 235000009697 arginine Nutrition 0.000 claims description 4
- 229960003121 arginine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 230000004709 cell invasion Effects 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- 229960002433 cysteine Drugs 0.000 claims description 4
- 229960001904 epirubicin Drugs 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 235000004554 glutamine Nutrition 0.000 claims description 4
- 229960002449 glycine Drugs 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 235000018977 lysine Nutrition 0.000 claims description 4
- 229960003646 lysine Drugs 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 229960005190 phenylalanine Drugs 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 229960001603 tamoxifen Drugs 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 3
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 claims description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 3
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 3
- 229960001220 amsacrine Drugs 0.000 claims description 3
- 229960002932 anastrozole Drugs 0.000 claims description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 3
- 101150044616 araC gene Proteins 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 229930013356 epothilone Natural products 0.000 claims description 3
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 229960000255 exemestane Drugs 0.000 claims description 3
- 229960002913 goserelin Drugs 0.000 claims description 3
- 229960000908 idarubicin Drugs 0.000 claims description 3
- 229960003881 letrozole Drugs 0.000 claims description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 3
- 201000011059 lobular neoplasia Diseases 0.000 claims description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
- 229960004844 lovastatin Drugs 0.000 claims description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229940086322 navelbine Drugs 0.000 claims description 3
- 229950006344 nocodazole Drugs 0.000 claims description 3
- 229960004622 raloxifene Drugs 0.000 claims description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 3
- 229960001278 teniposide Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 claims 1
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 106
- 238000000034 method Methods 0.000 abstract description 72
- YJWKVYOXTBSMBU-UHFFFAOYSA-N 3-(1H-pyrrolo[2,3-h]quinolin-2-yl)pyrrole-2,5-dione Chemical class O=C1NC(=O)C(C=2NC3=C4C=CN=C4C=CC3=CC=2)=C1 YJWKVYOXTBSMBU-UHFFFAOYSA-N 0.000 abstract description 9
- SCQZTFRNWYGYQT-UHFFFAOYSA-N O=C1CCC(=O)N1C(N1)=CC=C2C1=C1C=CN=C1C=C2 Chemical class O=C1CCC(=O)N1C(N1)=CC=C2C1=C1C=CN=C1C=C2 SCQZTFRNWYGYQT-UHFFFAOYSA-N 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 251
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 134
- 239000000203 mixture Substances 0.000 description 130
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 120
- 230000002829 reductive effect Effects 0.000 description 78
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 74
- 238000011282 treatment Methods 0.000 description 68
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 66
- ZOAMBXDOGPRZLP-UHFFFAOYSA-N indole-3-acetamide Chemical compound C1=CC=C2C(CC(=O)N)=CNC2=C1 ZOAMBXDOGPRZLP-UHFFFAOYSA-N 0.000 description 59
- 238000005481 NMR spectroscopy Methods 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
- 238000006243 chemical reaction Methods 0.000 description 56
- 235000019439 ethyl acetate Nutrition 0.000 description 45
- 229940093499 ethyl acetate Drugs 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 33
- 229940002612 prodrug Drugs 0.000 description 32
- 239000000651 prodrug Substances 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 28
- 239000002207 metabolite Substances 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 25
- 230000003902 lesion Effects 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 238000006722 reduction reaction Methods 0.000 description 24
- 230000004083 survival effect Effects 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- 230000030833 cell death Effects 0.000 description 22
- 230000007423 decrease Effects 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 20
- 210000004072 lung Anatomy 0.000 description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 19
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000012820 cell cycle checkpoint Effects 0.000 description 17
- 210000001072 colon Anatomy 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 239000012298 atmosphere Substances 0.000 description 16
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 230000004614 tumor growth Effects 0.000 description 15
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- 150000002431 hydrogen Chemical class 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 239000011777 magnesium Substances 0.000 description 14
- 206010061289 metastatic neoplasm Diseases 0.000 description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- KKNGNQGKYUBBKL-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)acetamide Chemical compound NC(=O)CC1=CC=C(F)C=C1Cl KKNGNQGKYUBBKL-UHFFFAOYSA-N 0.000 description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 230000001394 metastastic effect Effects 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 102000003923 Protein Kinase C Human genes 0.000 description 11
- 108090000315 Protein Kinase C Proteins 0.000 description 11
- 229910002092 carbon dioxide Inorganic materials 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 238000004808 supercritical fluid chromatography Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- HCUARRIEZVDMPT-UHFFFAOYSA-N indolyl-2-carboxylic acid Natural products C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 210000001672 ovary Anatomy 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 210000002307 prostate Anatomy 0.000 description 10
- 238000009097 single-agent therapy Methods 0.000 description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 206010054949 Metaplasia Diseases 0.000 description 9
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 230000015689 metaplastic ossification Effects 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 8
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 206010058314 Dysplasia Diseases 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000010293 colony formation assay Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- KFKXSMSQHIOMSO-UHFFFAOYSA-N methyl 2-oxoacetate Chemical compound COC(=O)C=O KFKXSMSQHIOMSO-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 102000015694 estrogen receptors Human genes 0.000 description 5
- 108010038795 estrogen receptors Proteins 0.000 description 5
- 210000005096 hematological system Anatomy 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000003880 polar aprotic solvent Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 125000005233 alkylalcohol group Chemical group 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000012501 chromatography medium Substances 0.000 description 4
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- YVUZUKYBUMROPQ-UHFFFAOYSA-N mercury zinc Chemical compound [Zn].[Hg] YVUZUKYBUMROPQ-UHFFFAOYSA-N 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- HUMMCEUVDBVXTQ-UHFFFAOYSA-N naphthalen-1-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CC=CC2=C1 HUMMCEUVDBVXTQ-UHFFFAOYSA-N 0.000 description 4
- 229910000510 noble metal Inorganic materials 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 108090000468 progesterone receptors Proteins 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000005005 sentinel lymph node Anatomy 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- HPKKEDGOBIXMHS-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(N)=O)=C1 HPKKEDGOBIXMHS-UHFFFAOYSA-N 0.000 description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 108700020463 BRCA1 Proteins 0.000 description 3
- 102000036365 BRCA1 Human genes 0.000 description 3
- 101150072950 BRCA1 gene Proteins 0.000 description 3
- 102000052609 BRCA2 Human genes 0.000 description 3
- 108700020462 BRCA2 Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101150008921 Brca2 gene Proteins 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 101150029707 ERBB2 gene Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 3
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 229940009456 adriamycin Drugs 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000011717 athymic nude mouse Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- TYRGLVWXHJRKMT-QMMMGPOBSA-N n-benzyloxycarbonyl-l-serine-betalactone Chemical compound OC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1 TYRGLVWXHJRKMT-QMMMGPOBSA-N 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZRDOIICSTDTKGC-UHFFFAOYSA-N 2-(1h-indol-7-ylmethylamino)ethanol Chemical compound OCCNCC1=CC=CC2=C1NC=C2 ZRDOIICSTDTKGC-UHFFFAOYSA-N 0.000 description 2
- KEPLFZWNVMCJLI-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)acetamide Chemical compound NC(=O)CC1=C(Cl)C=CC=C1Cl KEPLFZWNVMCJLI-UHFFFAOYSA-N 0.000 description 2
- WBJGNXYBEZIOES-UHFFFAOYSA-N 2-(2-chlorophenyl)acetamide Chemical compound NC(=O)CC1=CC=CC=C1Cl WBJGNXYBEZIOES-UHFFFAOYSA-N 0.000 description 2
- LDDGWOZIRBLTDL-UHFFFAOYSA-N 2-(4-phenylmethoxyphenyl)acetamide Chemical compound C1=CC(CC(=O)N)=CC=C1OCC1=CC=CC=C1 LDDGWOZIRBLTDL-UHFFFAOYSA-N 0.000 description 2
- UYHFTKXMOVFCKY-UHFFFAOYSA-N 2-[1h-indol-7-ylmethyl(phenylmethoxycarbonyl)amino]ethyl methanesulfonate Chemical compound C=1C=CC=2C=CNC=2C=1CN(CCOS(=O)(=O)C)C(=O)OCC1=CC=CC=C1 UYHFTKXMOVFCKY-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- YEALAJQPOVKTOH-UHFFFAOYSA-N 2-pyridin-4-ylacetamide Chemical compound NC(=O)CC1=CC=NC=C1 YEALAJQPOVKTOH-UHFFFAOYSA-N 0.000 description 2
- UUPZTFTUZUQRQT-UHFFFAOYSA-N 2-thiophen-2-ylacetamide Chemical compound NC(=O)CC1=CC=CS1 UUPZTFTUZUQRQT-UHFFFAOYSA-N 0.000 description 2
- SHNMAZJVVFUXAQ-UHFFFAOYSA-N 2h-quinoline-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)CC=CC2=C1 SHNMAZJVVFUXAQ-UHFFFAOYSA-N 0.000 description 2
- ARHMDWNDZLMSSD-UHFFFAOYSA-N 3-bromo-4-(1h-indol-3-yl)-1-phenylpyrrole-2,5-dione Chemical compound O=C1C(Br)=C(C=2C3=CC=CC=C3NC=2)C(=O)N1C1=CC=CC=C1 ARHMDWNDZLMSSD-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006189 Breast cancer in situ Diseases 0.000 description 2
- 108091007381 CBL proteins Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- HDFFVHSMHLDSLO-UHFFFAOYSA-N Dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(O)OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-N 0.000 description 2
- 208000000321 Gardner Syndrome Diseases 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 2
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- XQVZDADGTFJAFM-UHFFFAOYSA-N Indole-7-carboxaldehyde Chemical compound O=CC1=CC=CC2=C1NC=C2 XQVZDADGTFJAFM-UHFFFAOYSA-N 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 201000005027 Lynch syndrome Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004422 Phospholipase C gamma Human genes 0.000 description 2
- 108010056751 Phospholipase C gamma Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000055251 Proto-Oncogene Proteins c-cbl Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000003869 acetamides Chemical class 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000009925 apoptotic mechanism Effects 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 208000019493 atypical carcinoid tumor Diseases 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- PUDOWDJJLWXOQE-UHFFFAOYSA-N benzyl n-(2-hydroxyethyl)-n-(1h-indol-7-ylmethyl)carbamate Chemical compound C=1C=CC=2C=CNC=2C=1CN(CCO)C(=O)OCC1=CC=CC=C1 PUDOWDJJLWXOQE-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000003714 breast lobular carcinoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- JGDFBJMWFLXCLJ-UHFFFAOYSA-N copper chromite Chemical compound [Cu]=O.[Cu]=O.O=[Cr]O[Cr]=O JGDFBJMWFLXCLJ-UHFFFAOYSA-N 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 108700003601 dimethylglycine Proteins 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- GZVVNAWGGPWOOK-UHFFFAOYSA-N ethyl 2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OCC)CC=CC2=C1 GZVVNAWGGPWOOK-UHFFFAOYSA-N 0.000 description 2
- NGXHDIFRFPQYPV-UHFFFAOYSA-N ethyl 3-(3,4-dihydro-2h-quinolin-1-yl)-2-oxopropanoate Chemical compound C1=CC=C2N(CC(=O)C(=O)OCC)CCCC2=C1 NGXHDIFRFPQYPV-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- HSNUXDIQZKIQRR-UHFFFAOYSA-N hydroxy-imino-bis(phenylmethoxy)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1COP(=O)(N)OCC1=CC=CC=C1 HSNUXDIQZKIQRR-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000024312 invasive carcinoma Diseases 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical class CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 201000008632 juvenile polyposis syndrome Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 208000022499 mismatch repair cancer syndrome Diseases 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UCEQXRCJXIVODC-UXHICEINSA-N (+)-cis-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1h-indol-3-yl)pyrrolidine-2,5-dione Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-UXHICEINSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 description 1
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PFADLRMJVSJAGC-UHFFFAOYSA-N 1-methyl-3-(1-methylindol-3-yl)pyrrole-2,5-dione Chemical compound CN1C(C=C(C1=O)C1=CN(C2=CC=CC=C12)C)=O PFADLRMJVSJAGC-UHFFFAOYSA-N 0.000 description 1
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYLJXJSMGIOVIK-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,5-benzoxazepine Chemical compound O1CCCNC2=CC=CC=C21 HYLJXJSMGIOVIK-UHFFFAOYSA-N 0.000 description 1
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 description 1
- RVBMORRFIVVMNG-UHFFFAOYSA-N 2-(1-benzothiophen-2-yl)acetamide Chemical compound C1=CC=C2SC(CC(=O)N)=CC2=C1 RVBMORRFIVVMNG-UHFFFAOYSA-N 0.000 description 1
- SJFMPXJTNLKDLX-UHFFFAOYSA-N 2-(1h-indol-3-yl)-n-methylacetamide Chemical compound C1=CC=C2C(CC(=O)NC)=CNC2=C1 SJFMPXJTNLKDLX-UHFFFAOYSA-N 0.000 description 1
- NAYAHQPYRSIGCX-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)acetamide Chemical compound NC(=O)CC1=CC=C(Cl)C=C1Cl NAYAHQPYRSIGCX-UHFFFAOYSA-N 0.000 description 1
- ZIKPHGJVHWZEFH-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)acetamide Chemical compound COC1=CC=C(OC)C(CC(N)=O)=C1 ZIKPHGJVHWZEFH-UHFFFAOYSA-N 0.000 description 1
- DSZYKMGSRABUEN-UHFFFAOYSA-N 2-(2-bromophenyl)acetamide Chemical compound NC(=O)CC1=CC=CC=C1Br DSZYKMGSRABUEN-UHFFFAOYSA-N 0.000 description 1
- DJSDMLCYBAQMCB-UHFFFAOYSA-N 2-(2-fluorophenyl)acetamide Chemical compound NC(=O)CC1=CC=CC=C1F DJSDMLCYBAQMCB-UHFFFAOYSA-N 0.000 description 1
- QPCWSKDUWIYHBQ-UHFFFAOYSA-N 2-(2-methylphenoxy)acetamide Chemical compound CC1=CC=CC=C1OCC(N)=O QPCWSKDUWIYHBQ-UHFFFAOYSA-N 0.000 description 1
- FBSIKJFOVXUNMI-UHFFFAOYSA-N 2-(3-chlorophenyl)acetamide Chemical compound NC(=O)CC1=CC=CC(Cl)=C1 FBSIKJFOVXUNMI-UHFFFAOYSA-N 0.000 description 1
- AHCZRGFZVJHTFH-UHFFFAOYSA-N 2-(3-phenoxyphenyl)acetamide Chemical compound NC(=O)CC1=CC=CC(OC=2C=CC=CC=2)=C1 AHCZRGFZVJHTFH-UHFFFAOYSA-N 0.000 description 1
- ZBARBHKSSXDLMK-UHFFFAOYSA-N 2-(4-bromophenyl)acetamide Chemical compound NC(=O)CC1=CC=C(Br)C=C1 ZBARBHKSSXDLMK-UHFFFAOYSA-N 0.000 description 1
- BFYGROHYLCZLGS-UHFFFAOYSA-N 2-(4-chlorophenyl)acetamide Chemical compound NC(=O)CC1=CC=C(Cl)C=C1 BFYGROHYLCZLGS-UHFFFAOYSA-N 0.000 description 1
- YHZANKPQPBORBP-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanylacetamide Chemical compound NC(=O)CSC1=CC=C(Cl)C=C1 YHZANKPQPBORBP-UHFFFAOYSA-N 0.000 description 1
- PNGGWQMSHKIEAF-UHFFFAOYSA-N 2-(4-fluorophenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(F)C=C1 PNGGWQMSHKIEAF-UHFFFAOYSA-N 0.000 description 1
- YBPAYPRLUDCSEY-UHFFFAOYSA-N 2-(4-hydroxyphenyl)acetamide Chemical compound NC(=O)CC1=CC=C(O)C=C1 YBPAYPRLUDCSEY-UHFFFAOYSA-N 0.000 description 1
- OLKQIWCQICCYQS-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetamide Chemical compound COC1=CC=C(CC(N)=O)C=C1 OLKQIWCQICCYQS-UHFFFAOYSA-N 0.000 description 1
- NMQPIBPZSLMCFI-UHFFFAOYSA-N 2-(4-methylphenyl)acetamide Chemical compound CC1=CC=C(CC(N)=O)C=C1 NMQPIBPZSLMCFI-UHFFFAOYSA-N 0.000 description 1
- MIBZYKNHDPZAPG-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)acetamide Chemical compound CS(=O)(=O)C1=CC=C(CC(N)=O)C=C1 MIBZYKNHDPZAPG-UHFFFAOYSA-N 0.000 description 1
- JJLKXBIUMBGNNY-UHFFFAOYSA-N 2-(4-phenylphenyl)acetamide Chemical compound C1=CC(CC(=O)N)=CC=C1C1=CC=CC=C1 JJLKXBIUMBGNNY-UHFFFAOYSA-N 0.000 description 1
- VQXXRQMLQUGSQL-UHFFFAOYSA-N 2-(5-methyl-1h-indol-3-yl)acetamide Chemical compound CC1=CC=C2NC=C(CC(N)=O)C2=C1 VQXXRQMLQUGSQL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VKVCLXDFOQQABP-UHFFFAOYSA-N 2-[2-(diaminomethylideneamino)ethylsulfanyl]butanedioic acid Chemical compound NC(N)=NCCSC(C(O)=O)CC(O)=O VKVCLXDFOQQABP-UHFFFAOYSA-N 0.000 description 1
- COQPGZFYEKMABL-UHFFFAOYSA-N 2-[4-(2-morpholin-4-ylethoxy)phenyl]acetamide Chemical compound C1=CC(CC(=O)N)=CC=C1OCCN1CCOCC1 COQPGZFYEKMABL-UHFFFAOYSA-N 0.000 description 1
- HLWOZZQVALWHFP-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]acetamide Chemical compound NC(=O)CC1=CC=C(OC(F)(F)F)C=C1 HLWOZZQVALWHFP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SXRKNKLAGDXHDA-UHFFFAOYSA-N 2-bromoethyl 2-oxopropanoate Chemical compound CC(=O)C(=O)OCCBr SXRKNKLAGDXHDA-UHFFFAOYSA-N 0.000 description 1
- AOPRXJXHLWYPQR-UHFFFAOYSA-N 2-phenoxyacetamide Chemical compound NC(=O)COC1=CC=CC=C1 AOPRXJXHLWYPQR-UHFFFAOYSA-N 0.000 description 1
- UXVCEKRAZBZVSL-UHFFFAOYSA-N 2-pyridin-2-ylacetamide Chemical compound NC(=O)CC1=CC=CC=N1 UXVCEKRAZBZVSL-UHFFFAOYSA-N 0.000 description 1
- YDHIMEXEGOCNHU-UHFFFAOYSA-N 2-pyridin-3-ylacetamide Chemical compound NC(=O)CC1=CC=CN=C1 YDHIMEXEGOCNHU-UHFFFAOYSA-N 0.000 description 1
- ZZMOZLUSTUEYAN-UHFFFAOYSA-N 2-thiophen-3-ylacetamide Chemical compound NC(=O)CC=1C=CSC=1 ZZMOZLUSTUEYAN-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- LLSAYEJOVWWTJN-UHFFFAOYSA-N 3,3a,5,6-tetrahydro-2h-furo[3,2-b]pyran Chemical compound O1CCC=C2OCCC21 LLSAYEJOVWWTJN-UHFFFAOYSA-N 0.000 description 1
- SAOKSEAZOIEPGA-UHFFFAOYSA-N 3,4-dibromo-1-phenylpyrrole-2,5-dione Chemical compound O=C1C(Br)=C(Br)C(=O)N1C1=CC=CC=C1 SAOKSEAZOIEPGA-UHFFFAOYSA-N 0.000 description 1
- DGFUPZWFCOXLHE-UHFFFAOYSA-N 3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(2-chloro-4-fluorophenyl)pyrrole-2,5-dione Chemical compound ClC1=CC(F)=CC=C1C1=C(C=2C=3C=CC=C4CCCN(C=34)C=2)C(=O)NC1=O DGFUPZWFCOXLHE-UHFFFAOYSA-N 0.000 description 1
- FQKPINSZEPYQEY-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyrrole-2,5-dione Chemical compound COC1=CC=CC(C=2C(NC(=O)C=2)=O)=C1 FQKPINSZEPYQEY-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- NIFBNIANYCOETB-UHFFFAOYSA-N 8-methyl-n-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-amine Chemical compound CN1C(C2)CCC1CC2NCCC1=CC=CC=C1 NIFBNIANYCOETB-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000037068 Abnormal Karyotype Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010072813 Breast angiosarcoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101100447914 Caenorhabditis elegans gab-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000035865 Chronic mast cell leukemia Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010071161 Colon dysplasia Diseases 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000012287 DNA Binding Assay Methods 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N N-acetyl-para-amino-phenol Natural products CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000035823 Non-specific autoimmune cerebellar ataxia without characteristic antibodies Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 231100000071 abnormal chromosome number Toxicity 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000009287 biochemical signal transduction Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- 208000029610 breast phyllodes tumor Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000003306 cell dissemination Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 108010062049 chirobiotic T Proteins 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 101150042537 dld1 gene Proteins 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- NJCBOMBOMCXCRM-UHFFFAOYSA-N lithium;trimethyl(trimethylsilyl)silane Chemical compound [Li].C[Si](C)(C)[Si](C)(C)C NJCBOMBOMCXCRM-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 208000007282 lymphomatoid papulosis Diseases 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 208000029565 malignant colon neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- KTHADMDGDNYQRX-UHFFFAOYSA-N methyl (indol-3-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OC)=CNC2=C1 KTHADMDGDNYQRX-UHFFFAOYSA-N 0.000 description 1
- VFIJGAWYVXDYLK-UHFFFAOYSA-N methyl 2-(1h-indol-3-yl)-2-oxoacetate Chemical compound C1=CC=C2C(C(=O)C(=O)OC)=CNC2=C1 VFIJGAWYVXDYLK-UHFFFAOYSA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 201000009612 pediatric lymphoma Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000010491 poppyseed oil Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 201000010700 sporadic breast cancer Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 238000009095 third-line therapy Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.
Description
184951/2 Meleimide derivatives, pharmaceutical compositions comprising thereof and the uses thereof in treating cell proliferative disorder Arqule, Inc.
C. 176838 184951/2 BACKGROUND OF THE INVENTION Cancer is the second leading cause of death in the United States, exceeded only by heart disease. {Cancer Facts and Figures 2004, American Cancer Society, Inc.). Despite recent advances in cancer diagnosis and treatment, surgery and radiotherapy may be curative if a cancer is found early, but current drug therapies for metastatic disease are mostly palliative and seldom offer a long-term cure. Even with new chemotherapies entering the market, the need continues for new drugs effective in monotherapy or in combination with existing agents as first line therapy, and as second and third line therapies in treatment of resistant tumors.
Cancer cells are by definition heterogeneous. For example, within a single tissue or cell type, multiple mutational 'mechanisms' may lead to the development of cancer. As such, heterogeneity frequently exists between cancer cells taken from tumors of the same tissue and same type that have originated in different individuals. Frequently observed mutational mechanisms' associated with some cancers may differ between one tissue type and another (e.g., frequently observed mutational 'mechanisms' leading to colon cancer may differ from frequently observed 'mechanisms' leading to leukemias). It is therefore often difficult to predict whether a particular cancer will respond to a particular chemotherapeutic agent. {Cancer Medicine, 5th Edition, Bast et al. eds., B.C. Decker Inc., Hamilton, Ontario).
Breast cancer is the most frequently diagnosed non-skin cancer in women, and ranks second among cancer deaths in women, after lung cancer. {Cancer Facts and Figures 2004, American Cancer Society, Inc.) Current treatment options for breast cancer include surgery, radiotherapy, and chemotherapy/hormone therapy with agents such as tamoxifen, aromatase inhibitors, HERCEPTIN® (trastuzumab), TAXOL® (paclitaxel), cyclophosphamide, methotrexate, doxorubicin (adriamycin), and 5-fluoruracil. Despite improvements in cancer diagnostics and therapeutics, breast cancer incidence rates have continued to increase since 1980. In 2004, about 215,000 new cases of breast cancer are expected in women, and about 1,450 new cases of breast cancer are expected in men. Id.
Accordingly, new compounds and methods for treating breast cancer are needed.
Components of cellular signal transduction pathways that regulate the growth and differentiation of normal cells can, when dysregulated, lead to the development of cellular proliferative disorders and cancer. Mutations in cellular signaling proteins may cause such proteins to become expressed or activated at inappropriate levels or at inappropriate times during the cell cycle, which in turn may lead to uncontrolled cellular growth or changes in cell-cell attachment properties. For example, dysregulation of receptor tyrosine kinases by mutation, gene rearrangement, gene 184951/2 amplification, and overexpression of both receptor and ligand has been implicated in the developm ent and progression of human cancers.
The c-Met receptor tyrosine kinase is the only known high-affinity receptor for hepatocyte growth factor (HGF), also known as scatter factor. Binding of HGF to the c-Met extracellular ligand-binding domain results in receptor multimerization and phosphorylation of multiple tyrosine residues in the intracellular portion of c-Met. Activation of c-Met results in the binding and phosphorylation of adaptor proteins such as Gab-i, Grb-2, She, and c-Cbl, and subsequent activation of signal transducers such as P13K, PLC-γ, STATs, ERK1 and 2 and FAK. c-Met and HGF are expressed in numerous tissues, and their expression is normally confined predominantly to cells of epithelial and mesenchymal origin, respectively, c-Met and HGF are dysregulated in human cancers, and may contribute to dysregulation of cell growth, tumor cell dissemination, and tumor invasion during disease progression and metastasis. (See, e.g., Journal of Clinical Investigation 109: 863-867 (2002) and Cancer Cell pp 5-6 July 2004) c-Met and HGF are highly expressed relative to surrounding tissue in numerous cancers, and their expression correlates with poor patient prognosis. (See, e.g., Journal of Cellular Biochemistry 86: 665- 677 (2002); Int.. J. Cancer (Pred. Oncol.) 74: 301-309 (1997); Clinical Cancer Research 9: 1480-1488 (2003); and Cancer Research 62: 589-596 (2002)). Without intending to be bound by theory, c-Met and HGF may protect tumors against cell death induced by DNA damaging agents, and as such may contribute to chemoresistance and radioresistance of tumors. Without intending to be limited by any theory, inhibitors of c-Met may be useful as therapeutic agents in the treatment of proliferative disorders including breast cancer. (See, e.g., Cancer and Metastasis Reviews 22: 309-325 (2003)).
The references cited herein are not admitted to be prior art to the claimed invention.
SUMMARY OF THE INVENTION In one of its aspects, the present invention provides a pyrroloquinolinyl-pyrrolidine-2,5 -dione compound of formula IVa, IVb, Va, or Vb, or pharmaceutically acceptable salts thereof: 184951/1 where: Rl , R2 and R3 are independently selected from the group consisting of hydrogen, F, CI, Br, I,— NR5R6, -(Cr-Ce) alkyl, -(C,-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, -0-iCx-C6) alkyl, -0-(C,-C6) substituted alkyl, -0-(C3-C9) cycloalkyl, and— O— (C3— C9) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl; R4 is independently selected from the group consisting of hydrogen,— {C\— Ce) alkyl., -CH2R7; R5, R6 are independently selected from the group consisting of hydrogen, and— (C]— C6) alkyl; R7 is independently selected from the group consisting of — O— P(=0)(OH)2; -0-P(=0)(-OH)(-0-(C.-C6) alkyl); -O-P^OX-C-^-Q) alkyl)2; -0-P(=0)(-OH) (— O— (CH2)— phenyl);— O— P(=0)(— O— (CH2)— phenyl)2; a carboxylic acid group selected from a group consisting of -O-C(=0)-(C1-C6) alkyl, -O-C =0 -iC3-C9) cycloalkyl, alkyl-aryl, alkyl-heterocycle, which may be substituted with one or more substituent independently selected from the group) consisting of: F, CI, Br, I, -OH, -SH, -NR5'R6', -(Ci-Ce) alkyl, -(C,-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, -CHCi-Ce) alkyl, -0-(Ci-C6) substituted alkyl, -S-iQ-Ce) alkyl, -O-id-Cg) cycloalkyl, -0-(C3-C9) substituted cycloalkyl, —aryl,— O— aryl, — O— (Ci— C4) alkyl— aryl, heteroaryl, heterocyclyl,— O— (Q— C4) alkyl-heterocycle, alkyl, -NH-C(=NH)-NH2, -COOH, and — C(=0)— NR5 'R6', where R5 ' and R6' are independently selected from the group consisting of hydrogen, and— (Ci— C6) alkyl; an amino acid or an imino acid linked through an ester linkage involving its carboxylic acid, selected from the group consisting of alanine, arginine, asparagine., aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; and a. 2a 184951/1 peptide being a dipeptide, a tripeptide, a tetrapeptide, or a pentapeptide, linked through an ester linkage involving its carboxylic acid, comprised of two to five imino or amino acids selected from the group consisting of: L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine; Q is selected from the group consisting of aryl, heteroaryl, — O— aryl, — S— aryl, — O— heteroaryl, and— S— heteroaryl; X is selected from the group consisting of— (CH2)— ,— (NR8)— , S, and O; R8 is independently selected from the group consisting of hydrogen,— (C\— Ce) alkyl, — (C\— Ce) substituted alkyl, — (C3— C9) cycloalkyl, — (C3— C9) substituted cycloalkyl, and -O-id-Ce) alkyl, substituted alkyl; Y is selected from the group consisting of— (C¾)— or a bond; wherein said aryl, heteroaryl,— O— aryl,— S— aryl,— O— heteroaryl, and— S— heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, CI, Br, I, -NR5R6, -(d-Ce) alkyl, -(Ci-C6) substituted alkyl, -(C3-C9) cycloalkyl,— (C3— C9) substituted cycloalkyl,— O— (C,— C6) alkyl,— 0-(Ci— C6) substituted alkyl, -0-(C3-C9) cycloalkyl, -0-iC3-C9) substituted cycloalkyl, —aryl, -aryl-(Ci-C6) alkyl., — aryl— O — (C\— Ce) alkyl, — O— aryl, — O— (Q— C4) alkyl— aryl, heteroaryl, heterocyclyl, -0-(Ci-C ) alkyl-heterocycle, and -(S(=0)2)-(Ci-C6) alkyl; and m is 1 or 2.
In another of its aspects the present invention provides a pharmaceutical composition comprising a compound of formula IVa, IVb, Va, or Bv as defined herein or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or excipients.
In yet another of its aspects, the present invention provides a pharmaceutical composition for use in treating a cell proliferative disorder, comprising a therapeutically effective amount of a compound of formula IVa, IVb, Va, or Bv as defined herein, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides for pyrroloquinolinyl-pyrrolidine-2,5-dione compounds of formula IVa, IYb, Va, or Yb, and methods of preparing the compounds of formula IVa, IVb, Va, and Yb, 2b where: Rl, R2 and R3 are independently selected from the group consisting of hydrogen, F, CI, Br, I, -NR5R6, -(Ci-C6) alkyl, -(Ci-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, -0-(C]-C6) alkyl, -O-td-Cfi) substituted alkyl, -0-(C3-C9) cycloalkyl, and — O— (C3— C9) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl; R4 is independently selected from the group consisting of hydrogen,— (Ci— Ce) alkyl, -C¾R7; R5, R6 are independently selected from the group consisting of hydrogen, and— (C]— C6) alkyl; R7 is independently selected from the group consisting of— O— P(=0)(OH)2s -0-P(=0)(-OH)(-0-(C-C6) alkyl), -0-P(=0)(-0-(Ci-C6) alkyl)2, -0-P(=0)(-OH) (—0— (CH2)— phenyl),— O— P(=0)(— O— (CH2)— henyl)2, a carboxylic acid group, an amino carboxylic acid group and a peptide; Q is selected from the group consisting of aryl, heteroaryl,— O— aryl,— S— aryl, —O— heteroaryl, and—S— heteroaryl; X is selected from the group consisting of— (CH2)—— (NR8)— , S, and O; 3 R8 is independently selected from the group consisting of hydrogen,— (Cj— C6) alkyl, — (Ci— C6) substituted alkyl,— (C3— C9) cycloalkyl,— (C3— C9) substituted cycloalkyl, and— O— (Q— C,;) alkyl, substituted alkyl; Y is selected from the group consisting of— (C¾)— or a bond; wherein said aryl, heteroaryl,— O—aryl,— S— aryl,— O— heteroaryl, and— S— heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, CI, Br, I, -NR5R6, -(Q-Ce) alkyl, -(Ci-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, -0-(Ci— C6) alkyl, -0-(C]-C6) substituted alkyl, -0-(C3-C9) cycloalkyl, -0-(C3-C9) substituted cycloalkyl, -aryl, -aryl-(d-C6) alkyl, -aryl-0 -(Q-Ce) alkyl, —O—aryl,— O— (Ci— C4) alkyl— aryl, heteroaryl, heterocyclyl,— O— (Ci— C4) alkyl— heterocycle, and -(S(=0)2)-(C1-C6) alkyl; and m is 1 or 2.
In an embodiment, R4 is— CH2R7, and R7 is -0-P(=0)(OH)2, -O-P( )(-0HX-0-(Ci-C6) alkyl), alkyl)2, a carboxylic acid group, an amino carboxylic acid group or a peptide.
In an embodiment, X is selected from the group consisting of— (NR8)— , S, and O.
In an embodiment, m is 2.
In a preferred embodiment, the pyrroloquinolinyl-pyrrolidine-2,5-dione compound is selected from the group consisting of (+)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, (-)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4(lH-indol-3-yl) pyrroIidine-2, 5-dione, (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, and (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione. In a further preferred embodiment, the compound is (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione.
The present invention aslo provides for pyrroloquinolinyl-pyrrole-2,5-dione compounds of formula Ilia and their synthesis. 4 R4 where: Rl, R2 and R3 are independently selected from the group consisting of hydrogen, F, CI, Br, I, -NR5R6, -(Ci-C6) alkyl, -(Q-Ce) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, -0-(Ci-C6) alkyl, -0-(d-C6) substituted alkyl, -0-(C3-C9) cycloalkyl, and — O— (C3— C9) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl; R4 is independently selected from the group consisting of hydrogen,— (Ci— Ce) alkyl, -CH2R7; R5, R6 are independently selected from the group consisting of hydrogen, and— (Ci— C6) alkyl; R7 is independently selected from the group consisting of— O— P(=0)(OH)2, -O-P(=0)(-0H)(-O-(CI-C6) alkyl), -0-P(=0)(-0-(C1-C6) alkyl)2, -0-P(=0)(-OH) (— O— (CH2)— henyl),— O-P(=0)(— O— (CH2)— phenyl)2, a carboxylic acid group, an amino carboxylic acid group and a peptide; Q is selected from the group consisting of aryl, heteroaryl,— O— aryl,— S— aryl, — O— heteroaryl, and— S— heteroaryl, provided that when R4 is hydrogen, (C3-C4) cycloalkyl, or (Ci-C4) alkyl, Q is not 3-indolyl or substituted 3-indoIyl; X is selected from the group consisting of— (CH2)— ,— ( R8)— , S, and O; R8 is independently selected from the group consisting of hydrogen,— (Q— C6) alkyl, — (C]-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, -0-(Ci-C6) alkyl, substituted alkyl; Y is selected from the group consisting of— (CH2)— or a bond; wherein said aryl, heteroaryl,— O— aryl,— S— aryl,— O— heteroaryl, and— S— heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, CI, Br, I, - R5R6, -(Ci~C6) alkyl, -(Q-Q) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl,— O— (Ci-C6) alkyl,— 0-(Ci— C6) substituted alkyl,— 0-(C3-C9) cycloalkyl, -C—(C3-C9) substituted cycloalkyl, -aryl, -aryl-(Ci-C6) alkyl, -aryl-0 -(C]-C6) alkyl, — O— aryl,— O— (Ci— C ) alkyl— aryl, heteroaryl, heterocyclyl,— O— (Q— C4) alkyl— heterocycle, and -(S(=0)2)-(C1-C6) alkyl; and m is 1 or 2.
The present invention also provides a pharmaceutical composition comprising one or more compounds of formula H[a, IVa, IVb, Va, or Vb, and one or more pharmaceutically acceptable carriers or excipients. The present invention also provides a pharmaceutical composition comprising a compound of formula Ula, IVa, IVb, Va, or Vb, and one or more pharmaceutically acceptable carriers or excipients.
The present invention provides a method of treating a cell proliferative disorder, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula Ilia, IVa, IVb, Va, or Vb, or a pharmaceutically acceptable salt thereof, or a prodrug, metabolite, analog or derivative thereof, in combination with a pharmaceutically acceptable carrier, wherein said cell proliferative disorder is treated.
In an embodiment, the cell proliferative disorder is cancer.
In a preferred embodiment, the compound is selected from the group consisting of (+)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2.1-? ] quinohn-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, (-)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-i/] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yI)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, and (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione; or a pharmaceutically acceptable salt thereof, or a prodrug, metabolite, analog or derivative thereof.
The present invention also provides a method of modulating an activity of c-Met comprising contacting a cell with an effective amount of a compound of formula Ula, TVa, IVb, Va, or Vb, or a pharmaceutically acceptable salt thereof, or a prodrug, metabolite, analog or derivative thereof, wherein said contacting results in said modulating an activity of c-Met.
In an embodiment, the modulating is inhibiting.
In an embodiment, the compound modulating the activity of c-Met, without significantly modulating said activity of Protein Kinase C.
The present invention also provides a method of selectively inhibiting an activity of c-Met, without inhibiting an activity of Protein Kinase C, comprising contacting a cell with an effective amount of a compound of formula Ula, IVa, IVb, Va, or Vb, or a pharmaceutically acceptable salt thereof, or a prodrug, metabolite, analog or derivative thereof, wherein said contacting results in said selectively inhibiting said activity of c-Met, without inhibiting said activity of Protein Kinase C. 6 The present invention also provides a method of selectively inducing cell death in precancerous cells or cancer cells, comprising contacting a cell with an effective amount of a compound of formula IHa, IVa, IVb, Va, or Vb, or a pharmaceutically acceptable salt thereof, or a prodrug, metabolite, analog or derivative thereof, wherein said contacting results in said selectively inducing cell death in said precancerous cells or said cancer cells.
The present invention further provides a method of treating cancer comprising selectively modulating an activity of c-Met, or both, without significantly modulating an activity of Protein Kinase C.
The present invention further provides a method of screening for a candidate compound for treating cancer, comprising contacting a cell with a candidate compound, measuring the activity of c-Met, measuring the activity of Protein Kinase C, and selecting a candidate compound that is capable of selectively inhibiting the activity of c-Met, without significantly inhibiting the activity of Protein Kinase C, wherein said candidate compound that is capable of selectively inhibiting the activity of c-Met, without significantly inhibiting the activity of Protein Kinase C, is a candidate compound for treating cancer. In an embodiment, the Protein Kinase C activity is mesured in vitro.
Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 sets forth the chemical structures of (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione and (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione.
Figure 2 sets forth an effect of (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-1-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione on survival of MDA-MB-231 or Paca-2 cells in vitro.
Figure 3 sets forth an effect of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z)'] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-1-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione on survival of MDA-MB-231 cells in vitro.
Figure 4 sets forth an effect of (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-/ ] quinolin-1-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione on Protein Kinase C activity in vitro. 7 Figure 5 sets forth inhibition of c-Met phosphorylation and ERK1/2 phosphorylation by (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z;] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione.
Figure 6 sets forth an effect of (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ζ)'] quinolin-1-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, administered individually at 160 mg/kg, on the growth of xenografted MDA-MB-231 human breast cancer tumors in athymic female nude mice.
Figure 7 sets forth an effect of (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ζ)'] quinolin-1-yl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione, administered individually at 80 mg/kg, on the growth of xenografted MDA-MB-231 human breast cancer tumors in athymic female mice.
Figure 8 sets forth an effect of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione to induce apoptosis in cancer cells.
Figure 9 sets forth an effect of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione to inhibit metastatic cancer cell invasion.
Figure 10 sets forth an effect of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione on breast cancer xenograft model.
Figure 11 sets forth an effect of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione on colon cancer xenograft model.
Figure 12 sets forth an effect of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione on pancreatic cancer xenograft model. 8 184951/2 1. Pyrroloquinolinyl-pyrrole-2.5-diones and pyrroloquinolinyl-pyrrolidone-2,5-diones The present invention provides for pyrroloquinolinyl-pyrrole-2,5-dione compounds of formula III and Ilia and their synthesis R4 wherein: Rl, R2 and R3 are independently selected from the group consisting of hydrogen, F, CI, Br, I, -NR5R6, -(C,-C6) alkyl, -(Ci-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, —0-(Ci— C6) alkyl, -0-(Ci— C6) substituted alkyl, -O— (C3-C9) cycloalkyl, and— O— (C3— C9) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl; R4 is independently selected from the group consisting of hydrogen,— (Q— Ce) alkyl, -CH2R7; R5, R6 are independently selected from the group consisting of hydrogen, and— (C\— C6) alkyl; R7 is independently selected from the group consisting of— O— P(=0)(OH)2; -0-P(=0)(-OH)(-0-(Ci-C6) alkyl); -0-P(=0)(-0-(Ci-C6) alkyl)2; -O-P(=0)(-0H) (— O— (CH2)— phenyl);— O— P(=0)(— O— (CH2)— phenyl)2; a carboxylic acid group, an amino carboxylic acid group and a peptide; Q is selected from the group consisting of aryl, heteroaryl, — O— aryl, — S— aryl., — O— heteroaryl, and— S— heteroaryl; X is selected from the group consisting of— (CH2)— ,— (NR8)— , S, and O; 9 R8 is independently selected from the group consisting of hydrogen,— (Cj— C6) alkyl, -(C]-C6) substituted alkyl,— (C3— C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, and— 0-(Ci-C6) alkyl, -C(=0)-O-(Ci-C6) alkyl and -C(=0)-0-(Ci-C6) substituted alkyl; Y is selected from the group consisting of— (C¾)— or a bond; wherein said aryl, heteroaryl,— O— aryl,— S— aryl,— O— heteroaryl, and— S— heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, CI, Br, I, -NR5R6, -(Ci-C6) alkyl, -(Ci-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, -0-(Ci-C6) alkyl, -0-(Ci-C6) substituted alkyl, -0-(C3-C9) cycloalkyl, -0-(C3— C9) substituted cycloalkyl, -aryl, -aryl-(Ci-C6) alkyl, -aryl-0 -(C]-C6) alkyl, — O— aryl,— O— (Cj— C4) alkyl— aryl, heteroaryl, heterocyclyl,— O— (Cj— C4) alkyl— heterocycle, and -(S(=0)2HC1-C6) alkyl; and m is 1 or 2.
For the compound of formula Eta, Q is selected from the group consisting of aryl, heteroaryl , — O— aryl,— S— aryl,— O— heteroaryl, and—S— heteroaryl, provided that when R4 is hydrogen, (C3-C ) cycloalkyl, or (C1-C4) alkyl, Q is not 3-indolyl or substituted 3-indolyl.
The present invention also provides for pyrroloquinolinyl-pyrrolidine-2,5-dione compounds of formula rVa, IVb, Va, or Vb, and methods of preparing the compounds of formulas IVa, IVb, Va, and Vb, R4 R4 where: Rl, R2 and R3 are independently selected from the group consisting of hydrogen, F, CI, Br, I, — NR5R6, -(Ci-Ce) alkyl, -(d-C6) substituted alkyl, -(C3-C9) cycloalkyl,— (C3-C9) substituted cycloalkyl, -0-(Ci-C6) alkyl, -0-(Ci— C6) substituted alkyl, -0-(C3-C9) cycloalkyl, and — O— (C3— C9) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl; R4 is independently selected from the group consisting of hydrogen,— (Ci— Ce) alkyl, -C¾R7; R5, R6 are independently selected from the group consisting of hydrogen, and— (Ci— C< alkyl; R7 is independently selected from the group consisting of— O— P(=0)(OH)2, -0-P(=0)(-OH)(-0-(C1-C6) alkyl), -0-P(=0)(-0-(C1-C6) alkyl)2, -0-P(=0)(-OH) (— O— (C¾)— phenyl),— O— P(=0)(— O— (CH2)— phenyl)2, a carboxylic acid group, an amino carboxylic acid group and a peptide; Q is selected from the group consisting of aryl, heteroaryl,— 0— aryl,— S— aryl, —O— heteroaryl, and— S— heteroaryl; X is selected from the group consisting of— (CH2)— ,— (N 8)— , S, and O; 11 R8 is independently selected from the group consisting of hydrogen,— (Q— C6) alkyl, — (Ci— C6) substituted alkyl,— (C3-C9) cycloalkyl,— (C3— C9) substituted cycloalkyl, and— O— (Ci-C6) alkyl, substituted alkyl; Y is selected from the group consisting of— (CH2)— or a bond; wherein said aryl, heteroaryl,— O— aryl,— S— aryl,— O— heteroaryl, and— S— heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, CI, Br, I, -NR5R6, -(C]-C6) alkyl, -(Ci-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-Q>) substituted cycloalkyl, -0-(Ci-C6) alkyl, -CH i-Cg) substituted alkyl, -0-(C3-C9) cycloalkyl, -0-(C3-C9) substituted cycloalkyl, -aryl, -aryHA-Ce) alkyl, -aryl-0 -(Cr-C6) alkyl, — O— aryl,— O— (Cj— C ) alkyl— aryl, heteroaryl, heterocyclyl,— O— (Ci— C4) alkyl— heterocycle, and -(S(=0)2)-(Ci-C6) alkyl; and m is 1 or 2. 1.1. Definitions The term "alkyl" refers to radicals containing carbon and hydrogen, without unsaturation. Alkyl radicals can be straight or branched. Exemplary alkyl radicals include, without limitation, methyl, ethyl, propyl, isopropyl, hexyl, t-butyl, sec-butyl and the like. Akyl groups may be denoted by a range, thus, for example, a (Cj - Ce) alkyl group is an alkyl group having from one to six carbon atoms in the straight or branched alkyl backbone. Substituted and unsubstituted alkyl groups may independently be (Q - C5) alkyl, (Q - C6) alkyl, (d - C10) alkyl, (C3 - Qo) alkyl, or (C5 - C,0) alkyl. Unless expressly stated, the term "alkyl" does not include "cycloalkyl." A "cycloalkyl" group refers to a cyclic alkyl group having the indicated number of carbon atoms in the "ring portion," where the "ring portion" may consist of one or more ring structures either as fused, spiro, or bridged ring structures. For example, a C3 to C6 cycloalkyl group (e.g., (C3 - Ce) cycloalkyl) is a ring structure having between 3 and 6 carbon atoms in the ring. When no range is given, then cycloalkyl has between three and nine carbon atoms ((C3 - C9) cycloalkyl) in the ring portion. Exemplary cycloalkyl groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl. Preferred cycloalkyl groups have three, four, five, six, seven, eight, nine, or from three to nine carbon atoms in the ring structure.
The term substituted alkyl and substituted cycloalkyl, refer to alkyl and cycloalkyl groups, as defined above, substituted with one or more substituents independently selected from the group consisting of fluorine, aryl, heteroaryl,— O— (Q— Ce) alkyl, and— NR5R6, where R5 and R6 are independently selected from the group consisting of hydrogen and— (Ci— C6) alkyl.
The term "aryl" refers to an aromatic carbocyclic group, having one, two, or three aromatic rings. Exemplary aryl groups include, without limitation, phenyl, naphthyl, and the like. Aryl groups 12 include one, two, or three aromatic rings structures fused with one or more additional nonaromatic carbocyclic or hetercyclic rings having from 4-9 members. Examples of fused aryl groups include benzocyclobutanyl, indanyl, tetrahydronapthylenyl, 1,2,3,4-tetrahydrophenanthrenyl, tetrahydroanthracenyl, 1 ,4-dihydro-l ,4-methanonaphthalenyl, benzodioxolyl.
The term "heteroaryl" refers to a heteroaromatic (heteroaryl) group having one, two, or three aromatic rings containing from 1 - 4 heteroatoms (such as nitrogen, sulfur, or oxygen) in the aromatic ring. Heteroaryl groups include one, two, or three aromatic rings structures containing from 1 - 4 heteroatoms fused with one or more additional nonaromatic rings having from 4-9 members.
Heteroaryl groups containing a single type of hetroatom in the aromatic ring are denoted by the type of hetero atom they contain, thus, nitrogen-containing heteroaryl, oxygen-containing heteroaryl and sulfur-containing heteroaryl denote heteroaromatic groups containing one or more nitrogen, oxygen or sulfur atoms respectively. Exemplary heteroaryl groups include, without limitation, pyridyl, pyrimidinyl, triazolyl, quinolyl, quinazolinyl, thiazolyl, benzo[&]thiophenyl, furanyl, imidazolyl, indolyl, and the like.
The terms "heterocyclyl" or "heterocycle" refers to either saturated or unsaturated, stable nonaromatic ring structures that may be fused, spiro or bridged to form additional rings. Each heterocycle consists of one or more carbon atoms and from one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. "Heterocyclyl" or "heterocycle" include stable nonaromatic 3-7 membered monocyclic heterocyclic ring structures and 8-11 membered bicyclic heterocyclic ring structures. A heterocyclyl radical may be attached at any endocyclic carbon or nitrogen atom that results in the creation of a stable structure. Preferred heterocycles include 3-7 membered monocyclic heterocycles (more preferably 5-7-membered monocyclic heterocycles) and 8·· 10 membered bicyclic heterocycles. Examples of such groups include piperidinyl, piperazinyl, pyranyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl, azepinyl, isoxozolyl, tetrahydropyranyl, tetrahydrofuranyl, dioxolyl, dioxinyl, oxathiolyl, dithiolyl, sulfolanyl, dioxanyl, dioxolanyl, tetahydrofurodihydrofuranyl, tetrahydropyranodihydro-furanyl, dihydropyranyl, tetrahydrofurofuranyl, tetrahydropyranofuran, quinuclidinyl (1-azabicyclo[2.2.2]octanyl) and tropanyl (8-methyl-8-azabicyclo[3.2.1]octanyl).
For the purpose of the Q subsituent, the term "substituted 3-indolyl" refers to a 3-indolyl group substituted with one or more substituents seleced from the group consisting of: F, CI, Br, I, -NR5R6, -(Ci-C6) alkyl, -(C(-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, -0-(C,-C6) alkyl, -0-(C]-C6) substituted alkyl, -0-(C3-C9) cycloalkyl, -O— (C3-C9) substituted cycloalkyl,—aryl,— aryl-(Ci-C6) alkyl,— aryl-0 -(Q— C6) alkyl, — O— aryl,— O— (C]— C4) alkyl— aryl, heteroaryl, heterocyclyl,— O— (C\— C4) alkyl— heterocycle, and 13 — (S(=0)2)— (C]— ϋβ) alkyl; where R5, R6 are independently selected from the group consisting of hydrogen, and— (C]— C6) alkyl.
For the purposes of the R7 substituent, the term "carboxylic acid group" refers to a group of the form -0-C(=0)-(C,-C5) alkyl, -0-C(=0)-(C3-C9) cycloalkyl, -0-C(=0)-aryl, -0-C(=0)-heteroaryl, -0-C(=0)-heterocycle, -0-C(=0)-(C!-C6) alkyl-aryl, -0-C(=0)-(Ci— C6) alkyl-heteroaryl, or— O-C(=0)-(C1-C6) alkyl-heterocycle. Included in "carboxylic acid group" are groups of the form -0-C(=0)-(Ci-C6) alkyl, -0-C(=0)-(C3-C9) cycloalkyl,— O— C(=0)— aryl,— O— C(=0)— heteroaryl,— O— C(=0)— heterocycle, alkyl-aryl, alkyl-heteroaryl, or -0-C(O)-(Ci-C6) alkyl— heterocycle substituted with one or more substituent independently selected from the group consisting of: F, CI, Br, I, -OH, -SH, -NR5R6, -(Ci-C6) alkyl, -(Ci-C6) substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, -0-(Ci-C6) alkyl, -C— (Ci-C6) substituted alkyl, -S-(Ci-C6) alkyl, -0-(C3-C9) cycloalkyl, -C C3-C9) substituted cycloalkyl, -aryl, — O— aryl,— O— (Ci— C4) alkyl-aryl, heteroaryl, heterocyclyl,— O— (Cj— C4) alkyl— heterocycle, -(S(=0)2)-(C1-C6) alkyl, - H-C(=NH)-NH2 (i.e., guanido), -COOH, and -C(=0)-NR5R6, where R5 and R6 are independently selected from the group consisting of hydrogen, and— (Q— C6) alkyl. In addition, for the purposes of the R7 substituent the term "amino carboxylic acid group" refers to a carboxylic acid group, including carboxylic acid groups substituted with one or more of the above-stated substituents, which bears one or more independently selected amino groups of the form — NR5R6 where R5 and R6 are independently selected from the group consisting of hydrogen and (C1-C6) alkyl.
In one embodiment of this invention, R7 is an alpha amino or imino acid, including but not limited to alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or stereoisomers or racemic mixtures thereof. In another embodiment the of the invention R7 is alpha amino or imino acid selected from the group consisting of L-alanine, L-arginine:, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine.
For the purposes of the R7 substituent, the term "peptide" refers to a dipeptide, tripeptide, tetrapeptide or pentapeptide, which release two, three, four, or five amino or imino acids (e.g., proline) respectively upon hydrolysis. For the purpose of R7, peptides are linked to the remainder of the molecule through an ester linkage. In one embodiment, peptides of R7 are comprised of alpha amino or imino acid, including but not limited to alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, 14 proline, serine, threonine, tryptophan, tyrosine, valine or stereoisomers or racemic mixtures thereof; and in a more preferred version of this embodiment, the carboxyl group involved in the ester linkage is the carboxyl terminal COOH group of the peptide, as opposed to a side chain carboxyl. In another embodiment the of the invention R7 is alpha amino or imino acid selected from the group consisting of L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine; and in a more preferred version of this preferred embodiment, the carboxyl group involved in the ester linkage is the carboxyl terminal COOH group of the peptide, as opposed to a side chain carboxyl. 1.2. Preferred Compounds Included in the preferred embodiments are compounds of formula ΙΠ, IVa, IVb, Va, or Vb, wherein Q is selected from the group consisting of aryl, heteroaryl,— O— aryl,— S— aryl, — O— heteroaryl, and— S— heteroaryl, provided that Q is not 3-indolyl or a substituted 3-indolyl. In other preferred embodiments Q is selected from the group consisting of aryl, heteroaryl,— O— aryl, — S— aryl,— O— heteroaryl, and— S— heteroaryl, provided that when R4 is hydrogen, cycloalkyl, or alkyl, Q is not 3-indolyl or a substituted 3-indolyl. In still other preferred embodiments Q is selected from the group consisting of aryl, heteroaryl,— O— aryl,— S— aryl,—O— heteroaryl, and— S— heteroaryl, provided that when R4 is hydrogen, (C3-C4) cycloalkyl, or (Q-Ct) alkyl, Q is not 3-indolyl or substituted 3-indolyl. In anot er preferred embodiment Q is 3-indolyl or a substituted 3-indolyl provided that R4 is not hydrogen, cycloalkyl, or alkyl. In still another preferred embodiment Q is 3-indolyl or a substituted 3-indolyl provided that R4 is not hydrogen, (C3-C4) cycloalkyl, or (C]-C4) alkyl.
Other preferred embodiments include compounds of formulas Ilia, IVa, IVb, Va, or Vb where R4 is— CH2R7. These compounds may serve as prodrug forms of the corresponding compounds of formulas Ula, IVa, IVb, Va, or Vb where R4 is H. The prodrug form is cleaved by hydrolysis to release the corresponding compound where R4 is H. The hydrolysis may occur by en2ymatic or nonenzymatic routes that produce the corresponding hydroxymethylene derivative, which upon subsequent hydrolysis, result in the release of compounds where R4 is H. In one such preferred embodiment R4 is -CH2R7, where R7 is -0~P(=0)(OH)2, -0-P(=0)(-0H)(-O-(C1-C6)alkyI), or the alkyl groups are independently sleeted. In another preferred embodiment, R4 is— CH2R7, where R7 is a carboxylic acid group or an amino carboxylic acid group. In still another preferred embodiment R7 is a peptide; where in a more preferred embodiment the peptide is linked through an ester bond formed with the carboxyl terminal COOH group of the peptide chain to the remainder of the compound. In other preferred separate and independent embodiments of compounds of formulas ffla, IVa, IVb, Va, or Vb where R4 is— CH2R7 and R7 is a peptide, the peptide may be a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide. Preferred amino acid compositions for peptides of the R7 functionality are described above.
Embodiments of compounds of formulas HI, Ilia, IVa, IVb, Va, or Vb include those where X is selected from the group consisting of — (NR8)— , S, and O, where R8 is independently selected from the group consisting of hydrogen,— (C\— C6) alkyl,— (Cj— C6) substituted alkyl,— (C3— C9) cycloalkyl, — (C3— C9) substituted cycloalkyl, and— O— (Q— C6) alkyl. Other embodiments of compounds of formulas EL, Hla, IVa, IVb, Va, or Vb include those where X is -CH2-. In other embodiments of compounds of formulas HI, Ilia, IVa, IVb, Va, or Vb, X is oxygen (O). In other embodiments of compounds of formulas ΠΙ, LUa, IVa, IVb, Va, or Vb, X is sulfur (S). In still other embodiments of compounds of formulas Ed, Hla, IVa, IVb, Va, or Vb, X is— (NR8)— , where R8 is independently selected from the group consisting of hydrogen,— (C1— C6) alkyl,— (Ci— C6) substituted alkyl, — (C3-C9) cycloalkyl, -(C3-C9) substituted cycloalkyl, and -0-(Ci-C6) alkyl.
Other preferred embodiments of the invention include compounds of formula Hla, where Q is a heteroaryl or an optionally substituted heteroaryl group. In four separate alternative preferred embodiments of compounds of formula Hla, Q is an optionally substituted monocyclic heteroaryl group, an optionally substituted bicyclic heteroaryl group, an optionally substituted bicyclic heteroaryl group with the proviso that the bicyclic heteroaryl group is not an indolyl group or a substituted indolyl, or an optionally substituted tricyclic heteroaryl group. Optional substituents, when present, are independently selected from those recited for aryl, heteroaryl,— O— aryl,— S— aryl,— O— heteroaryl, and— S— heteroaryl.
Included in the preferred embodiments of the invention are compounds of formulas IVa, IVb, Va, or Vb, where Q is a heteroaryl or an optionally substituted heteroaryl group. In four separate alternative preferred embodiments of compounds of formulas IVa, IVb, Va, or Vb, Q is an optionally substituted monocyclic heteroaryl group, an optionally substituted bicyclic heteroaryl group, an optionally substituted bicyclic heteroaryl group with the proviso that the bicyclic heteroaryl group is not indolyl, or an optionally substituted tricyclic heteroaryl group. In a more preferred embodiment, Q is an optionally substituted nitrogen-containing heteroaryl group. In a related embodiment, Q is an optionally substituted indolyl. Optional substituents, when present are independently selected from those recited for aryl, heteroaryl,— O— aryl,— S— aryl,— O— heteroaryl, and—S— heteroaryl.
Preferred embodiments of the invention include mixtures of compounds of formulas IVa and IVb, including racemic mixtures. In another preferred embodiment, the compounds of formula IVa and IVb are the separate enantiomers of (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione. In this embodiment the preparation of (+)-cis-3-(5,6-dihydro- 16 4H-pyrrolo [3,2,1-z;] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione is prepared as a mixture beginning with the starting materials 1,2,3,4-tetrahydroquinoline and indole-3-acetamide. The 1,2,3,4-tetrahydroquinoline is converted into 5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl) oxoacetic acid methyl ester as described in Example 1, steps 1-5. The 5, 6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl) oxoacetic acid methyl ester is reacted with indole-3-acetamide as described in Example 1, step 6, to yield 3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-lyI)-4(lH-indol-3-yl) pyrrole-2, 5-dione. The mixture of (+)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-lyl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione is then prepared by catalytic hydrogenation as described in Example 2 using Procedure B.
Preferred embodiments of the invention also include mixtures of compounds of formulas Va and Vb, including racemic mixtures. In another preferred embodiment, the compounds of Va and Vb are the separate enantiomers of (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione. In this embodiment, the compounds are prepared as a mixture by first preparing (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-iy] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, as described above. The mixture of cis compounds is then treated with a mixture of potassium tert-butoxide in tert-butanol to obtain a mixture of (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z)-] quinolin-l-yl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione as described in Example 3.
All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form, including crystalline forms of reacemic mixtures and crystalline forms of individual isomers. The definition of the compounds according to the invention embraces all possible stereoisomers (e.g., the R and S configurations for each asymmetric center) and their mixtures. It very particularly embraces the racemic forms and the isolated optical isomers having a specified activity. The racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives, separation by chiral column chromatography or supercritical fluid chromatography. The individual optical isomers can be obtained from the racemates by conventional methods, such as, for example, salt formation, with an optically active acid followed by crystallization. Furthermore, all geometric isomers, such as E- and Z-configurations at a double bond, are within the scope of the invention unless otherwise stated. Certain compounds of this invention may exist in tautomeric forms. All such tautomeric forms of the compounds are considered to be within the scope of this invention unless otherwise stated. The present invention also includes one or more regioisomeric mixtures of an analog or derivative.
As used herein, the term "salt" is a pharmaceutically acceptable salt and can include acid addition salts including hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates, and tartrates; alkali metal cations such as Na+, K+, Li+, alkali earth metal salts such as Mg or Ca, or organic amine salts. 17 As used herein, the term "metabolite" means a product of metabolism of a compound of the present invention, or a pharmaceutically acceptable salt, analog or derivative thereof, that exhibits a similar activity in vivo to said compound of the present invention.
As used herein, the term "prodrug" means a compound of the present invention covalently linked to one or more pro-moieties, such as an amino acid moiety or other water solubilizing moiety. A compound of the present invention may be released from the pro-moiety via hydrolytic, oxidative, and/or enzymatic release mechanisms. In an embodiment, a prodrug composition of the present invention exhibits the added benefit of increased aqueous solubility, improved stability, and improved pharmacokinetic profiles. The pro-moiety may be selected to obtain desired prodrug characteristics. For example, the pro-moiety, e.g., an amino acid moiety or other water solubilizing moiety such as phosphate within R4, may be selected based on solubility, stability, bioavailability, and/or in vivo delivery or uptake. 2. The Synthesis of Pyrroloquinolinyl-pyrrole-2.5-diones and pyrroloquinolinyl-pyrrolidine-2,S-diones Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations including the use of protective groups can be obtained from the relevant scientific literature or from standard reference textbooks in the field.
Although not limited to any one or several sources, recognized reference textbooks of organic synthesis include: Smith, M. B.; March, J. March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th ed.; John Wiley & Sons: New York, 2001; and Greene, T.W.; Wuts, P.G. M. Protective Groups in Organic Synthesis, 3rd; John Wiley & Sons: New York, 1999. The following descriptions of synthetic methods are designed to illustrate, but not limit, general procedures for the preparation of compounds of the invention. 2.1 General Procedures for the Synthesis of pyrroloquinolinyl-pyrrole-2.5-dione and pyrroloquinolinyl-pyrrolidine-2.5-diones where R4 is hydrogen The present invention provides for pyrroloquinolinyl-pyrrole-2,5-dione compounds of formula Ilia, rVa, IVb, Va, or Vb. The preparation of compounds of formulas ΓΠ, IJJa, IVa, lYb, Va, and Vb may be achieved by a series of reactions commencing with the reaction of a 5, 6 -dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl) oxoacetic acid ester of formula I with an amide of formula Π, to form a 3-(5,6-dihydro H-pyrrolo [3,2,1-zy] quinolin-lyl)-4(lH-indol-3-yl) pyrrole-2, 5-dione of formula ΓΠ, including compounds of formula IHa, where R4 is hydrogen, as shown in Scheme 1. 18 Scheme 1 2.1.1. Synthesis of 3-i5.6-d vdro-4H-pyrrolo Γ3.2.1-//Ί qu olin-lylV4aH-indol-3-vD pyrrole-2. 5-diones of formula III where R4 is hydrogen The condensation of an ester of formula I and a compound of formula Π to produce compounds of formula ΠΙ, including compounds of formula Ilia, where R4 is hydrogen is conducted in any suitable anhydrous polar aprotic solvent including, but not limited to, tetrahydrofuran (THF), tetrahydropyran, diethyl ether and the like in the presence of base. For the purposes of the reaction, suitable esters of formula I include, but are not limited to, alkyl esters where R9 is a (C1-C4) alkyl group, and preferred esters include the methyl and ethyl esters. Suitable bases for the reaction include alkaline metal salts of low molecular weight alkyl alcohols, including, but not limited to, alkaline metal salts of methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, and tert-butanol. Preferred alkaline metal salts of low molecular weight alkyl alcohols include sodium and potassium salts, with potassium tert-butoxide (tBuOK) being the preferred base. Typically the reactions are conducted at 0° C for 2 hours, however, both the time and temperature may be altered depending upon the specific substituents present on compounds of formula I and Π, and the solvent employed. The reaction temperature may be varied from -78° C to 37° C, and is preferably from -35° C to 25° C, or 19 more preferably from -15° C to 10° C. Reaction times will generally vary inversely with the temperature employed, suitable times from about 15 minutes to 24 hours may be employed, more preferably, 30 minutes to 12 hours, and more preferably 1 to 6 hours. 2.1.2. Preparation of Compounds of Formulas IVa. IVb. Va and Vb where R4 is hydrogen Reduction of compounds of formulas ΠΙ and IHa, where R4 is hydrogen to yield the corresponding 3-(5,6-dihydro-4H-pyrrolo [3,2,1-zj] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-diones having formula IVa, IVb, Va, or Vb may be conducted employing a variety of procedures including, but not limited to, reduction with zinc-mercury (Procedure A), catalytic hydrogenation (Procedure B), and reduction with magnesium in methanol (Procedure C). As indicated in Scheme 1, depending on the reduction reaction and conditions chosen, the reaction will yield principally compounds of formulas IVa and IVb, or principally compounds of formulas Va and Vb, or alternatively a mixture of compounds of formulas IVa, IVb, Va, and Vb.
Mixtures of compounds of formulas IVa, IVb, Va, and Vb may be prepared by the direct reduction of compounds of formulas ΙΠ or Ilia with a zinc-mercury reducing agent. The reaction is generally carried out with fresh reducing agent prepared by mixing Zn powder with HgCl2 deionized water followed by acidification with HC1. After drying, the solid reducing agent (zinc-mercury) is suitable for reduction of compounds of formulas ΠΙ or Ilia in refluxing dry ethanol under a dry HC1 gas atmosphere as described in Example 2, Procedure A, for the reduction of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4(lH-indol-3-yl) pyrrole-2, 5-dione.
An alternative method of preparing pyrrolidine-2, 5-diones is catalytic hydrogenation, which yields a mixture consisting principally of the (±)-cis pyrrolidine-2, 5-diones of formulas IVa and IVb. Catalytic hydrogenation of compounds of formulas ΙΠ or Ula may be conducted in an anhydrous alcohol over a noble metal catalyst under 1 atmosphere of hydrogen for 48 hours. A variety of low molecular weight alkyl alcohols may be employed to conduct the reduction, including n-propyl alcohol, isopropyl alcohol, ethanol or methanol. Preferably the alcohol is ethanol or methanol, and most preferably methanol. A noble metal catalyst (e.g., platinum, palladium, rhodium, ruthenium etc.) on charcoal is preferred for the reduction of compounds of formulas ΙΠ or Ula. In more preferred embodiments, the noble metal catalyst is palladium on activated charcoal. While reduction compounds of formulas IHa or ΙΠ under 1 atmosphere of hydrogen at room temperature (25° C) for 12-48 hours is generally suitable for preparation of pyrrolidine-2, 5-diones, the pressure of hydrogen, reaction time, and the reaction temperature may be varied. Catalytic hydrogenation of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-l-yl)-4(lH-indol-3-yl) pyrrole-2, 5-dione is described in Example 2, Procedure B.
Pyrrole-2,5-diones of formula Ula or ΙΠ may be reduced to yield a mixture of compounds of formulas Va and Vb by the reduction in anhydrous alcohol with a metal reducing agent. Preferred W 2 metals include sodium, calcium and magnesium, with magnesium as a more preferred metal reducing agent. The reaction is typically carried out under an inert atmosphere of nitrogen for 30 minutes to 2 hours by refluxing a compound of formula ΙΠ or formula Ula in an alcohol selected from the group consisting of methanol, ethanol, n-propanol, and isopropanol with magnesium turnings. In preferred embodiments the reaction is conducted for about 40 minutes in methanol as described in Example 2, Procedure C, for the preparation of (±)-ira77i-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zj] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione.
Compounds of IVa and/or IVb, which have the pyrrolidine ring substituents in the cis configuration, may be converted into a mixture of compounds of Va and Vb, where the substituents are in the trans configuration, or into a mixture of all four isomers of formulas IVa, IVb, Va, and Vb by treatment with base in a polar protic solvent. Typically the reaction employs an alkaline metal salt of a (C1-C4) alkyl alcohol in an alcohol solvent (e.g., sodium or potassium methoxide in methanol, sodium or potassium ethoxide in ethanol, sodium or potassium tert-butoxide in tert-butanol), with potassium tert-butoxide in tert-butanol as the preferred alkaline metal salt and solvent mixture.
Reactions are generally conducted from 0° C to the reflux temperature of the reaction mixture for 4 to 48 hours. In more preferred embodiments, the reaction are conducted from room temperature (25° C) to the reflux temperature of the mixture for 8 to 24 hours, and in an even more preferred embodiment, the reaction is conducted at about 50° C in a mixture of potassium tert-butoxide in tert-butanol for about 16 hours. Short reaction times and low temperatures favor formation of mixtures still containing compounds IVa and/or IVb. 2.1.3. Introduction of aryl or heteroaryl substituents into compounds of HI, Hla, IVa, IVb, Va, and Vb The introduction of additional substituted and unsubstituted aryl or heteroaryl substituents on to aromatic rings of compounds of formulas HI, Dla, IVa, IVb, Va, or Vb may be accomplished by the reaction of a substituted or unsubstituted aryl or heteroaryl boronic acid with an aromatic halogen substituerit on a compound of formula IE, D a, IVa, IVb, Va, or Vb. The reaction is typically carried out by heating a mixture of a compound of formula III, Ula, IVa, IVb, Va, or Vb bearing an aryl or heteroaryl bromide or iodide, more preferably an arylbromide or hetroarylbromide, with an aryl or heteroaryl boronic acid in the presence of tetrakistriphenylphosphine palladium in a solvent mixture consisting of 5 parts toluene, 5 parts ethanol, 1 part saturated NaHC03, and 2 parts water to 100° C under nitrogen for 5 hours. After cooling to room temperature, the mixture is extracted with ethyl acetate and concentrated. The residue is purified by silica gel chromatography. In a preferred embodiment, the halogenated compound of formula HI, Dla, IVa, IVb, Va, or Vb bears the halogen on an aryl or heteroaryl group Q functionality resulting in the introduction of substituted aryl or heteroaryl group donated by the boronic acid on to the Q substituent. In a more preferred embodiment, the Q functionality is a brominated aromatic or heteroaromatic Q functionality. In 21 another more preferred embodiment the halogenated Q functionality reacted with the boronic acid is a halogenated 3-indolyl. Examples 31-34 describe the introduction of substituted and unsubstituted aromatic groups into compounds of formula Va and Vb employing a brominated Q functionality where Q is a brominated 3-indolyl.
Aromatic and heteroaromatic boronic acids including 2-thienylboronic acid, 3-thienylboronic acid, and 2-naphthylboronic acid are available from a variety of commercial sources including Sigma-Aldrich (St. Louis, MO). Alternatively aromatic and heteroaromatic boronic acids may be prepared from the corresponding aryl or heteroaryl bromides by reaction with triisopropyl borate in the presence of n-butyllithium followed by quenching with aqueous HC1. (See, e.g., W. Li, et. al, J. Organic Chem. 67: 5394-97 (2002) and C. M. Marson, et al, Tetrahedron 59: 4377-81 (2003). 2.1.4. Preparation of Compounds of Formulas ΓΠ. Eta. IVa. IVb, Va. and Vb where R4 is— C¾R7 Compounds of formula HI, Hla, IVa, IVb, Va, or Vb, where R4 is hydrogen, can be converted into compounds of formula ΠΙ, Hla, IVa, IVb, Va, or Vb where R4 is— CH2R7. The conversion begins with the preparation of the hydroxymethylene derivative of the compounds as indicated in the partial structures shown in Scheme 2.
Scheme 2 lene IVa, IVb, Va, or Vb where R4 is H Preparation of the hydroxymethylene derivatives is accomplished by reaction of a compound of formula ΠΙ, Ilia, IVa, IVb, Va, or Vb where R4 is H with aqueous formaldehyde in tetrahydrofuran (THF). Typical reaction conditions employ equal volumes of THF and 37% formaldehyde in water with the reaction stirred for 14-16 hours at room temperature. Reaction times and temperatures may vary from 1 hour to 48 hours and the temperature may be from 0° C to 50° C or more preferably from 22 ° C to 37° C. Upon completion the reaction is partitioned between water and an organic solvent, typically ethyl acetate. The organic layer is dried over sodium sulfate, concentrated, and subject to chromatography on silica gel as necessary to yield the hydroxymethylene product. The preparation of the hydroxymethylene derivative of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, 3-(5,6-dihydro-4H-pyrrolo[3,2,l-zy]quinolin-l-yl)-l-hydroxymethyl-4-(lH-indol-3-yl)-pyrrolidine-2,5-dione, is described in Example 56, step 1.
Compounds of formulas IE, ma, IVa, IVb, Va, or Vb where R4 is -CH2R7 and R7 is phosphate (-0-P(=0)(OH)2), monoalkyl phosphate (e.g., -0-P(=0)(-OH)(-0-(C,-C6) alkyl)), dialkyl phosphate (e.g.,— O— P(=0)(— O— ( — C6) alkyl)2) a monobenzylphosphate ester (— O-P(=0)(-0H) (-0-(CH2)-phenyl)), or a dibenzylphosphate ester (— O— P(=0)(— O— (CH2)— phenyl)2) may be prepared from the desired hydroxymethylene derivative and a suitably substituted phosphoric acid by any reaction suitable for the formation of a phosphate ester bond between the phosphoric acid compound and the hydroxymethylene derivative. In a preferred method, the formation of phosphate esters is conducted by reaction of a hydroxymethylene derivative of a compound of formula ΓΠ, Ilia, IVa, IVb, Va, or Vb with a suitably protected phosphoramidate followed by deprotection. Reactions with the desired phosphoramidate are typically conducted at room temperature in anhydrous THF. Following the addition of the phosphoramidate, the reaction is treated with tetrazole (3% in acetonitrile) and stirred 5 minutes to 1 hour, after which the reaction is cooled to -78° C. The cooled reaction is treated with m-chloroperbenzoic acid, and after stirring at -78° C for 5 minutes, the reaction is warmed to room temperature and stirred for 5 minutes further. Following the removal of solvent, the product is purified by flash chromatography on silica gel using ethyl acetate hexane. The protecting groups are removed by suitable deprotection reactions. Where the phosphoramidate employed is dibenzylphosphoramidate, the benzyl protecting groups may be removed by hydrogenation of the compound over Pd/C under 1 atmosphere of hydrogen at room temperature. The preparation of phosphoric acid mono-[3-(5,6-dihydro-4H-pyrrolo[3,2,l-zy]qumolin-l-yl)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-l-ylmethyl] ester from 3-(5,6-dihydro-4H-pyrrolo[3,2,l-z)']quinolin-l-yl)-l-hydroxymethyl-4-(lH-indol-3-yl)-pyrrolidine-2,5-dione is described in Example 56, steps 2-3.
Compounds of formulas ΓΠ, Ufa, IVa, IVb, Va, or Vb where R7 is a carboxylic acid group, or an amino carboxylic acid group, may be prepared by coupling the desired hydroxymethylene derivative with a carboxylic acid or amino carboxylic acid (amino acid) under conditions suitable for the formation of an ester linkage. A variety of dehydrating agents, including DCC (dicyclohexylcarbodiimide), HBTU (0-(benzotriazol-l -yl)-N,N,N' N'-tetramethyluronium hexafluorophosphate), or BOP ((benzotriazol-l-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate) may be employed to drive the formation of the ester bond. In a preferred 23 embodiment, the reactions are conducted in anhydrous THF in the presence of HBTU and DIEPA (Ν,Ν-diisopropylethylamine) at room temperature for 10 hours to 24 hours. Following completion of the dehydration reaction, solvent is removed under reduced pressure and the compounds are taken up in an organic solvent (e.g., ethyl acetate) and washed with water. The organic layer is dried and the residue purified by silica gel chromatography as necessary.
Where R7 is an amino carboxylic acid group, the starting materials for introducing the amino carboxylic acid group must contain a suitably protected amine. A variety of suitable amine-protecting groups may be advantageously employed including carbobenzyloxy-protected amines (e.g., the reactions may employ N-carboben2yloxy glycine or N-carbobenzyloxy alanine etc.). Subsequent deprotection will yield the free product. Where the protecting group employed is carbobenzyloxy, deprotection may be accomplished by treating the amine protected product suspended in methanol with HC1 (4M) in ethyl acetate in the presence of palladium on charcoal (Pd/C) under 1 atmosphere of hydrogen for 1-3 hours at room temperature. Examples 58 - 60 describe the preparation of compounds where R7 is a carboxylic acid group, or an amino carboxylic acid group.
Compounds of formulas ΠΙ, Ula, IVa, IVb, Va, or Vb where R7 is a peptide, may be prepared by coupling the desired hydroxymethylene derivative with a peptide bearing a free carboxylic acid group to form an ester linkage. Linking of a carboxyl functionality of a peptide and the hydroxymethylene group in an ester linkage may be conducted employing a suitably protected peptide, bearing for example, protected free amine groups protected with conventional N-protecting groups. Conditions suitable for the formation of an ester linkage, include those employing dehydrating agents, such as those described for the preparation of compounds of formulas ΓΠ5 Ilia, IVa, IVb, Va, or Vb where R4 is— CH2R7 and R7 is a carboxylic acid group, or an amino carboxylic acid group. 2.1.5. Preparation of Compounds of Formula ΙΠ. nia. IVa, IVb. Va. and Vb where R4 is— fCr- C* alkvl Compounds of formulas ΙΠ, Ula, IVa, IVb, Va, or Vb where R4 is a— (C]— Ce) alkyl may be prepared by reacting by reacting the desired compound of formula HI, Ula, IVa, TVb, Va, or Vb where R4 is H with a (Q— Ce) alkyl halide, where the halide is preferably CI, Br or I, in the presence of a suitable base at room temperature. Suitable bases include organic bases such as potassium tert-butoxide, sodium methoxide, and inorganic bases such as KOH, NaOH and K2C03. Suitable solvents include polar aprotic solvents such as DMSO, THF, dioxane or other ethers, or DMF. In an alternative embodiment, the compound of formula HI, Ilia, IVa, TVb, Va, or Vb where R4 is H is reacted with an organic or inorganic base to yield the conjugate base of the compound of formula ΠΙ, nia, IVa, IVb, Va, or Vb, and the conjugate base is then reacted with the alkylhalide. Where the alkyl group is introduced into a compound of formula ΠΙ or nia, the resulting alkylated compounds can be reduced to yield compounds of formulas IVa and IVb, Va and Vb, or a mixture of compounds of formulas IVa, 24 IVb, Va, and Vb employing the reduction procedures described in Section 1(b)(1). Example 61 describes the preparation of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4(l-methylindol-3-yl)-1 -methyl pyrrole-2, 5-dione using iodomethane as an alkylating agent, and its reduction by catalytic hydrogenation to yield (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ζ)'] quinolin-l-yl)-4(l-methylindol-3-yl)-l-methyl pyrrolidine-2, 5-dione.
Compounds of formulas ΙΠ, Ufa, IVa, IVb, Va, or Vb where R4 is a— (Cj— C6) alkyl group may also be prepared by reacting the desired compound of formula ΙΠ, Ida, IVa, IVb, Va, or Vb where R4 is Η with a (Ci— C6) alkyl alcohol in the presence of diethylzodicarboxylate (DEAD) and triphenylphosphine. (See, e.g., Mitsunobu, O.; Wade, M.; Sano, T. J. Am Chem. Soc. 94: 694 (1972); Hughes, D. L., Organic Reactions, 42; 335-656(1992)). The reactions may be conducted in a variety of solvents including tetrahydrofuran (THF), dichloromethane, chloroform, acetonitrile, and benzene, preferably the solvent is THF. 2.1.6. Separation of Compounds of Formula HI. Dla. IVa, IVb. Va, and Vb Where the isolation of an individual product having the structure of formulas HI, IHa, IVa, TVb, Va, or Vb is desired, the products may be separated by chromatography on one or more cliromatography media. Chromatography may be carried out on a preparative scale or on an analytical scale to determine the identity and purity of the products present in a sample. Although any suitable chromatography media including, but not limited to, silica, reverse phase, ion exchange, chiral chromatographic media, or any combination thereof, may be advantageously employed for separations, the suitability of specific chromatographic media and conditions for the separation of products having formulas ΠΙ, Hla, TVa, IVb, Va, and Vb will depend upon the substituents present on the compounds. In preferred embodiments, chromatographic separations are conducted employing HPLC. In other preferred embodiments the separation is carried out using supercritical fluid chromatography. Where supercritical fluid chromatography is employed, C02, or mixtures of C02 with other solvents including acetonitrile (ACN), methanol, ethanol, isopropanol, or hexane, are the preferred mobile phase, with mixtures of C02 and methanol most preferred. A variety of chromatographic media (stationary phases) may be employed in supercritical fluid chromatography including, but not limited to: ChiralCel OA, OB, OD, or OJ; ChiralPak AD or AS; Cyclobond I, II, or ΠΙ; and Chirobiotic T, V, and R media.
In more preferred embodiments, where the products are individual isomers of formulas IVa, IVb, Va, or Vb, mixtures containing two or more of the isomeric forms may be separated by using supercritical fluid chromatography on chiral media. In one more preferred embodiment, separations are conducted on CHIRALPAK® AD columns (Daicel (U.S.A.) Inc. Fort Lee, NT). In that embodiment, products are applied to the AD column in a mixture of methanol and acetonitrile, or in acetonitrile, and the column is subsequently eluted with 35% methanol in C02 (65%). The separation of 3(R),4(S)-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z;] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione and 3(S),4(R)-3-(5,6-dihydro-4H-pyrrolo [3,2,Uj] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione on a CHIRALPAK® AD column is set forth in Example 4. The separation of (+) trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione and (-) trans--3-(5,6-dihydro-4H-pyrroIo [3,2,1-z)"] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione is set forth in Example 5.
The individual racemic forms of compounds of formulas ΓΠ, nia, IVa, IVb, Va, or Va may also be resolved by physical methods, such as, for example, fractional crystallization or crystallization of diastereomeric derivatives. In addition, individual optical isomers can be obtained from racemic mixtures by conventional methods, such as, for example, salt formation with an optically active acid, where applicable, followed by crystallization. 2.2. Preparation of compounds of formula I and Π where Y is a bond Compounds of formulas I and Π, which are employed in the synthesis of pyrroloquinolinyl-pyrrole-2,5-dione of formulas III and IHa, may be purchased or obtained via a variety of synthetic routes such as those set forth below. 2.2.1. Preparation of compounds of formula I where Y is a bond Compounds of formula I may be prepared from the corresponding compound of formula A, where X is selected from the group consisting of— (CH2)—— (NR8)— , S and O, R8 is selected from the group consisting of hydrogen,— (Q— C6) alkyl,— (C\— C6) substituted alkyl,— (C3— C9) cycloalkyl, — (C3— C9) substituted cycloalkyl, and— O— (C— C6) alkyl, and m is 1 or 2. Exemplary compounds of formula A include 1,2,3,4- terra hydroquinoline, 1,2,3,4-tetrahydro-quinoxaline, 3,4-dihydro-2H-benzo[l,4]oxazine, 3,4-dihydro-2H-benzo[l,4]thiazine, 2,3,4,5-tetrahydro-lH-benzo[b]azepine, 2,3,4,5-tetrahydro-lH-benzo[b][l,4]diazepine, 6,7,8,9-tetrahydro-5-oxa-9-aza-benzocycloheptene, or 2,3,4,5-tetrahydro-benzo[b][l,4]thiazepine). The preparation begins with the conversion of a compound of formula A to the corresponding 3-substituted-2-oxopropionic acid ethyl ester of formula B. The ethyl ester of formula B is cyclized to form a compound of formula C, which is converted to the free acid D, which is decarboxylated to yield the desired tricyclic product E. Subsequent reaction of the tricyclic product E with oxalyl chloride and work-up in alcoholic base yields the corresponding compound of formula I. Scheme 3 illustrates the reaction sequence beginning with compounds of formula A, which is further illustrated in Example 1, steps 1-5 for the preparation of 5, 6-dihydro-4H-pyrrolo [3,2,1-z;] quinolin-l-yl) oxoacetic methyl ester of formula I from 1,2,3,4-tetrahydroquinoline and bromoethylpyrruvate (3-bromo-pyruvic acid ethyl ester).
Some suitable conditions for the conversion of compounds of formula A into compounds of formula I through the reaction sequence of Scheme 3 are described herein. Compounds of formula A 26 may be converted to the corresponding 3-substituted-2-oxopropionic acid ethyl ester of formula B by treatment with bromoethyl pyruvate in an anhydrous ether, such as THF, at room temperature for about 24 hours. Treatment of the 3-substituted-2-oxopropionic acid ethyl ester of formula B with anhydrous MgC¾ in 2-methoxyethanol at about 125° C for 30 minutes to 2 hours, preferably for 1 hour, results in the formation of the corresponding tricyclic carboxylic acid ester of formula C.
Subsequent conversion of this compound to the free acid of formula D may be accomplished by hydrolysis in aqueous base. In preferred embodiments the reaction is carried out in an aqueous base, including but not limited to NaOH or KOH, in the presence of alcohol as a co-solvent. Preferred alcohol co-solvents include methanol, ethanol, n-propanol, and isopropanol, with ethanol as a more preferred co-solvent. Reactions are typically conducted by heating the mixture to reflux for 2 hours, although the time and temperature of the reaction may be varied as needed. Oxidative decarboxylatioQ of compounds of formula D may be conducted by a variety of procedures suitable for the decarboxylation of aromatic acids. In preferred embodiments the decarboxylation of compounds of formula D is conducted by heating the free acid with copper-chromite (0ι0-(¾03) in quinolone for about 2 hours to yield the decarboxylated product of formula E. Conversion of compounds of formula E to compounds of formula I may be accomplished by reaction with oxalyl chloride, followed by treatment with a mixture of an anhydrous alcohol and the alkaline metal salt of the alcohol, preferably sodium methoxide, or sodium ethoxide. The reaction of oxalyl chloride with compounds of formula E is typically conducted in anhydrous polar aprotic solvents including ethers at a temperature from about -78° C to about 10" C. In preferred embodiments, the reaction is conducted at a temperature from about -25° C to about 5° C employing an ether as a solvent. In more preferred embodiments the reaction is conducted at 0° C. Preferred solvents for conducting the reaction include, but are not limited to tetrahydrofuran (THF), tetrahydropyran, diethyl ether and the like. 27 Scheme 3. Preparation of Compounds of Formula (I) where Y is a bond 2.2.2. Preparation of compounds of formula Π Compounds of formula Π, which are substituted acetamides, may be purchased or prepared from commercially available starting materials. Commercially available acetamides including: indole-3-acetamide, 2-(5-methyl-lH-indol-3-yl)acetamide, 2-(5-methoxy-lH-indol-3-yI)acetamide, 2-(4- 28 hydroxy-lH-indol-3-yl)acetamide3 2-phenylacetamide, 2-(4-methylphenyl)acetamide, 4-hydroxyphenylacetamide, 4-h droxyphenylacetamide, N-cyclopentyl-2-(4-hy droxy-2-oxo- 1 ,2-dihydro-3-quinolinyl)acetamide, 2-phenoxyacetamide, 2-(2-methylphenoxy)acetamide, 2-(4-fluorophenoxy)acetamide, 2-(4-pyridinyl)acetamide, and 2-[(4-chlorophenyl)sulfanyl] acetamide are available from a variety of sources including Sigma Aldrich Chemical Co., St. Louis Mo. A compound of formula Π may also be prepared from its corresponding free acid by conversion of the free acid to its acid chloride followed by reaction with ammonia. 2.3. Additional Routes for the Preparation of Pyrroloquinolinyl-pyrrolidine-2,5-diones In addition to those routes for the preparation of pyrroloquinolinyl-pyrrolidine-2,5-diones described above, additional routes of preparing the compounds exemplified for (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione are described in Examples 62-64. 3. Methods of Treatment As used herein, a "subject" can be any mammal, e.g., a human, a primate, mouse, rat, dog, cat, cow, horse, pig, sheep, goat, camel. In a preferred aspect, the subject is a human.
As used herein, a "subject in need thereof is a subject having a cell proliferative disorder, or a subject having an increased risk of developing a cell proliferative disorder relative to the population at large. In one aspect, a subject in need thereof has a precancerous condition. In a preferred aspect, a subject in need thereof has cancer.
As used herein, the term "cell proliferative disorder" refers to conditions in which unregulated or abnormal growth, or both, of cells can lead to the development of an unwanted condition or disease, which may or may not be cancerous. In one aspect, a cell proliferative disorder includes a noncancerous condition, e.g., rheumatoid arthritis; inflammation; autoimmune disease; lymphoproliferative conditions; acromegaly; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gram-negative sepsis; toxic shock syndrome; asthma; adult respiratory distress syndrome; chronic obstructive pulmonary disease; chronic pulmonary inflammation; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; pancreatic fibrosis; hepatic fibrosis; acute and chronic renal disease; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute and chronic pain; allergic rhinitis; allergic conjunctivitis; chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synovitis; muscle degeneration, bursitis; tendonitis; tenosynovitis; herniated, ruptures, or prolapsed intervertebral disk syndrome; 29 osteopetrosis; thrombosis; restenosis; silicosis; pulmonary sarcosis; bone resorption diseases, such as osteoporosis; graft-versus-host reaction; Multiple Sclerosis; lupus; fibromyalgia; AIDS and other viral diseases such as Herpes Zoster, Herpes Simplex I or Π, influenza virus and cytomegalovirus; and diabetes mellitus. In another aspect, a cell proliferative disorder includes a precancer or a precancerous condition. In another aspect, a cell proliferative disorder includes cancer. Various cancers to be treated include but are not limited to breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, renal carcinoma, hepatoma, brain cancer, melanoma, multiple myeloma, chronic myelogenous leukemia, hematologic tumor, and lymphoid tumor, including metastatic lesions in other tissues or organs distant from the primary tumor site. Cancers to be treated include but are not limited to sarcoma, carcinoma, and adenocarcinoma. In one aspect, a "precancer cell" or "precancerous cell" is a cell manifesting a cell proliferative disorder that is a precancer or a precancerous condition. In another aspect, a "cancer cell" or "cancerous cell" is a cell manifesting a cell proliferative disorder that is a cancer. Any reproducible means of measurement may be used to identify cancer cells or precancerous cells. In a preferred aspect, cancer cells or precancerous cells are identified by histological typing or grading of a tissue sample (e.g., a biopsy sample). In another aspect, cancer cells or precancerous cells are identified through the use of appropriate molecular markers.
A "cell proliferative disorder of the hematologic system" is a cell proliferative disorder involving cells of the hematologic system. In one aspect, a cell proliferative disorder of the hematologic system includes lymphoma, leukemia, myeloid neoplasms, mast cell neoplasms, myelodysplasia, benign monoclonal gammopathy, lymphomatoid granulomatosis, lymphomatoid papulosis, polycythemia vera, chronic myelocytic leukemia, agnogenic myeloid metaplasia, and essential thrombocythemia. In another aspect, a cell proliferative disorder of the hematologic system includes hyperplasia, dysplasia, and metaplasia of cells of the hematologic system. In a preferred aspect, compositions of the present invention may be used to treat a cancer selected from the group consisting of a hematologic cancer of the present invention or a hematologic cell proliferative disorder of the present invention. In one aspect, a hematologic cancer of the present invention includes multiple myeloma, lymphoma (including Hodgkin's lymphoma, non-Hodgkin's lymphoma, childhood lymphomas, and lymphomas of lymphocytic and cutaneous origin), leukemia (including childhood leukemia, hairy-cell leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, chronic myelogenous leukemia, and mast cell leukemia), myeloid neoplasms and mast cell neoplasms.
A "cell proliferative disorder of the lung" is a cell proliferative disorder involving cells of the lung. In one aspect, cell proliferative disorders of the lung include all forms of cell proliferative disorders affecting lung cells. In one aspect, cell proliferative disorders of the lung include lung W 2 cancer, a precancer or precancerous condition of the lung, benign growths or lesions of the lung, and malignant growths or lesions of the lung, and metastatic lesions in tissue and organs in the body other than the lung. In a preferred aspect, compositions of the present invention may be used to treat lung cancer or cell proliferative disorders of the lung. In one aspect, lung cancer includes all forms of cancer of the lung. In another aspect, lung cancer includes malignant lung neoplasms, carcinoma in situ, typical carcinoid tumors, and atypical carcinoid tumors. In another aspect, lung cancer includes small cell lung cancer ("SCLC"), non-small cell lung cancer ("NSCLC"), squamous cell carcinoma, adenocarcinoma, small cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and mesothelioma. In another aspect, lung cancer includes "scar carcinoma," bronchioalveolar carcinoma, giant cell carcinoma, spindle cell carcinoma, and large cell neuroendocrine carcinoma. In another aspect, lung cancer includes lung neoplasms having histologic and ultrastructual heterogeneity (e.g., mixed cell types).
In one aspect, cell proliferative disorders of the lung include all forms of cell proliferative disorders affecting lung cells. In one aspect, cell proliferative disorders of the lung include lung cancer, precancerous conditions of the lung. In one aspect, cell proliferative disorders of the lung include hyperplasia, metaplasia, and dysplasia of the lung. In another aspect, cell proliferative disorders of the lung include asbestos-induced hyperplasia, squamous metaplasia, and benign reactive mesothelial metaplasia. In another aspect, cell proliferative disorders of the lung include replacement of columnar epithelium with stratified squamous epithelium, and mucosal dysplasia. In another aspect, individuals exposed to inhaled injurious environmental agents such as cigarette smoke and asbestos may be at increased risk for developing cell proliferative disorders of the lung. In another aspect, prior lung diseases that may predispose individuals to development of cell proliferative disorders of the lung include chronic interstitial lung disease, necrotizing pulmonary disease, scleroderma, rheumatoid disease, sarcoidosis, interstitial pneumonitis, tuberculosis, repeated pneumonias, idiopathic pulmonary fibrosis, granulomata, asbestosis, fibrosing alveolitis, and Hodgkin's disease.
A "cell proliferative disorder of the colon" is a cell proliferative disorder involving cells of the colon. In a preferred aspect, the cell proliferative disorder of the colon is colon cancer. In a preferred aspect, compositions of the present invention may be used to treat colon cancer or cell proliferative disorders of the colon. In one aspect, colon cancer includes all forms of cancer of the colon. In another aspect, colon cancer includes sporadic and hereditary colon cancers. In another aspect, colon cancer includes malignant colon neoplasms, carcinoma in situ, typical carcinoid tumors, and atypical carcinoid tumors. In another aspect, colon cancer includes adenocarcinoma, squamous cell carcinoma, and adenosquamous cell carcinoma. In another aspect, colon cancer is associated with a hereditary syndrome selected from the group consisting of hereditary nonpolyposis colorectal cancer, familial adenomatous polyposis, Gardner's syndrome, Peutz-Jeghers syndrome, Turcot's syndrome and 31 juvenile polyposis. In another aspect, colon cancer is caused by a hereditary syndrome selected from the group consisting of hereditary nonpolyposis colorectal cancer, familial adenomatous polyposis, Gardner's syndrome, Peutz-Jeghers syndrome, Turcot's syndrome and juvenile polyposis.
In one aspect, cell proliferative disorders of the colon include all forms of cell proliferative disorders affecting colon cells. In one aspect, cell proliferative disorders of the colon include colon cancer, precancerous conditions of the colon, adenomatous polyps of the colon and metachronous lesions of the colon. In one aspect, a cell proliferative disorder of the colon includes adenoma. In one aspect, cell proliferative disorders of the colon are characterized by hyperplasia, metaplasia, and dysplasia of the colon. In another aspect, prior colon diseases that may predispose individuals to development of cell proliferative disorders of the colon include prior colon cancer. In another aspect, current disease that may predispose individuals to development of cell proliferative disorders of the colon include Crohn's disease and ulcerative colitis. In one aspect, a cell proliferative disorder of the colon is associated with a mutation in a gene selected from the group consisting of p53, ras, FAP and DCC. In another aspect, an individual has an elevated risk of developing a cell proliferative disorder of the colon due to the presence of a mutation in a gene selected from the group consisting of p53, ras, FAP and DCC.
A "cell proliferative disorder of the prostate" is a cell proliferative disorder involving cells of the prostate. In one aspect, cell proliferative disorders of the prostate include all forms of cell proliferative disorders affecting prostate cells. In one aspect, cell proliferative disorders of the prostate include prostate cancer, a precancer or precancerous condition of the prostate, benign growths or lesions of the prostate, and malignant growths or lesions of the prostate, and metastatic lesions in tissue and organs in the body other than the prostate. In another aspect, cell proliferative disorders of the prostate include hyperplasia, metaplasia, and dysplasia of the prostate.
A "cell proliferative disorder of the skin" is a cell proliferative disorder involving cells of the skin. In one aspect, cell proliferative disorders of the skin include all forms of cell proliferative disorders affecting skin cells. In one aspect, cell proliferative disorders of the skin include a precancer or precancerous condition of the skin, benign growths or lesions of the skin, melanoma, malignant melanoma and other malignant growths or lesions of the skin, and metastatic lesions in tissue and organs in the body other than the skin. In another aspect, cell proliferative disorders of the skin include hyperplasia, metaplasia, and dysplasia of the skin.
A "cell proliferative disorder of the ovary" is a cell proliferative disorder involving cells of the ovary. In one aspect, cell proliferative disorders of the ovary include all forms of cell proliferative disorders affecting cells of the ovary. In one aspect, cell proliferative disorders of the ovary include a precancer or precancerous condition of the ovary, benign growths or lesions of the ovary, ovarian cancer, malignant growths or lesions of the ovary, and metastatic lesions in tissue and organs in the 32 body other than the ovary. In another aspect, cell proliferative disorders of the skin include hyperplasia, metaplasia, and dysplasia of cells of the ovary.
A "cell proliferative disorder of the breast" is a cell proliferative disorder involving cells of the breast. In one aspect, cell proliferative disorders of the breast include all forms of cell proliferative disorders affecting breast cells. In one aspect, cell proliferative disorders of the breast include breast cancer, a precancer or precancerous condition of the breast, benign growths or lesions of the breast, and malignant growths or lesions of the breast, and metastatic lesions in tissue and organs in the body other than the breast. In another aspect, cell proliferative disorders of the breast include hyperplasia, metaplasia, and dysplasia of the breast.
In one aspect, a cell proliferative disorder of the breast is a precancerous condition of the breast. In one aspect, compositions of the present invention may be used to treat a precancerous condition of the breast. In one aspect, a precancerous condition of the breast includes atypical hyperplasia of the breast, ductal carcinoma in situ (DCIS), intraductal carcinoma, lobular carcinoma in situ (LCIS), lobular neoplasia, and stage 0 or grade 0 growth or lesion of the breast (e.g., stage 0 or grade 0 breast cancer, or carcinoma in situ). In another aspect, a precancerous condition of the breast has been staged according to the TNM classification scheme as accepted by the American Joint Committee on Cancer (AJCC), where the primary tumor (T) has been assigned a stage of TO or Tis; and where the regional lymph nodes (N) have been assigned a stage of NO; and where distant metastasis (M) has been assigned a stage of MO.
In a preferred aspect, the cell proliferative disorder of the breast is breast cancer. In a preferred aspect, compositions of the present invention may be used to treat breast cancer. In one aspect, breast cancer includes all forms of cancer of the breast. In one aspect, breast cancer includes primary epithelial breast cancers. In another aspect, breast cancer includes cancers in which the breast is involved by other tumors such as lymphoma, sarcoma or melanoma. In another aspect, breast cancer includes carcinoma of the breast, ductal carcinoma of the breast, lobular carcinoma of the breast, undifferentiated carcinoma of the breast, cystosarcoma phyllodes of the breast, angiosarcoma of the breast, and primary lymphoma of the breast. In one aspect, breast cancer includes Stage I, Π, ΙΠΑ, ΠΙΒ, Hie and IV breast cancer. In one aspect, ductal carcinoma of the breast includes invasive carcinoma, invasive carcinoma in situ with predominant intraductal component, inflammatory breast cancer, and a ductal carcinoma of the breast with a histologic type selected from the group consisting of comedo, mucinous (colloid), medullary, medullary with lymphcytic infiltrate, papillary, scirrhous, and tubular. In one aspect, lobular carcinoma of the breast includes invasive lobular carcinoma with predominant in situ component, invasive lobular carcinoma, and infiltrating lobular carcinoma. In one aspect, breast cancer includes Paget's disease, Paget's disease with intraductal carcinoma, and Paget's 33 disease with invasive ductal carcinoma. In another aspect, breast cancer includes breast neoplasms having histologic and ultrastructual heterogeneity {e.g., mixed cell types).
In a preferred aspect, a compound of the present invention may be used to treat breast cancer. In one aspect, a breast cancer that is to be treated includes familial breast cancer. In another aspect, a breast cancer that is to be treated includes sporadic breast cancer. In one aspect, a breast cancer that is to be treated has arisen in a male subject. In one aspect, a breast cancer that is to be treated has arisen in a female subject. In one aspect, a breast cancer that is to be treated has arisen in a premenopausal female subject or a postmenopausal female subject. In one aspect, a breast cancer that is to be treated has arisen in a subject equal to or older than 30 years old, or a subject younger than 30 years old. In one aspect, a breast cancer that is to be treated has arisen in a subject equal to or older than 50 years old, or a subject younger than 50 years old. In one aspect, a breast cancer that is to be treated has arisen in a subject equal to or older than 70 years old, or a subject younger than 70 years old.
In one aspect, a breast cancer that is to be treated has been typed to identify a familial or spontaneous mutation in BRCA1, BRCA2, or p53. In one aspect, a breast cancer that is to be treated has been typed as having a HER2/neu gene amplification, as overexpressing HER2/neu, or as having a low, intermediate or high level of HER2/neu expression. In another aspect, a breast cancer that is to be treated has been typed for a marker selected from the group consisting of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2, Ki-67, CA15-3, CA 27-29, and c-Met. In one aspect, a breast cancer that is to be treated has been typed as ER-unknown, ER-rich or ER-poor. In another aspect, a breast cancer that is to be treated has been typed as ER-negative or ER-positive. ER-typing of a breast cancer may be performed by any reproducible means. In a preferred aspect, ER-typing of a breast cancer may be performed as set forth in Onkologie 27: 175-179 (2004). In one aspect, a breast cancer that is to be treated has been typed as PR-unknown, PR-rich or PR-poor. In another aspect, a breast cancer that is to be treated has been typed as PR-negative or PR-positive. In another aspect, a breast cancer that is to be treated has been typed as receptor positive or receptor negative. In one aspect, a breast cancer that is to be treated has been typed as being associated with elevated blood levels of CA 15-3, or CA 27-29, or both.
In one aspect, a breast cancer that is to be treated includes a localized tumor of the breast. In one aspect, a breast cancer that is to be treated includes a tumor of the breast that is associated with a negative sentinel lymph node (SLN) biopsy. In one aspect, a breast cancer that is to be treated includes a tumor of the breast that is associated with a positive sentinel lymph node (SLN) biopsy. In another aspect, a breast cancer that is to be treated includes a tumor of the breast that is associated with one or more positive axillary lymph nodes, where the axillary lymph nodes have been staged by any applicable method. In another aspect, a breast cancer that is to be treated includes a tumor of the breast that has been typed as having nodal negative status (e.g., node-negative) or nodal positive status 34 (e.g., node-positive). In another aspect, a breast cancer that is to be treated includes a tumor of the breast that has metastasized to other locations in the body. In one aspect, a breast cancer that is to be treated is classified as having metastasized to a location selected from the group consisting of bone, lung, liver, or brain. In another aspect a breast cancer that is to be treated is classified according to a characteristic selected from the group consisting of metastatic, localized, regional, local-regional, locally advanced, distant, multicentric, bilateral, ipsilateral, contralateral, newly diagnosed, recurrent, and inoperable.
In one aspect, a compound of the present invention may be used to treat or prevent a cell proliferative disorder of the breast, or to treat or prevent breast cancer, in a subject having an increased risk of developing breast cancer relative to the population at large. In one aspect, a subject with an increased risk of developing breast cancer relative to the population at large is a female subject with a family history or personal history of breast cancer. In another aspect, a subject with an increased risk of developing breast cancer relative to the population at large is a female subject having a germ-line or spontaneous mutation in BRCA1 or BRCA2, or both. In one aspect, a subject with an increased risk of developing breast cancer relative to the population at large is a female subject with a family history of breast cancer and a germ-line or spontaneous mutation in BRCA1 or BRCA2, or both. In another aspect, a subject with an increased risk of developing breast cancer relative to the population at large is a female who is greater than 30 years old, greater than 40 years old, greater than 50 years old, greater than 60 years old, greater than 70 years old, greater than 80 years old, or greater than 90 years old. In one aspect, a subject with an increased risk of developing breast cancer relative to the population at large is a subject with atypical hyperplasia of the breast, ductal carcinoma in situ (DCIS), intraductal carcinoma, lobular carcinoma in situ (LCIS), lobular neoplasia, or a stage 0 growth or lesion of the breast (e.g., stage 0 or grade 0 breast cancer, or carcinoma in situ).
In another aspect, a breast cancer that is to be treated has been histologically graded according to the Scarff-Bloom-Richardson system, wherein a breast tumor has been assigned a mitosis count score of 1, 2, or 3; a nuclear pleiomorphism score of 1, 2, or 3; a tubule formation score of 1, 2, or 3; and a total Scarff-Bloom-Richardson score of between 3 and 9. In another aspect, a breast cancer that is to be treated has been assigned a tumor grade according to the International Consensus Panel on the Treatment of Breast Cancer selected from the group consisting of grade 1, grade 1-2, grade 2, grade 2-3, or grade 3.
In one aspect, a cancer that is to be treated has been staged according to the American Joint Committee on Cancer (AJCC) T M classification system, where the tumor (T) has been assigned a stage of TX, Tl, Tlmic, Tla, Tib, Tic, T2, T3, T4, T4a, T4b, T4c, or T4d; and where the regional lymph nodes (N) have been assigned a stage of NX, NO, Nl, N2, N2a, N2b, N3, N3a, N3b, or N3c; and where distant metastasis (M) has been assigned a stage of MX, M0, or Ml . In another aspect, a cancer that is to be treated has been staged according to an American Joint Committee on Cancer (AJCC) classification as Stage I, Stage ΠΑ, Stage ΠΒ, Stage ΙΠΑ, Stage ΠΙΒ, Stage ILIC, or Stage IV. In another aspect, a cancer that is to be treated has been assigned a grade according to an AJCC classification as Grade GX {e.g., grade cannot be assessed), Grade 1, Grade 2, Grade 3 or Grade 4. In another aspect, a cancer that is to be treated has been staged according to an AJCC pathologic classification (pN) of pNX, pNO, PNO (I-), PNO (I+), PNO (mol-), PNO (mol+), PN1, PNl(mi), PNla, PNlb, PNlc, pN2, pN2a, pN2b, pN3, pN3a, pN3b, or pN3c.
In one aspect, a cancer that is to be treated includes a tumor that has been determined to be less than or equal to about 2 centimeters in diameter. In another aspect, a cancer that is to be treated includes a tumor that has been determined to be from about 2 to about 5 centimeters in diameter. In another aspect, a cancer that is to be treated includes a tumor that has been determined to be greater than or equal to about 3 centimeters in diameter. In another aspect, a cancer that is to be treated includes a tumor that has been determined to be greater than 5 centimeters in diameter. In another aspect, a cancer that is to be treated is classified by microscopic appearance as well differentiated, moderately differentiated, poorly differentiated, or undifferentiated. In another aspect, a cancer that is to be treated is classified by microscopic appearance with respect to mitosis count {e.g., amount of cell division) or nuclear pleiomorphism {e.g., change in cells). In another aspect, a cancer that is to be treated is classified by microscopic appearance as being associated with areas of necrosis {e.g., areas of dying or degenerating cells). In one aspect, a cancer that is to be treated is classified as having an abnormal karyotype, having an abnormal number of chromosomes, or having one or more chromosomes that are abnormal in appearance. In one aspect, a cancer that is to be treated is classified as being aneuploid, triploid, tetraploid, or as having an altered ploidy. In one aspect, a cancer that is to be treated is classified as having a chromosomal translocation, or a deletion or duplication of an entire chromosome, or a region of deletion, duplication or amplification of a portion of a chromosome.
In one aspect, a cancer that is to be treated is evaluated by DNA cytometry, flow cytometry, or image cytometry. In one aspect, a cancer that is to be treated has been typed as having 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of cells in the synthesis stage of cell division {e.g., in S phase of cell division). In one aspect, a cancer that is to be treated has been typed as having a low S-phase fraction or a high S-phase fraction.
As used herein, a "normal cell" is a cell that cannot be classified as part of a "cell proliferative disorder." In one aspect, a normal cell lacks unregulated or abnormal growth, or both, that can lead to the development of an unwanted condition or disease. Preferably, a normal cell possesses normally functioning cell cycle checkpoint control mechanisms. 36 As used herein, "contacting a cell" refers to a condition in which a compound or other composition of matter is in direct contact with a cell, or is close enough to induce a desired biological effect in a cell.
As used herein, "candidate compound" refers to a compound of the present invention that has been or will be tested in one or more in vitro or in vivo biological assays, in order to determine if that compound is likely to elicit a desired biological or medical response in a cell, tissue, system, animal or human that is being sought by a researcher or clinician. In one aspect, a candidate compound is a compound of formula Ilia; in another aspect, a candidate compound is a compound of formula IVa, IVb, Va, or Vb. In a preferred aspect, the biological or medical response is treatment of cancer. In another aspect, the biological or medical response is treatment or prevention of a cell proliferative disorder. In one aspect, in vitro or in vivo biological assays include, but are not limited to, enzymatic activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays., and the assays set forth in Examples 65-73 herein.
As used herein, "monotherapy" refers to administration of a single active or therapeutic compound to a subject in need thereof. Preferably, monotherapy will involve administration of a therapeutically effective amount of an active compound. For example, cancer monotherapy with (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione comprises administration of a therapeutically effective amount of (+)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zj] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, to a subject in need of treatment of cancer.
Monotherapy may be contrasted with combination therapy, in which a combination of multiple active compounds is administered, preferably with each component of the combination present in a therapeutically effective amount. In one aspect, montherapy with a compound of the present invention is more effective than combination therapy in inducing a desired biological effect.
As used herein, "treating" describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition or disorder.
In one aspect, treating cancer results in a reduction in size of a tumor. A reduction in size of a tumor may also be referred to as "tumor regression." Preferably, after treatment, tumor size is reduced! by 5% or greater relative to its size prior to treatment; more preferably, tumor size is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater. Size of a tumor may be measured by any 37 reproducible means of measurement. In a preferred aspect, size of a tumor may be measured as a diameter of the tumor.
In another aspect, treating cancer results in a reduction in tumor volume. Preferably, after treatment, tumor volume is reduced by 5% or greater relative to its size prior to treatment; more preferably, tumor volume is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater. Tumor volume may be measured by any reproducible means of measurement.
In another aspect, treating cancer results in a decrease in number of tumors. Preferably, after treatment, tumor number is reduced by 5% or greater relative to number prior to treatment; more preferably, tumor number is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. Number of tumors may be measured by any reproducible means of measurement. In a preferred aspect, number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification. In a preferred aspect, the specified magnification is 2x, 3x, 4x, 5x, lOx, or 50x.
In another aspect, treating cancer results in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site. Preferably, after treatment, the number of metastatic lesions is reduced by 5% or greater relative to number prior to treatment; more preferably, the number of metastatic lesions is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. The number of metastatic lesions may be measured by any reproducible means of measurement. In a preferred aspect, the number of metastatic lesions may be measured by counting metastatic lesions visible to the naked eye or at a specified magnification. In a preferred aspect, the specified magnification is 2x, 3x, 4x, 5x, lOx, or 50x.
In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. In a preferred aspect, an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. In another preferred aspect, an increase in average survival time of a population may also be 38 measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more; preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. In a preferred aspect, an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. In another preferred aspect, an increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
In another aspect, treating cancer results in increase in average survival time of a population o f treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. In a preferred aspect, an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. In another preferred aspect, an increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
In another aspect, treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone. In another aspect, treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. In a further aspect, treating cancer results a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof. Preferably, the mortality rate is decreased by more than 2%; more preferably, by more than 5%; more preferably, by more than 10%; and most preferably, by more than 25%. In a preferred aspect, a decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means. In another preferred aspect, a decrease in the mortality rate of a population may be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with an active compound. In 39 another preferred aspect, a decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with an active compound.
In another aspect, treating cancer results in a decrease in tumor growth rate. Preferably, after treatment, tumor growth rate is reduced by at least 5% relative to number prior to treatment; more preferably, tumor growth rate is reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. Tumor growth rate may be measured by any reproducible means of measurement. In a preferred aspect, tumor growth rate is measured according to a change in tumor diameter per unit time.
In another aspect, treating cancer results in a decrease in tumor regrowth. Preferably, after treatment, tumor regrowth is less than 5%; more preferably, tumor regrowth is less than 10%; more preferably, less than 20%; more preferably, less than 30%; more preferably, less than 40%; more preferably, less than 50%; even more preferably, less than 50%; and most preferably, less than 75%. Tumor regrowth may be measured by any reproducible means of measurement. In a preferred aspect, tumor regrowth is measured, for example, by measuring an increase in the diameter of a tumor after a prior tumor shrinkage that followed treatment. In another preferred aspect, a decrease in tumor regrowth is indicated by failure of tumors to reoccur after treatment has stopped.
In another aspect, treating or preventing a cell proliferative disorder results in a reduction in the rate of cellular proliferation. Preferably, after treatment, the rate of cellular proliferation is reduced by at least 5%; more preferably, by at least 10%; more preferably, by at least 20%; more preferably, by at least 30%; more preferably, by at least 40%; more preferably, by at least 50%; even more preferably, by at least 50%; and most preferably, by at least 75%. The rate of cellular proliferation may be measured by any reproducible means of measurement. In a preferred aspect, the rate of cellular proliferation is measured, for example, by measuring the number of dividing cells in a tissue sample per unit time.
In another aspect, treating or preventing a cell proliferative disorder results in a reduction in the proportion of proliferating cells. Preferably, after treatment, the proportion of proliferating cells is reduced by at least 5%; more preferably, by at least 10%; more preferably, by at least 20%; more preferably, by at least 30%; more preferably, by at least 40%; more preferably, by at least 50%; even more preferably, by at least 50%; and most preferably, by at least 75%. The proportion of proliferating cells may be measured by any reproducible means of measurement. In a preferred aspect, the proportion of proliferating cells is measured, for example, by quantifying the number of dividing 40 cells relative to the number of nondividing cells in a tissue sample. In another preferred aspect, the proportion of proliferating cells is equivalent to the mitotic index.
In another aspect, treating or preventing a cell proliferative disorder results in a decrease in size of an area or zone of cellular proliferation. Preferably, after treatment, size of an area or zone of cellular proliferation is reduced by at least 5% relative to its size prior to treatment; more preferably, reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. Size of an area or zone of cellular proliferation may be measured by any reproducible means of measurement. In a preferred aspect, size of an area or zone of cellular proliferation may be measured as a diameter or width of an area or zone of cellular proliferation.
In another aspect, treating or preventing a cell proliferative disorder results in a decrease in the; number or proportion of cells having an abnormal appearance or morphology. Preferably, after treatment, the number of cells having an abnormal morphology is reduced by at least 5% relative to its size prior to treatment; more preferably, reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. An abnormal cellular appearance or morphology may be measured by any reproducible means of measurement. In one aspect, an abnormal cellular morphology is measured by microscopy, e.g., using an inverted tissue culture microscope. In one aspect, an abnormal cellular morphology takes the form of nuclear pleiomorphism.
As used herein, the term "selectively" means tending to occur at a higher frequency in one population than in another population. In one aspect, the compared populations are cell populations. In a preferred aspect, a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, acts selectively on a cancer or precancerous cell but not on a normal cell. In another preferred aspect, a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, acts selectively to modulate one molecular target (e.g., c-Met) but does not significantly modulate another molecular target (e.g., Protein Kinase C). In another preferred aspect, the invention provides a method for selectively inhibiting the activity of an enzyme, such as a kinase. Preferably, an event occurs selectively in population A relative to population B if it occurs greater than two times more frequently in population A as compared to population B. More preferably, an event occurs selectively if it occurs greater than five times more frequently in population A. More preferably, an event occurs selectively if it occurs greater than ten times more frequently in population A; more preferably, greater than fifty times; even more preferably, greater than 100 times; and most preferably, greater than 1000 times 41 more frequently in population A as compared to population B. For example, cell death would be said to occur selectively in cancer cells if it occurred greater than twice as frequently in cancer cells as compared to normal cells.
In a preferred aspect, a compound of the present invention or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, modulates the activity of a molecular target (e.g., c-Met). In one aspect, modulating refers to stimulating or inhibiting an activity of a molecular target. Preferably, a compound of the present invention modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 2-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound. More: preferably, a compound of the present invention modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound. The activity of a molecular target may be measured by any reproducible means. The activity of a molecular target may be measured in vitro or in vivo. For example, the activity of a molecular target may be measured in vitro by an enzymatic activity assay or a DNA binding assay, or the activity of a molecular target may be measured in vivo by assaying for expression of a reporter gene.
In one aspect, a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, does not significantly modulate the activity of a molecular target if the addition of the compound does not stimulate or inhibit the activity of the molecular target by greater than 10% relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound. In a preferred aspect, a compound of the present invention does not significantly modulate the activity of Protein Kinase C.
As used herein, the term "isozyme selective" means preferential inhibition or stimulation of a first isoform of an enzyme in comparison to a second isoform of an enzyme (e.g., preferential inhibition or stimulation of a kinase isozyme alpha in comparison to a kinase isozyme beta).
Preferably, a compound of the present invention demonstrates a minimum of a four fold differential, preferably a ten fold differential, more preferably a fifty fold differential, in the dosage required to achieve a biological effect. Preferably, a compound of the present invention demonstrates this differential across the range of inhibition, and the differential is exemplified at the IC50, i.e., a 50% inhibition, for a molecular target of interest.
In a preferred embodiment, administering a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, to a cell or a subject in need thereof results in modulation (i.e., stimulation or inhibition) of an activity of c-Met. As used herein, an activity of c-Met refers to any biological function or activity that is carried out by 42 c-Met. For example, a function of c-Met includes phosphorylation of downstream target proteins. Other functions of c-Met include autophosphorylation, binding of adaptor proteins such as Gab-1, Grb-2, She, SHP2 and c-Cbl, and activation of signal transducers such as Ras, Src, PI3K, PLC-γ, STATs, ERKl and 2 and FAK.
In a preferred embodiment, administering a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, to a cell or a subject in need thereof results in modulation (i.e., stimulation or inhibition) of an activity of ERK 1 or ERK 2, or both. As used herein, an activity of ERK 1 or ERK 2 refers to any biological function or activity that is carried out by ERK 1 or ERK 2. For example, a function of ERK 1 or ERK 2 includes phosphorylation of downstream target proteins.
In one aspect, activating refers to placing a composition of matter (e.g., protein or nucleic acid) in a state suitable for carrying out a desired biological function. In one aspect, a composition of matter capable of being activated also has an unactivated state. In one aspect, an activated composition of matter may have an inhibitory or stimulatory biological function, or both.
In one aspect, elevation refers to an increase in a desired biological activity of a composition of matter (e.g., a protein or a nucleic acid). In one aspect, elevation may occur through an increase in concentration of a composition of matter.
As used herein, "a cell cycle checkpoint pathway" refers to a biochemical pathway that is involved in modulation of a cell cycle checkpoint. A cell cycle checkpoint pathway may have stimulatory or inhibitory effects, or both, on one or more functions comprising a cell cycle checkpoint. A cell cycle checkpoint pathway is comprised of at least two compositions of matter, preferably proteins, both of which contribute to modulation of a cell cycle checkpoint. A cell cycle checkpoint pathway may be activated through an activation of one or more members of the cell cycle checkpoint pathway. Preferably, a cell cycle checkpoint pathway is a biochemical signaling pathway.
As used herein, "cell cycle checkpoint regulator" refers to a composition of matter that can function, at least in part, in modulation of a cell cycle checkpoint. A cell cycle checkpoint regulator may have stimulatory or inhibitory effects, or both, on one or more functions comprising a cell cycle checkpoint. In one aspect, a cell cycle checkpoint regulator is a protein. In another aspect, a cell cycle checkpoint regulator is not a protein.
In one aspect, treating cancer or a cell proliferative disorder results in cell death, and preferably, cell death results in a decrease of at least 10% in number of cells in a population. More preferably, cell death means a decrease of at least 20%; more preferably, a decrease of at least 30%; more preferably, a decrease of at least 40%; more preferably, a decrease of at least 50%; most preferably, a decrease of at least 75%. Number of cells in a population may be measured by any reproducible means. In one aspect, number of cells in a population is measured by fluorescence 43 activated cell sorting (FACS). In another aspect, number of cells in a population is measured by immunofluorescence microscopy. In another aspect, number of cells in a population is measured by light microscopy. In another aspect, methods of measuring cell death are as shown in Li et al., (2003) Proc Natl Acad Sci USA. 100(5): 2674-8. In an aspect, cell death occurs by apoptosis.
In a preferred aspect, an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof is not significantly cytotoxic to normal cells. A therapeutically effective amount of a compound is not significantly cytotoxic to normal cells if administration of the compound in a therapeutically effective amount does not induce cell death in greater than 10% of normal cells. A therapeutically effective amount of a compound does not significantly affect the viability of normal cells if administration of the compound in a therapeutically effective amount does not induce cell death in greater than 10% of normal cells. In an aspect, cell death occurs by apoptosis.
In one aspect, contacting a cell with a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, induces or activates cell death selectively in cancer cells. Preferably, administering to a subject in need thereof a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, induces or activates cell death selectively in cancer cells. In another aspect, contacting a cell with a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, induces cell death selectively in one or more cells affected by a cell proliferative disorder. Preferably, administering to a subject in need thereof a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, induces cell death selectively in one or more cells affected by a cell proliferative disorder. In a preferred aspect, the present invention relates to a method of treating or preventing cancer by administering a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof to a subject in need thereof, where administration of the compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof results in one or more of the following: accumulation of cells in Gl and/or S phase of the cell cycle, cytotoxicity via cell death in cancer cells without a significant amount of cell death in normal cells, antitumor activity in animals with a therapeutic index of at least 2, and activation of a cell cycle checkpoint. As used herein, "therapeutic index" is the maximum tolerated dose divided by the efficacious dose.
One skilled in the art may refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include Ausubel et al, Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2005); Sambrook et al, Molecular Cloning, A Laboratory Manual (3d ed.), Cold Spring Harbor Press, Cold Spring Harbor, New York 44 (2000); Coligan et al, Current Protocols in Immunology, John Wiley & Sons, N.Y.; Enna et al, Current Protocols in Pharmacology, John Wiley & Sons, N.Y.; Fingl et al, The Pharmacological Basis of Therapeutics (1975), Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 18th edition (1990). These texts can, of course, also be referred to in making or using an aspect o the invention.
In additional aspects, a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, may be administered in combination with a second chemotherapeutic agent. The second chemotherapeutic agent can be ataxane, an aromatase inliibitor, an anthracycline, a microtubule targeting drug, a topoisomerase poison drug, a targeted monoclonal or polyconal antibody, an inhibitor of a molecular target or enzyme (e.g., a kinase inhibitor), or a cytidine analogue drug. In preferred aspects, the chemotherapeutic agent can be, but not restricted to, tamoxifen, raloxifene, anastrozole, exemestane, letrozole, HERCEPTIN® (trastuzumab), GLEEVEC® (imatanib), TAXOL® (paclitaxel), cyclophosphamide, lovastatin, minosine, , araC, 5-fluorouracil (5-FU), methotrexate (MTX), TAXOTERE® (docetaxel), ZOLADEX" (goserelin), vincristin, vinblastin, nocodazole, teniposide, etoposide, GEMZAR® (gemcitabine), epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin (adriamycin), epirubicin or idarubicin or agents listed in www.cancer.org docroot/cdg/cdg_0.asp. In another aspect, the second chemotherapeutic agent can be a cytokine such as G-CSF (granulocyte colony stimulating factor). In another aspect, a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, may be administered in combination with radiation therapy. In yet another aspect, a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, may be administered in combination with standard chemotherapy combinations such as, but not restricted to, CMF (cyclophosphamide, methotrexate and 5-fluorouracil), CAF (cyclophosphamide, adriamycin and 5-fluorouracil), AC (adriamycin and cyclophosphamide), FEC (5· fluorouracil, epirubicin, and cyclophosphamide), ACT or ATC (adriamycin, cyclophosphamide, and paclitaxel), or CMFP (cyclophosphamide, methotrexate, 5-fluorouracil and prednisone).
A compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the compound (i.e. including the active compound), and a pharmaceutically acceptable excipient or carrier. As used herein, "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard 45 reference text in the field. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin.
Pharmaceutically acceptable carriers include solid carriers such as lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary liquid carriers include syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time-delay material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like. Other fillers, excipients, flavorants, and other additives such as are known in the art may also be included in a pharmaceutical composition according to this invention. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.
Supplementary active compounds can also be incorporated into the compositions.
In one aspect, a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, is administered in a suitable dosage form prepared by combining a therapeutically effective amount (e.g., an efficacious level sufficient to achieve the desired therapeutic effect through inhibition of tumor growth, killing of tumor cells, treatment or prevention of cell proliferative disorders, etc.) of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, (as an active ingredient) with standard pharmaceutical carriers or diluents according to conventional procedures (i.e., by producing a pharmaceutical composition of the invention). These procedures may involve mixing, granulating, and compressing or dissolving the ingredients as appropriate to attain the desired preparation. 4. The Pharmaceutical Compositions and Formulations A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g.,, intravenous, intradermal, subcutaneous, oral (e.g.,, inhalation), transdermal (topical), and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral 46 preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
A compound or pharmaceutical composition of the invention can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment. For example, for treatment of cancers, a compound of the invention may be injected directly into tumors, injected into the blood stream or body cavities or taken orally or applied through the skin with patches. The dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects. The state of the disease condition (e.g., cancer, precancer, and the like) and the health of the patient should preferably be closely monitored during and for a reasonable period after treatment.
The term "therapeutically effective amount," as used herein, refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician. In a preferred aspect, the disease or condition to be treated is cancer. In another aspect, the disease or condition to be treated is a cell proliferative disorder.
For any compound, the therapeutically effective amount can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic/prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation. 47 The pharmaceutical compositions containing active compounds of the present invention may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N. J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the 48 form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
In one aspect, the active compounds are prepared with pharmaceutically acceptable carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of 49 W 2006 4 the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.
In therapeutic applications, the dosages of the pharmaceutical compositions used in accordance with the invention vary depending on the agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage. Generally, the dose should be sufficient to result in slowing, and preferably regressing, the growth of the tumors and also preferably causing complete regression of the cancer. Dosages can range from about 0.01 mg/kg per day to about 3000 mg/kg per day. In preferred aspects, dosages can range from about 1 mg/kg per day to about 1000 mg/kg per day. In an aspect, the dose will be in the range of about 0.1 mg/day to about 50 g/day; about 0.1 mg/day to about 25 g/day; about 0.1 mg/day to about 10 g/day; about 0.1 mg to about 3g/day; or about 0.1 mg to about 1 g/day, in single, divided, or continuous doses (which dose may be adjusted for the patient's weight in kg, body surface area in m2, and age in years). An effective amount of a pharmaceutical agent is that which provides an objectively identifiable improvement as noted by the clinician or other qualified observer. For example, regression of a tumor in a patient may be measured with reference to the diameter of a tumor. Decrease in the diameter of a tumor indicates regression. Regression is also indicated by failure of tumors to reoccur after treatment has stopped. As used herein, the term "dosage effective manner" refers to amount of an active compound to produce the desired biological effect in a subject or cell.
The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
All patents, patent applications and references cited herein are incorporated by reference herein in their entirety.
EXAMPLES Examples are provided below to further illustrate different features of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention. 50 Example 1. Preparation of 3-f5,6-Dihydro-4H-pyrrolo [3.2.1-/71 quholin-l-yiy4flH-indol-3-yr) pyrrole-2. 5-dione To a solution of 1,2,3,4- tetrahydroquinoline (100 ml) in anhydrous tetrahydrofuran (300 ml), bromoethylpyrruvate (53ml) was added dropwwase over 30 minutes. The mixture was stirred for 24 hours at room temperature. The reaction mixture was filtered and the solid washed with tetrahydrofuran (100 ml). The filtrate was evaporated to dryness to give 3-(3,4-dihydro-2H-quinolin-l -yl)-2-oxopropionic acid ethyl ester as a brown oil 117 g.
Anhydrous magnesium chloride (29.4 g, 0.31 mol) was suspended in 2-methoxyethanol (400 ml), and the mixture was stirred for 15 minutes at 125° C. A solution of 3-(3,4-dihydro-2H-quinolin-l-yl)-2-oxopropionic acid ethyl ester (76.57 g 0.31 mol) in 2-methoxyethanol (100 ml) was then added and the mixture stirred at 125° C for 60 minutes. The mixture was stirred for a further 5 hours at reflux, cooled and evaporated to dryness. The residue was then acidified with 2 M hydrochloric acid (500 ml) and extracted with dichloromethane (3x500 ml). The combined organic layers were then washed with 5 % sodium bicarbonate solution and dried over anhydrous magnesium sulfate before being evaporated to dryness. The residue was then purified on a silica gel chromatography column, eluting with ethyl acetate/hexanes (1:4) to provide 5,6-dihydro-4H-pyrrolo [3,2,1-ζ)'] quinoline-1-carboxylic acid ethyl ester (31.0 g, 47%). Ή NMR (CDC13) 400 MHz δ: 7.9(d, 1H, J=8 Hz), 7.79(s, 1H), 7.17(m, 1H), 6.99(d, 1H, J=7.2 Hz), 4.37(m, 2H), 4.18(t, 2H, J=5.6 Hz), 3.0(t, 2H, J=6 Hz), 2.24(t, 2H, J=6 Hz), 1.42(t, 3H, J=7.2 Hz). 51 To a solution of 5,6-dihydro-4H-pyrrolo [3 ,2, 1 -y ] quinoline-l-carboxylic acid ethyl ester (31 g, 0.14 mol) in ethanol (200 ml) and water (200 ml) was added sodium hydroxide (30.8 g, 0.77 mol). The mixture was heated to reflux for 2 hours before being cooled to room temperature and diluted with water (2.64 L). The mixture was then washed with dichloromethane (2X300 ml) and the aqueous layer was acidified with concentrated hydrochloric acid to pH 1.0. The precipitate formed was collected by filtration, washed with water and dried to yield 5,6-dihydro-4H-pyrrolo [3,2,1-//] quinoline-l-carboxylic acid as a dark yellow solid (23 g, 85 %). Ή NMR (DMSO-d6) 400 MHz δ: 11.95(brs, IH), 7.96(s, IH), 7.69(d, IH, J=8.4 Hz), 7.06(t, IH, J=6.8 Hz), 6.92(d, IH, J=6.8 Hz), 4.19(t, 2H, J=6 Hz), 2.91(t, 2H, J=6 Hz), 2.1 l(t, 2H, J=5.6 Hz). ,6-dihydro-4H-pyrrolo [3,2,1-y] quinoline-l-carboxylic acid (37.5 g, 0.186 mol), copper chromite (13.5 g, 43 mmol) and quinoline (180 ml) were heated with stirring to 185° C for 2 hours. The mixture was cooled, diluted with dichloromethane (1 L) and filtered over hyflo. The filtrate was washed with 2 M hydrochloric acid (2x600 ml) and twice with 2 M sodium hydroxide (150 ml) before being evaporated to dryness. The residue was purified by silica gel chromatography, eluting with a ethyl acetate/hexanes (1 :6) to afford 5, 6-dihydro-4H-pyrrolo [3,2,1-z ] quinoline (21 g, 72%) as a pale yellow solid. lH NMR (CDC13) 400 MHz δ: 7.44(dd, IH, J=0.8 and 7.6 Hz), 7.07(d, IH, J=3.2 Hz), 7.01(t, IH, J=7.2 Hz), 6.9 (dd, IH, J=0.8 and 6.8 Hz), 6.43(d, IH, J=3.2 Hz), 4.16(t, 2H, J=6 Hz), 2.99(t, 2H, J=6.4 Hz), 2.24(m, 2H). 52 To a solution of 5, 6-dihydro-4H-pyrroloquinoIine (4.0 g, 25.3 mmol), in anhydrous ether (300 ml) at 0° C, was added oxalyl chloride (2.22 ml, 25.3 mmol). The mixture was stirred for 30- 45 minutes at 0° C before being cooled to -78° C. Sodium methoxide in methanol (0.5M) (60 ml) was then added slowly and the mixture allowed to warm to room temperature. The mixture was then diluted with ethyl acetate (200 ml), washed with water (100 ml) followed by a wash with saturated aqueous sodium chloride (50 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was dissolved in ethyl acetate (100 ml) filtered through a 2 inch plug of coarse silica gel and evaporated to give 5, 6 -dihydro-4H-pyrrolo [3,2,1-ζ)'] quinolin-l-yl) oxoacetic acid methyl ester as a yellow solid (5.3 g, 85 %). !H MR (CDC13) 400 MHz δ: 8.3(s, IH), 8.14(d, IH), 7.22(t, IH), 7.04(d, IH), 4.2(t, 2H), 3.95(s, 3H), 3.0(t, 2H), 2.3(t, 2H).
To a solution of 5, 6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl) oxoacetic acid methyl ester (1.0 g, 4.12 mmol) and indole-3-acetamide (0.8 g, 4.5 mmol) in anhydrous tetrahydrofuran at 0° C was added a solution of potassium t-butoxide (1M in tetrahydrofuran) (12.4 ml, 12.4 mmol) dropwise over 30 minutes. The mixture was stirred at 0° C for 2 hours. Concentrated hydrochloric acid (10 ml) was then added and the mixture stirred for 1 hour at room temperature. The mixture was then diluted with ethyl acetate (200 ml), washed twice with water (50 ml), and saturated aqueous sodium chloride solution (50 ml) and the organic layer dried over anhydrous sodium sulfate. The residue was purified by silica gel chromatography, eluting with ethyl acetate/hexanes (1 :4) to afford 3-(5,6-dihydro-4H-pyrrolo [3,2,1-i/] quinolin-l-yl)-4(lH-indol-3-yl) pyrrole-2, 5-dione as a bright red solid (1.2 g, 80 %).. ¾ NMR (CDC13) 400 MHz δ: 8.5(brs, IH), 7.78(s, IH), 7.63(d, IH, J=2.8 Hz), 7.44(s, IH), 7.35(d, IH, J=8 Hz), 7.16(d, IH, J=8.4 Hz), 7.1 l(t, IH, J=7.6 Hz), 6.86 (t, IH, J=7.6 Hz), 6.80(d, IH, J=7.2 Hz),6.64(t, IH, J=8 Hz), 6.57(d, IH, J=8 Hz), 4.2(t, 2H, J=6 Hz), 2.96(t, 2H, J=6 Hz), 2.24(m, 2H).
Example 2. Preparation of ("+')-Cis-3-('5.6-dihydro-4H-pyrrolo l~3,2.1-z7l quinolin-l-yl)-4(lH-indol-3-yl) pyrroIidine-2, 5-dione and (+)-Trans-3-(5.6-dihydro-4H-pyrrolo Γ3.2.1- ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione Preparation of the (+)-cis compounds, (±)-trans compounds, or mixtures thereof were obtained using reducing conditions as described in each of Procedures A through C. 53 Procedure A: Reduction of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4(lH-indol-3-yl) py CIS TRANS 2:1 The active zinc-mercury reducing agent for the reduction of 3-(5,6-dihydro-4H-pyrrolo [3,2,1 -if] quinolin-lyl)-4(lH-indol-3-yl) pyrrole-2, 5-dione was prepared from metallic zinc and ¾<¾. Zinc powder (2.5 g) and mercury (Π) chloride (0.25 g) were suspended in de-ionized water (3 ml) and stirred for 20 minutes. A few drops of concentrated hydrochloric acid was then added and the mixture stirred for few minutes. The solid was filtered off, washed with de-ionized water (50 ml), ethanol (50 ml) and dried.
To a suspension of the Zn(Hg) reducing agent prepared as above in dry ethanol (50 ml) was added 3-(5,6-dihydro-4H-pyrrolo [3,2,1-ί)'] quinolin-l-yl)-4(lH-indol-3-yl) pyrrole-2, 5-dione (0.35 g., 95.4 umol.). The mixture was heated to reflux for 30-60 minutes while dry hydrogen chloride gas was slowly passed through the mixture. The mixture was then cooled, filtered, and evaporated to dryness. A 5% potassium carbonate solution (150 ml) and ethyl acetate (300 ml) were then added. The organic; layer was dried over anhydrous magnesium sulfate and evaporated to give ~2:1 mixture of (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione and (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (0.2g). 54 Procedure B: Reduction of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl)-4(lH-indol-3-yl) pyrroIe-2, 5-dione with hydrogen in the presence of palladium on carbon.
A suspension of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-iy] quinolin-l-yl)-4(lH-indol-3-yI) pyrrole-2, 5-dione (16 g, 43.6 mmol) and 10% palladium on carbon (Pd/C, wet catalyst) (8 g) were stirred under 1 atmosphere of hydrogen in methanol (600 ml) at room temperature for 48 hours. The catalyst was then filtered through a bed of Celite and the filtrate evaporated to dryness. The residue was re-dissolved in methanol and the product precipitated by the addition of cold water. The precipitate was filtered, washed with water and dried under vacuum to yield (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (9.2 g). ¾ NMR (DMSO-d6) 400 MHz δ: 11.56(s, 1H), 10.66(8, 1H), 7.43(d, 1H, J=7.6 Hz), 7.14(d, 2H, J=8 Hz), 6.86-6.97(m, 4H), 6.78(t, 1H, J=7.2 Hz), 6.69(d, 1H, J=6.8 Hz), 4.88(dd, 2H, J=9.2 and 45.6 Hz), 3.88(m, 2H), 2.76(t, 2H, J=5,6 Hz), 1.94(t, 2H, J=6 Hz).
Procedure C: Reduction of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl)-4(lH-indol-3-yl) pyrrole-2, 5-dione by magnesium in methanol.
Magnesium turnings (3.05 g, 0.125 mol) were added to a solution of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-/ ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrole-2, 5-dione (2.56 g, 6.97 mmol) in anhydrous methanol (100 ml) and heated to reflux under an atmosphere of nitrogen for 40 minutes. After cooling to room temperature the mixture was poured into ethyl acetate (300 ml), washed with 1M hydrochloric acid (300 ml) and water (500 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was then purified by silica gel chromatography using 40-50% ethyl acetate in hexanes to yield (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-*;] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione as a pale pink solid (2.3 g). !H NMR (DMSO-d6) 400 MHz δ: 11.54(s, 1H), 11.03(s, 1H), 7.32-7.4(m, 4H), 7.17(d, 1H, J=7.2 Hz), 7.07(t, 1H, J=7.6 Hz), 6.96(t, 1H;> 55 J=7.6 Hz), 6.82-6.89(m, 2H), 4.5(dd, 2H, J=7.2 and 20 Hz), 4.07(t, 2H, J=5.2 Hz), 2.87(t, 2H, J=6 Hz), 2.08(m, 2H).
Example 3. Preparation of (+)-Trans-3-(5.6-dihydro-4H-pyrrolo [3.2,l-z71 quinolin-l-yl flH-indol-:?- indol-3-νΓ) pyrrolidine-2. 5-dione A preparation of (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (378 mg, 1.02 mmol) was heated to 50 °C in tert-butanol (10 ml) and potassium t-butoxide (11 mg, 98 μιηοΐ) for 16 hours. The mixture was poured into ethyl acetate (100 ml) and washed with water (100 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness to give (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yI)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione as a tan powder (276 mg). Ή NMR (DMSO-d6) 400 MHz δ: 1 1.54(s, 1H), 11.03(s, 1H), 7.32-7.4(m, 4H), 7.17(d, 1H, J=7.2 Hz), 7.07(t, 1H, J=7.6 Hz), 6.96(t, 1H, J=7.6 Hz), 6.82-6.89(m, 2H), 4.5(dd, 2H, J=7.2 and 20 Hz), 4.07(t, 2H, J=5.2 Hz), 2.87(t, 2H, J=6 Hz), 2.08(m, 2H).
Example 4. Chromatographic Separation of 3fR).4fS)-3-f5,6-Dihvdro-4H-pyrrolo [3.2,l-z7] quinolin-l-ylV4nH-indol-3-yl pyrrolidine-2. 5-dione and 3(S).4(R)-3-i5.6-Dihvdro-4H-pyrrolo Γ3.2.1-/7Ί quinolin-l-ylV4f lH-indol-3-vD pyrrolidine-2. 5-dione A mixture of (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (135 mg ) in methanol (10 ml) and acetonitrile (6 ml) was subjected to preparative supercritical fluid chromatography, using a chiral AD column 20 mm x 250 mm, eluting with 35% methanol/C02 at a flow rate of 3.5 ml/minutes. To give a faster eluting peak at 4.55 minutes (60 mg) assigned 3(R),4(S)-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z;] quinolin-l-yl)-4(lH-indol-3- 56 yl) pyrrolidine-2, 5-dione and a slower eluting peak 6.05 minutes (56 mg), assigned 3(S),4(R)-3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione. The absolute stereochemical assignments were based solely upon the relative retention time of related compounds and may be reversed.
Example 5. Chromatographic Separation of 3fR).4iR)-3-('5.6-Dihvdro-4H-pyrrolo Γ3.2.1- /] quinolin-l-ylV4aH-indol-3-vn pyrrolidine-2. 5-dione and 3fS iSV3-i5.6-Dihvdro-4H-Pyrrolo Γ3.2.1-ζ71 quinolin-l-ylMf lH-indol-3-νΓ) pyrrolidine-2, 5-dione A mixture of (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (200 mg ) in acetonitrile (1 ml) was subjected to preparative supercritical fluid chromatography using a CHERALPAK® AD column (Daicel, U.S.A.) 20 mm x 250 mm, eluting with 35% methanol/C02 at a flow rate of 3.5 ml/minutes. Chromatography yielded a faster eluting peak of the trans isomer (82 mg) having a negative optical rotation assigned (-)-3(R),4(R)-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione and a slower eluting peak of the trans isomer (86 mg) having a postitive optical rotation assigned (+)-3(S),4(R)-3-(5,6-dihydro-4H-pyrrolo [3,2,l-z7] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione. Absolute stereochemical assignments were based solely upon relative retention time of related compounds they may be reversed. All optical rotation measurements were conducted in chloroform at 25° C at 589 run.
Crystals of the chromatographically separated (+) or (-) isomers of trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z)'] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione may be prepared from 2,2,2-trifluoroethanol using vapor stress techniques and slow evaporation at 49° C. Crystals of these isomers may also be prepared from ethanol at room temperature by evaporation employing seed crystals, such as those prepared by vapor stress techniques.
Example 6. Preparation of 3-f5.6-dihvdro-4H-pyrrolo Γ3,2.1- /1 quinolin-l-yl)-4C2-trifluoromethyl-phenylVpyrrole-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yI)-4(2-trifluoromethyl-phenyI)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 2'-trifluoromethylphenyl acetamide in place of indoIe-3 -acetamide in step 6. 'H NMR (CDC13) 400 MHz 6: 8.16(s, 1H), 7.83(d, 2H, J=7.2 57 Hz), 7.58(m, 2H), 7.37(d, IH, J=7.6 Hz), 7.33(s, IH), 6.85(d, IH, J=6.8 Hz), 6.66(t, IH, J=7.2 Hz), 5.96(d, IH, J=8.8 Hz), 4.2(t, 2H, J=5.6 Hz), 2.95(t, 2H, J=6.4 Hz), 2.22(m, 2H).
Example 7. Preparation of 3-("5.6-Dihvdro-4H-pyrrolo Γ3.2.1-//Ί quinolin-l-ylV4-thiophen-2-yl-pyrrole-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4-thiophen-2-yl-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 2-thienylacetamide in place of indole-3-acetamide in step 6. LH MR (CDC13) 400 MHz δ: 7.87(s, IH), 7.49(d, IH, J=5.2 Hz), 7.37(s, IH), 7.3 (d, IH, J=4 Hz), 7.02(t, IH, J=4 Hz), 6.89-6.98(m, 2H), 6.53(d, IH, J=7.6 Hz), 4.92(t, 2H, J=6 Hz), 3.04(t, 2H, J=6 Hz), 2.3 l(m, 2H).
Example 8. Preparation of 3-f5.6-Dihvdro-4H-pyrrolo Γ3.2.1-//Ί quinolin-l-vn-4i3-methoxy-phenyl)-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4(3-methoxy-phenyl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 3-methoxyphenylacetamide in place of indole-3-acetamide in step 6. 'H NMR (CDC13) 400 MHz δ: 8.01(s, IH), 7.31(s, IH), 7.23 (t, IH, J=7.6 Hz), 7.09(m, 2H), 6.87-6.92(m, 2H), 6.73(t, IH, J=7.6 Hz), 6.14(d, IH, J=8 Hz), 4.25(t, 2H, J=5.2 Hz), 2.99(t, 2H, J=5.6 Hz), 2.67(m, 2H).
Example 9. Preparation of 3-(5.6-Dmydro-4H-pyrrolo ["3.2,l-z'/1 quinolin-l-yl)-4-pyridin-2-yl-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,l-ij] quinolin-l-yl)-4-pyridin-2-yl-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing pyridin-2-ylacetamide in place of indole-3-acetamide in step 6. 'H NMR (CDC13) 400 MHz δ: 8.58(d, IH, J=4.4 Hz), 8.12(s, IH), 7.78(dt, IH, J=1.6 and 7.6 Hz), 7.68(d, IH, J=8 Hz), 7.31 (s, IH), 7.25(m, IH), 6.87(d, IH, J=6 Hz), 6.68(t, IH, J=8 Hz), 5.91(d, IH, J=7.6 Hz), 4.24(t, 2H, J=5.6 Hz), 2.97(t, 2H, J=6 Hz), 2.25(m, 2H).
Example 10. Preparation of 3-C5.6-Dihydro-4H-pynOlo [3.2.1-ζ/Ί quinolin-l-yl' ^-methoxy-phenyl)-pyrrole-2. 5-dione. 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4(4-methoxy-phenyl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 4-methoxyphenylacetamide in place of indole-3-acetamide in step 6. Ή N R (CDC13) 400 MHz δ: 7.95(s, IH), 7.51(m, 2H), 7.25(s, IH), 6.85-6.89(m, 3H), 6.75(t, IH, J=8 Hz), 6.24(d, IH, J=8 Hz), 4.26(t, 2H, J=5.6 Hz), 3.82(s, 3H), 2.99(t, 2H, J=6.4 Hz), 2.27(m, 2H). 58 Example 11. Preparation of 3-Benzori.31dioxol-5-yl-4-(5,6-dihvdro-4H-pyrrolo |"3.2,l-z7| quinolin-1-ylVpyrrole-2. 5-dione 3-Benzo[l,3]dioxol-5-yl-4-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 3,4- (methylenedioxy)phenylacetamide in place of indole-3-acetamide in step 6. 'H NMR (CDC13) 400 MHz δ: 7.98(s, IH), 7.04-7.07(m, 2H), 6.90(d, IH, J=7.2 Hz), 6.76-6.82(m, 2H), 6.30(d, IH, J=8 Hz), 5.98(s, 2H,), 4.26(t, 2H, J=5.6 Hz), 2.99(t, 2H, J=6 Hz), 2.28(m, 2H).
Example 12. Preparation of 3-f5.6-Dihydro-4H-pyrrolo [3.2.1-zYI quinolin-l-ylV4-phenyl-pyrrole-2, 5 -dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yI)-4-phenyl-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing phenylacetamide in place of indole-3-acetamide in step 6. 'HNMR (CDC13) 400 MHz δ: 8.01(s, IH), 7.52(m, 2H), 7.35 (m, 3H), 7.27(s, IH), 6.87 (d, IH, J=7.2 Hz), 6.7 (t, IH, J=7.2 Hz), 6.08(d, IH, J=8 Hz), 4.26(t, 2H, J=5.6 Hz), 2.99(t, 2H, J=5.6 Hz), 2.27(m, 2H).
Example 13. Preparation of 3-Benzo["-7lthiophen-2-yl-4-('5.6-dihvdro-4H-pyrrolo \3,2Λ-ϋ] quinolin-1-yl)-pyrrole-2. 5-dione 3-Benzo[¾]thiophen-2-yl-4-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 2-benzothiophenylacetamide in place of indole-3-acetamide in step 6. Ή MR (DMSO-d6) 400 MHz δ: l l. l l(s, IH), 8.14(s, IH), 8.01(d, IH, J=8 Hz), 7.84(s, IH), 7.45(d, IH, J=8 Hz), 7.3 (t, IH, J=7.2 Hz), 7.15 (t, IH, J=7.6 Hz), 6.71(d, IH, J=6.8 Hz), 6.43(t, IH, J=7.6 Hz), 5.99(d, IH, J=8 Hz), 4.26(t, 2H, J=5.2 Hz), 2.86(t, 2H, J=5.6 Hz), 2.1(m, 2H).
Example 14. Preparation of 3-f5.6-Dihydro-4H-pyrrolo Γ3.2.1-Ζ/1 quinolin-l-vD^-CS-phenoxy-phenyl)-pyrrole-2. 5-dione 3-(5,6-Di ydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4-(3-phenoxy-phenyl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 3-phenoxyphenylacetamide in place of indole-3-acetamide in step 6. ]H NMR (DMSO-d6) 400 MHz δ: 11.03(s, IH), 8.01(s, IH), 7.43(t, IH, J=7.6 Hz), 7.28(d, IH, J=7.6 Hz), 7.15 (t, 2H, J=7.6 Hz), 7.03(t, 2H, J=7.6 Hz), 6.92(d, IH, J=6.8 Hz), 6.8(s, IH), 6.76(t, IH, J=8 Hz), 6.60(d, 2H, J=7.6 Hz), 6.08(d, IH, J=8 Hz), 4.27(t, 2H, J= 5.6 Hz), 2.97(t, 2H, J= 6 Hz), 2.16(m, 2H). 59 Example 15. Preparation of 3-(5.6-Dihvdro-4H-pyrrolo [3,2.1-z71 quinolin-l-yl)-4-0-chloro-phenyl)-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4-(3-c loro-phenyl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 3-chlorophenylacetamide in place of indole-3-acetamide in step 6. Ή NMR (DMSO-ds) 400 MHz δ: 11.11 (s, IH), 8.13(s, IH), 7.47-7.43(m, 2H), 7.36(t, IH, J=7.6 Hz), 7.29 (d, IH, J=7.6 Hz), 6.86(d, IH, J=6.8 Hz), 6.68(t, IH, J=7.6 Hz), 5.97(d, IH, J=8 Hz), 4.31(t, 2H, J= 5.6 Hz), 2.93(t, 2H, J= 5.6 Hz), 2.16(m, 2H).
Example 16. Preparation of 3-("5.6-Dihydro-4H-pyrrolo Γ3.2.1-ζ71 quinolin-l-yiy4-(2-chloro-phenvD-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-z/] quinolin-l-yl)-4-(2-chloro-phenyl)-pyrroIe-2, 5-dione was prepared according to Example 1, steps 1-6, employing 2-chlorophenylacetamide in place of indole-3-acetamide in step 6. 1H MR (DMSO-d6) 400 MHz 5: 11.1 (s, IH), 8.17(s, IH), 7.55(d, IH, J=8 Hz), 7.45-7.49(m, IH), 7.36 (d, 2H, J=4.4 Hz), 6.81(d, IH, J=7.2 Hz), 6.58(t, IH, J=8 Hz), 5.92(d, IH, J=8.4 Hz), 4.27(m, 2H), 2.89(t, 2H, J= 6 Hz), 2.1 l(m, 2H).
Example 17. Preparation of 3-(5,6-Dihvdro-4H-pyrrolo Γ3.2.1-//"| quinolin-l-ylV4-(2.5-dimethoxy-phenyl)-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4-(2,5-dimethoxy-phenyl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 2,5-dimethoxyphenylacetamide in place of indole-3-acetamide in step 6. ¾ NMR (DMSO-d6) 400 MHz δ: 10.93 (s, IH), 8.06(s, IH), 6.97(s, 2H), 6.81(d, IH, J=7.6 Hz), 6.77(s, IH), 6.6(t, IH, J=8 Hz), 5.92(d, IH, J=8 Hz), 4.26(t, 2H, J=5.2 Hz), 3.63(s, 3H), 3.3(s, 3H), 2.9(t, 2H, J= 5.6 Hz), 2.1 l(m, 2H).
Example 18. Preparation of 3-(5.6-Dihvdro-4H-pyrrolo 3.2Λ-ϋ] quinolin-l-yl -4-(2-chloro-4-fluoro-phenvn-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3 ,2, 1 -if] quinolin- 1 -yl)-4-(2-chloro-4-fluoro-phenyl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 2-chloro-4-fluorophenylacetamide in place of indole-3-acetamide in step 6. Ή NMR (DMSO-d6) 400 MHz δ: I I .11 (s, IH), 8.16(s, IH), 7.57(dd, IH, J=2.8 and 9.2 Hz), 7.44(dd, IH, J=6.8 and 8.4 Hz), 7.28 (dt, IH, J=2.4 and 8.4 Hz), 6.84(d, IH, J=7.2 Hz), 6.66(t, IH, J=8 Hz), 5.98(d, IH, J=8 Hz), 4.27(m, 2H), 2.9(t, 2H, J= 5.6 Hz), 2.11 (m, 2H). 60 Example 19. Preparation of S-fS^-Dihydro^H-pyrrolo [3.2,1-z/] quinolin-l-vD-4-naphthalene-l-yl-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-y] quinoli -l-yl)-4-napb.thalene-l-yl-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 1 -naphthylacetami.de in place of indole-3-acetamide in step 6. ¾ NMR (DMSO-d6) 400 MHz δ: 11.1 (s, IH), 8.17(s, IH), 8.02(d, IH, J=8 Hz), 7.97(d, IH, J=8 Hz), 7.75(d, IH, J=8 Hz), 7.43-7.55(m, 3H), 7.37 (t, IH, J=8 Hz), 6.66(d, IH, J=6.8 Hz), 6.27(t, IH, J=8 Hz), 5.57(d, IH, J=8 Hz), 4.24(t, 2H, J=5.2 Hz, 2.83(t, 2H, J= 5.6 Hz), 2.08(m, 2H).
Example 20. Preparation of 3-(5.6-Dihvdro-4H-pyrrolo Γ3.2.1-//] quuiolin-l-vD-4-('2.6-dichloro-phenyl)-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1- /] quinolin-l-yl)-4-(2,6-dichloro-phenyl)-pyrrole-25 5-dione was prepared according to Example 1, steps 1-6, employing 2,6-dichlorophenylacetamide in place of indole-3-acetamide in step 6. Ή NMR (DMSO-d6) 400 MHz δ: 11.23 (s, IH), 8.27(s, IH), 7.53-7.62(m, 3H), 6.85(d, IH, J=7.2 Hz), 6.64(t, IH, J=8.4 Hz), 6.01(d, IH, J=8 Hz), 4.27(t, 2H, J=5.6 Hz), 2.9(t, 2H, J= 5.6 Hz), 2.1 l(m, 2H).
Example 21. Preparation of 3-(5,6-Dihvdro-4H-pyrrolo [3.2.1-»") quinolin-l-yr)-4-(2-bromo-phenyl')-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1- ] quinolin-l-yl)-4-(2-bromo-phenyl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 2-bromophenylacetamide in place of indole-3-acetamide in step 6. lH NMR (DMSO-d6) 400 MHz δ: 11.09 (s, IH), 8.17(s, IH), 7.75(m, IH), 7.37(m, 2H), 7.33(m, IH), 6.81(d, IH, J=7.2 Hz), 6.58(t, IH, J=8 Hz), 5.95(d, IH, J=8 Hz), 4.26(t, 2H, J=5.6 Hz), 2.9(t, 2H, J= 5.6 Hz), 2.1 l(m, 2H).
Example 22. Preparation of 3-f5.6-Dihvdro-4H-pyrrolo [3.2.1-//] quinolin-l-yl -4-indol-l-yl-pyrrole-2. 5-dione 3-(5,6-Dihydro- H-pyrrolo [3,2,1-z)'] quinolin-l-yl)-4-indol-l-yl-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing N-indolyl-2-acetamide in place of indole-3-acetamide in step 6. lE NMR (DMSO-d6) 400 MHz δ: 11.21 (s, IH), 8.18(s, IH), 7.58(d, IH, J=8 Hz), 7.52(d, IH, J=3.2 Hz), 7.01(m, 2H), 6.91(t, IH, J=6.8 Hz), 6.74(d, IH, J=2.8 Hz), 6.71(d, IH, J=7.2 Hz), 6.4(t, IH, J=8 Hz), 5.63(d, IH, J=8 Hz), 4.28(t, 2H, J=4.8 Hz), 2.85(t, 2H, J= 5.6 Hz), 2.11(m, 2H). 61 Example 23. Preparation of 3-(5.6-Dihvdro-4H-pyrrolo [3.2.1- /1 quinolm-l-yl -4-pyridine-3-yl-PVrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4-pyridine-3-yl-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing pyridine-3-ylacetamide in place of indole-3-acetamide in step 6. 'H NMR (DMSO-d6) 400 MHz δ: 11.14 (s, IH), 8.53(m, 2H), 8.12(s, IH), 7.78(d, IH, J=7.6 Hz), 7.41(dd, IH, J=4.8 and 8 Hz), 6.86(d, IH, J=7.2 Hz), 6.66(t, IH, J=7.6 Hz), 5.97(d, IH, J=8.4 Hz), 4.3(t, 2H, J=5.2 Hz), 2.93(t, 2H, J= 5.6 Hz), 2.16(m, 2H).
Example 24. Preparation of 3 -i5.6-Dihvdro-4H-pyrrolo Γ3.2,1-ζ ] quinolin-l-ylV4 -(5-bromo-lH-indol-3-vD-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-ζϊ] quinolin-l-yl)-4 -(5-bromo-lH-indol-3-yl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 5-bromo-lH-indoly-3-ylacetamide in place of indole-3-acetamide in step 6. Ή MR (DMSO-d6) 400 MHz δ: 11.77(s, IH), 10.92 (s, IH), 7.82(s, IH), 7.69(d, IH, J=2.4 Hz), 7.33(d, IH, J=8.4 Hz), 7.10(dd, IH, J=2 and 8.4 Hz), 6.99(d, IH, J=1.6 Hz), 6.76(d, IH, J=7.2 Hz), 6.55(t, IH, J=8 Hz), 6.36(d, IH, J=8 Hz), 4.25(t, 2H, J=5.6 Hz), 2.92(t, 2H, J= 5.6 Hz), 2.17(m, 2H).
Example 25. Preparation of 3-f5.6-Dihvdro-4H-pyrrolo Γ3,2,1-ζ';'1 quinolin-l-yl)-4-pyridine-4-yl-pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-zj] quinolin-l-yl)-4-pyridine-4-yl-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing pyridine-4-ylacetamide in place of indole-3-acetamide in step 6. !H NMR (DMSO-d6) 400 MHz δ: 11.17 (s, IH), 8.53(m, 2H), 8.54(d, 2H, J=6 Hz), 8.17(s, IH), 7.32(d, 2H, J=4.8 Hz), 6.88(d, IH, J=7.2 Hz), 6.69(t, IH, J=7.6 Hz), 5.93(d, IH, J=8 Hz), 4.31(t, 2H, J=6 Hz), 2.94(t, 2H, J= 6 Hz), 2.16(m, 2H).
Example 26. Preparation of 3-Biphenyl-4-yl-4-(5,6-dihvdro-4H-pyrrolo [3,2,1-z/l quinolin-l-vD-pyrrole-2. 5-dione 3-Biphenyl-4-yl-4-(5,6-diliydro-4H-pyrrolo [3,2,1-/ ] quinolin-l-yl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 4-phenylphenylacetamide in place of indole-3 -acetamide in step 6. ¾ NMR (acetone-d6) 400 MHz δ: 8.08(s, IH), 7.6-7.73(m, 7H), 7.48(t, 2H, J=6.8 Hz), 7.39(d, IH, J=7.2 Hz), 6.84(d, IH, J=8 Hz), 6.65(t, IH, J=8.4 Hz), 6.23(t, IH, J=7.2 Hz), 5.97(d, IH, J=8.4 Hz), 4.38(m, 2H), 2.98(m, 2H), 2.28(m, 2H). 62 Example 27. Preparation of 3-r5.6-Dihydro-4H-pyrrolo [3.2.1-ζϊΊ quinolin-1 -νΙ -^-methanesulfonyl-phenylVpyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-z/] quinolin-l-yI)-4-(4-methanesulfonyl-phenyl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 4-methanesulfonylphenylacetamide in place of indole-3-acetamide in step 6. ¾ NMR (CDC13) 400 MHz δ: 8.09(s, lH), 7.9(d, 2H5 J=8.4 Hz), 7.71(d, 2H, J=8.4 Hz), 7.64(s, lH), 6.91(d, 1H, J=7.2 Hz), 6.73(t, 1H, J=7.6 Hz), 5.95(d, 1H, J=8.4 Hz), 4.29(t, 2H, J=5.6 Hz), 3.06(s, 3H), 3.0(t, 2H, J= 6 Hz), 2.29(m, 2H).
Example 28. Preparation of 3-(5.6-Dihydro-4H-pyrrolo [3.2.1-i/l quinolin-l-ylV4-('2-trifluoromethyl-quinolin-4-yl-sulfanylVpyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2, 1 -ij] quinolin-1 -yl)-4-(2-trifluoromet yl-quinolin-4-yl-sulfanyl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 2-[[2-(1rifluoromethyl)-4-quinolinyl]thio]acetamide in place of indole-3-acetamide in step 6. XH NMR (CDC13) 400 MHz δ: 8.3(d, 1H, J=7.6 Hz), 8.11(41H, J=8.4 Hz), 8.05(s, lH), 7.68-7.82(m, 4H), 7.23(s, 1H)5 6.83(m, 2H), 4.21(t, 2H, J=6 Hz), 2.92(t, 2H, J= 6 Hz), 2.21(m, 2H).
Example 29. Preparation of 3-f4-Benzoyloxyphenyl -(5,6-dihvdro-4H-pyrrolo [3.2.1-z l quinolin-1-vD-pyrrole-2, 5-dione 3-(4-Benzoyloxyphenyl)-4-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-1 -yl)-pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 4-benzyloxyphenylacetamide in place of indole-3-acetamide in step 6. ¾ NMR (CDC13) 400 MHz δ: 7.95(s, lH), 7.5(d, 2H, J=8.8 Hz), 7.33-7.43(m, 6H), 6.93(d, 2H, J=8.8 Hz), 6.88(d, 1H, J=7.2 Hz), 6.73(t, 1H, J=7.2 Hz), 6.23(d, 1H, J=8.4 Hz), 5.08(s, 2H), 4.25(t, 2H, J=5.6 Hz), 2.99(t, 2H, J= 6 Hz), 2.27(m, 2H).
Example 30. Preparation of 3-f5.6-Dihvdro-4H-pyrrolo [3.2.1-/y'l quinolin-l-yl)-4-r4-('2-morpholin-4-yl-ethoxyVphenyll -pyrrole-2, 5-dione 3 -(5,6-Dihy dro-4H-py rro lo [3 ,2, 1 -ij] quinolin- 1 -y l)-4-[4-(2-morpholin-4-yl-ethoxy)-pheny 1]■· pyrrole-2, 5-dione was prepared according to Example 1, steps 1-6, employing 4-(2-morpholin-4-yl-ethoxy)-phenylacetamide in place of indole-3-acetamide in step 6. !H NMR (CDC13) 400 MHz δ: 7.95(s, 1H), 7.48(m, 3H), 6.86(m, 3H), 6.74(t, 1H, J=8 Hz), 6.23(d, 1H, J=8. Hz), 4.26(t, 2H, J=5.2 Hz), 4.16(t, 2H, J=5.6 Hz), 3.77(t, 4H, J=4.8 Hz), 2.99(t, 2H, J= 6 Hz), 2.87(t, 2H, J=5.2 Hz), 2.65(m, 4H), 2.28(m, 2H). 63 Example 31. Preparation of 3-(5.6-Dihvdro-4H-pyrrolo [3.2,1-//] qu olm-lyl -f5-l-naphthyl-lH-indol-3-νΠ pyrrole-2. 5-dione A mixture of 1-naphthyl boronic acid (41 mg, 0.24 mmol), 3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-lyl)-4-(5-bromo-lH-indol-3-yl) pyrrole-2, 5-dione (88 mg, 0.2 mmol) (prepared as in Example 24), tetrakistriphenylphosphine palladium (5 mol %) in toluene (4 ml), ethanol (4 ml), saturated NaHC03 (1 ml), and water (2 ml) was heated at 100°C under nitrogen for 5 hours. After cooling to room temperature, the mixture was extracted with ethyl acetate (3x15 ml) and concentrated. The residue was purified by silica gel chromatography, eluting with ethyl acetate/hexanes (1 :4) to afford 3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-l-yl)-4(5-l-naphthyl-lH-indol-3-yl) pyrrole-2, 5-dione as a bright red solid (70 mg, 71%). !H NMR (CD3OD) δ: 1.80-1.92 (m, 2H), 2.72-2.80 (t, J=6.0 Hz, 2H), 3.94-3.99(t, J=6.0 Hz, 2H), 6.50-6.58(m, 3H), 6.66(s, IH), 6.72(m, IH), 6.98(dd, J= 8.4 Hz, J'=2.0 Hz, IH), 7.00-7.50(m, 2H), 7.28(dd, J= 6.8 Hz, J'= 8.4 Hz, IH), 7.38-7.43(m, 2H), 7.61(s, IH), 7.72(d, J= 8.4 Hz, IH), 7.82(d, J= 8.4 Hz, IH), 7.97(s, IH).
Example 32. Preparation of 3-(5,6-Dihvdro-4H-pyrrolo Γ3.2.1- /"] quinolin-lylV4-('5-phenyl-lH-mdo].-3-yl) pyrrole-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-y] quinolin-lyl)-4-(5-phenyl-lH-indol-3-yl) pyrrole-2, 5-dione was prepared according to the method of Example 31 employing phenyl boronic acid in place of 1-naphthyl boronic acid. 'H NMR (CD3OD) δ: 2.10-2.18(m, 2H), 2.90(t, J= 5.6 Hz, 2H), 4.18(t, J= 5.6 Hz, 2H), 6.63(t, J= 7.6 Hz, IH), 6.75-6.83(m, 5H), 7.11-7.20(m, 3H), 7.22(dd, J = 8.4 Hz, J'= 1.2 Hz, IH), 7.38(d, J= 8.4 Hz, IH), 7.59(s, IH), 7.93(s, IH).
Example 33. Preparation of 3-f5.6-Dihvdro-4H-pyrrolo [3,2,1-i:/] quinolin-lyl)-4-(5-f4-methoxyphenyl)-lH-indol-3-vD pyrrole-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-y] quinoIin-lyl)-4-(5-(4-methoxyphenyl)-lH-indol-3-yl) pyrrole-2, 5-dione was prepared according to the method of Example 31 employing 4-methoxyphenyl boronic acid in place of 1-naphthyl boronic acid. Ή NMR (CD3OD) δ: 2.09-2.18(m, 2Η), 2.90(t, J= 6.0 Hz, 2H), 4.15(t, J= 6.0 Hz, 2H), 6.62-6.68(m, 2H), 6.73(s, 4H), 6.77-6.82(m, 2H), 7.18(d, J= 8.4 Hz, IH), 7.33(d, J= 8.4 Hz, IH), 7.53(s, IH), 7.91(s, IH).
Example 34. Preparation of 3-f5.6-Dihydro-4H-pyrrolo [3.2.1-;'/] quinolin-lyl)-4-('5-('3-methylphenyl)-lH-indol-3-νΓ) pyrrole-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-z;] quinolin-lyl)-4-(5-(3-methylphenyl)-lH-indol-3-yl) pyrrole-2, 5-dione was prepared according to the method of Example 31 employing 3-methylphenyl 64 boronic acid in place of 1-naphthyl boronic acid. !HNMR (CD3OD) δ: 2.00-2.10(m, 2H), 2.1 l(s, 3H), 2.81-2.88(t, J=6.0 Hz, 2H), 4.03-4.1 l(t, J=5.6 Hz, 2H), 6.50(d, J= 7.2 Hz, IH), 6.64(t, J= 7.6 Hz, 1H); 6.74-6.81(ra, 3H), 6.86(d, J= 8.0 Hz, IH), 6.94(d, J=7.6 Hz, IH), 7.03(t, J=7.2 Hz, IH), 7.22(dd, J= 8.4 Hz, J'= 2.0 Hz, IH), 7.36(d, J= 8.8 Hz, IH), 7.48(s, IH), 7.90(s, IH).
Example 35. Preparation of (+)-Trans-3-('5.6-dihvdro-4H-pyrrolo Γ3.2,1-ζ'/Ί qumolin-lvI)-4-f5-bromo-lH-indol-3-yl) pyrrolidine-2. 5-dione 3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4-(5-bromo-lH-indol-3-yl) pyrrole-2, 5-dione, prepared as in Example 24, was reduced with Mg in methanol as described in Example 2, Procedure C, to yield (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zj] quinolin-lyl)-4-(5-bromo-lH-indol-3-yl) pyrrolidine-2, 5-dione. ¾ NMR (CD3OD) δ: 2.18-2.26(m, 2Η), 2.96(t, J= 6.0 Hz, 2H), 4.12(t, J= 6.4 Hz, 2H), 4.40(d, J= 6.8 Hz, IH), 4.52(d, J= 6.8 Hz, IH), 6.86-6.96(m, 2H), 7.08(s, IH), 7.13-7.30 (m, 5H) Example 36. Preparation of f±)-Trans-3-C5.6-dihvdro-4H-pyrrolo [3.2J-z7] quinolin-lyl)-4-f5-phenyl-lH-indol-3-yl) pyrrolidine-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-z)'] quinoIin-lyl)-4-(5 -phenyl- lH-indol-3-y I) pyrrole-2, 5-dione, prepared as in Example 32, was reduced with Mg in methanol as described in Example 2, Procedure C, to yield (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-lyl)-4-(5-phenyl-lH-indol-3-yl) pyrrolidine-2, 5-dione. Ή NMR (CD3OD) δ: 2.00-2.16 (m, 2Η), 2.94(t, J= 6.0 Hz, 2H), 3.92-3.99(m, IH), 4.00-4.08(m, IH), 4.36(d, J= 6.4 Hz, IH), 4.68(d, J= 6.4 Hz IH), 6.88-6.97(m, 2H), 7.04(s, IH), 7.12-7.15(m, IH), 7.17-7.47(m, 9H).
Example 37. Preparation of f+)-Trans-3-f5.6-dihvdro-4H-pyrrolo f3.2.1-z>'l quinorin-lyl -CS-Cl-naphthyl)-lH-indol-3-yl) pyrrolidine-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-z/] quinolin-lyl)-4-(5-l-naphthyl-lH-indol-3-yl) pyrrole-2, 5-dione, prepared as in Example 31, was reduced with Mg in methanol as described in Example 2, Procedure C, to yield (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z;] quinolin-lyl)-4-(5-(l-naphthyl)-lH-indol-3-yI) pyrrolidine-2, 5-dione. Ή NMR (CD3OD) δ: 1.85-1.95(m, 1Η), 1.95-2.05(m, 1Η), 2.74-2.88(m, 2Η), 3.72-3.83(m, 1Η), 3.88-3.98(m, 1Η), 4.40(d, J= 6.4 Hz, IH), 4.62(d, J= 6.4 Hz, IH), 6.80(d, J= 6.8 Hz, IH), 6.78(t, J= 8.0 Hz, IH), 7.46(s, IH), 7.07-7.13(m, 2H), 7.18-7.23(dd, J= 8.4 Hz, J= 1.6 Hz, 2H), 7.27-7.34(m, 2H), 7.41-7.49(m, 3H), 7.78-7.83(dd, J= 8.4 Hz, J=3.2 Hz, 2H), 7.86-7.90(d, J= 7.6 Hz, IH). 65 Example 38. Preparation of +VTrans-3-("5,6-dihydro-4H-pyrrolo ["3.2.1-z"/] qumolin-lviy4-C5-r4-methoxyphenyl lH-indol-3-yl pyrrolidine-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3.2,1-y] quinolin-lyl)-4-(5-(4-methoxyphenyl)-lH-indol-3-yl) pyrrole-2, 5-dione, prepared as in Example 33, was reduced with Mg in methanol as described in Example 2, Procedure C, to yield (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4-(5-(4-methoxyphenyl)-lH-indol-3-yl) pyrrolidine-2, 5-dione. !H NMR (CD3OD) δ: 2.03-2.22(m, 2H), 2.98(t, J= 6.0 Hz, 2H), 3.80(s, 3H), 3.97-4.06(m, 1H), 4.06-4.14(m, 1H), 4.38(d, J= 6.8 Hz, 1H), 4.67(d, J= 6.8 Hz, 1H), 6.86(d, J= 8.4 Hz, 2H), 6.91-7.00(m, 2H), 7.08(s, 2H), 7.17-7.27(m, 4H), 7.3 l(d, J= 8.4 Hz, lH), 7.37(d, J= 8.8 Hz, 1H).
Example 39. (±yTrans-3-(5,6-dihvdro-4H-pyrrolo Γ3,2.1-ζ Ί quinolin- lyIV4-(5 -(3 -methylphenyn-l H-indol-3-yl) pyrrolidine-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2, 1 -ij] quinolin- 1 yl)-4-(5-(3 -methylphenyl)- lH-indol-3-yl) pyrrole-2, 5-dione, prepared as in Example 34, was reduced with Mg in methanol as described in Example 2, Procedure C, to yield (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-lyl)-4-(5-(3 -methylphenyl)-lH-indol-3-yl) pyrrolidine-2, 5-dione. Ή NMR (CD3OD) δ: 1.98-2.18(m, 2Η), 2.34(s, 3Η), 2.85-3.00(m, 2Η), 3.90-3.98(m, 1Η), 3.98-4.09(m, 1Η), 4.35(d, J= 7.2 Hz, 1H), 4.64(d, J= 6.8 Hz, 1H), 6.88-6.99(m, 2H), 7.00-7.10(m, 3H), 7.13-7.26(m, 5H), 7.36(m, 2H).
Example 40. Preparation of (±)-Trans-3-(5,6-dihvdro-4H-pyrrolo ["3,2.1-z/") quinolin-lyl)-4-('2-chloro-4-fluorophenyn pyrrolidine-2. 5-dione To a solution of 5, 6-dihydro-4H-pyrrolo [3,2,1-ζ)'] quinolin- 1-yl) oxoacetic acid methyl ester (0.243 g, 1 mmol) and 2-chloro-4-fluorophenylacetamide (1 mmol) in anhydrous tetrahydrofuran (5 ml) at 0° C was added a solution of potassium t-butoxide (1 M in tetrahydrofuran) (2.5 ml, 2.5 mmol). The mixture was stirred at 0° C for 2 hours. Concentrated hydrochloric acid (0.5 ml) was then added and the mixture stirred for 1 hour at room temperature. The mixture was then diluted with ethyl acetate (20 ml), washed with water (2x 15 ml) and saturated aqueous sodium chloride solution (15 ml). The organic layer was then dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield an oil. This residue was diluted in anhydrous methanol (15ml) and the resulting solution charged with oven dried magnesium turnings (0.5 g, 20.5 mmol) and stirred at 70° C in a ventilated vial until the Mg turnings fully dissolved or for two hours. The vial was then allowed to cool to room, temperature. The mixture was diluted with ethyl acetate (25 ml) and washed with 10% hydrochloric acid (2x 25 m,) and saturated aqueous sodium chloride solution (20 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by 66 silica gel chromatography, eluting with an ethyl acetate/hexanes gradient (10% ethyl acetate to 50% ethyl acetate over 40 minutes) to yield (25.6 mg, 6.7%) of (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-lyl)-4-(2-chIoro-4-fluorophenyl) pyrrolidine-2, 5-dione. ]H NMR (DMSO-d6) 400 MHz 5: 12.5(s, IH), 7.52(t, IH, J=6.4 Hz), 7.49 (dd, IH, J=6.4 2.4 Hz), 7.34 (s, IH), 7.21 (td, IH, J=6.0 2.8 Hz), 7.10 (d, IH, J=7.6 Hz), 6.87 (m, 2H), 4.67 (d, IH, J=8.0 Hz), 4.51 (d, IH, J=7.2 Hz), 2.90 (t, 2H, J=5.6 Hz), 2.11 (t, 2H, J=5.2 Hz).
Example 41. Preparation of (±)-Trans-3-(5.6-dihvdro-4H-pyrrolo Γ3,2.1-ζΥ1 quinolin-lyl)-4-(2.6-dichlorophenyl) pyrrolidine-2, 5-dione (+)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-lyl)-4-(2,6-dichlorophenyl) pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with 2,6-dichlorophenylacetamide. Yield 52.2 mg, 13.0%. !H NMR (DMSO--d6) 400 MHz δ: 11.82 (s, IH), 7.34 (m, 3H), 7.10 (d, IH, J=7.2 Hz), 6.87 (m, 2H), 5.16 (d, IH J=7.6 Hz), 5.10 (d, IH, J=7.6 Hz), 2.91 (t, 2H, J=6.0 Hz) 2.10 (m, 2H).
Example 42. Preparation of (+)-Trans-3-(5.6-dihvdro-4H-pyrrolo ["3.2.1-z/l quinolin-lyl)^-^-bromophenyl) pyrrolidine-2. 5-dione (±)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4-(4-bromophenyl) pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with 4-bromophenylacetamide. Yield 33.1 mg, 8.1%. !H NMR (DMSO-d6) 400 MHz 5: 11.55 (s, IH), 7.53 (dt, 2H, J=8.8 2.0 Hz), 7.34 (dt, 3H, J=8.0 2.0 Hz), 7.15 (dd, IH, J=7.6 1.0 Hz), 6.86 (m, 2H), 4.53 (d, IH, J=8.0 Hz), 4.37 (d, IH, J=8.0 Hz), 4.10 (t, 2H, J=1.6 Hz), 2.90 (t, 2H, J=2.0 Hz), 2.12 (t, 2H, J=1.8 Hz).
Example 43. Preparation of (+)-Trans-3-(5.6-dihydro-4H-pyrrolo [3.2,l-z71 quinolin-lyl)-4-(4-chlorophenyl) pyrrolidine-2. 5-dione (+)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4-(4-chlorophenyl) pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with 4-chlorophenylacetamide. Yield 32.7 mg, 9.0%. ¾ NMR (DMSO-d5) 400 MHz δ: 11.54 (s, IH), 7.40 (m, 4H), 7.33 (s, IH), 7.15 (dd, IH, J=6.8 0.8 Hz), 6.86 (m, 2H), 4.54 (d, IH, J=8.0 Hz), 7.38 (d, IH, J=7.6 Hz), 4.10 (t, 2H, J=5.6 Hz), 2.90 (t, 2H, J=6.0 Hz), 2.11 (m, 2H). 67 Example 44. Preparation of (±VTrans-3-i5.6-dihvdro-4H-pyrrolo [3.2.1-//1 quinolin-lyl)-4-(4-trifluoromethoxyphenyl') pyrrolidine-2. 5-dione (±)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1- ] quinolin-lyl)-4-(4-trifluoromethoxyphenyl) pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with 4-trifluoromethoxyphenylacetamide. Yield 67.8 mg, 16.4%. ^NMR (DMSO-de) 400 MHz δ: 11.56 (s, IH), 7.52 (d, 2H, J=8.4 Hz), 7.35 (s, IH), 7.33 (d, 2H, J=8.0 Hz), 7.15 (d, IH, J=7.2 Hz), 6.86 (m, 2H), 4.58 (d, IH, J=8.0 Hz), 4.45 (d, IH, J=8.0 Hz), 4.10 (t, 2H, J=6.0 Hz), 2.90 (t, 2H, J=6.0), 2.10 (t, 2H, J=5.6).
Example 45. Preparation of r±)-Trans-3-f5,6-dihydro-4H-pyrrolo 3.2.1-z7] quinolin-lyl)-4-fthiophen-3-yl) pyrrolidine-2. 5-dione (+)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-r)'] quinolin-lyl)-4-(thiophen-3-yl) pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with thiophen-3-ylacetamide. Yield 50.3 mg, 15.0%. ¾ NMR (DMSO-d6) 400 MHz δ: 11.50 (s, IH), 7.52 (m, IH), 7.49 (m, IH), 7.35 (s, IH), 7.21 (dd, IH, J=4.0 1.2 Hz), 7.16 (d, IH, 7.6 Hz), 6.89 (d, IH, J=4.4 Hz), 6.85 (t, IH, J=6.8 Hz), 4.56 (d, IH, J=7.2 Hz), 4.41 (d, IH, J=7.2 Hz), 4.10 (t, 2H, J=6.0 Hz), 2.90 (t, 2H, J=6.0 Hz), 2.10 (m, 2H).
Example 46. Preparation of r± -Trans-3-(5.6-dihydro-4H-pyrrolo [3.2,l-r7] quinolin-lyl>4-C2-fluorophenyl) pyrrolidine-2. 5-dione (±)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-;)'] quinolin-lyl)-4-(2-fluorophenyl) pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with 2-fluorophenylacetamide. Yield 30.6 mg, 8.8%. 1HNMR (DMSO-d6) 400 ΜΗζ δ: 11.64 (s, IH), 7.3 (m, 3H), 7.17 (m, 3H), 6.84 (m, 2H), 4.44 (d, IH, J=7.2 Hz), 4.40 (d, IH, J=7.6 Hz), 4.10 (s, 2H), 2.88 (s, 2H), 2.09 (s, 2H).
Example 47. Preparation of (±VTrans-3-C5.6-dihvdro-4H-pyrrolo [3.2.1-z71 quinolin-lyD-4-(2-thiophen-2-νΠ pyrrolidine-2. 5-dione (+)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-iy] quinolin-lyl)-4-(2-thiophen-2-yI) pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with 2-thiophen-2-ylacetamide. Yield 30.6 mg, 8.8%. Ή MR (DMSO-d6) 400 MHz δ: 11.58 (s, IH), 7.45 (dd, IH, J=5.2 0.8 Hz), 7.40 (s, IH), 7.22 (d, IH, J=8.0 Hz), 7.12 (d, IH, J=3.2 Hz), 6.99 (dd, IH, J=5.2 and 3.6 Hz), 4.63 (d, IH, J=8.0 Hz), 4.60 (d, IH, J=7.6 Hz), 2.90 (t, 2H, J=6.0 Hz), 2.12 (t, 2H, J=6.0 Hz). 68 W 2006/086484 Example 48. Preparation of f±>Trans-3-f5,6-di vdro-4H-pyrrolo [3.2,1- /l guinolin-lylV4-C2.4-dichlorophenvD pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4-(2,4-dichlorophenyl) pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with 2,4-dichlorophenylacetamide. Yield 20.9 mg, 5.2%. !H NMR (DMSO-d6) 400 MHz δ: 11.65 (s, IH), 7.69 (s, IH), 7.51 (d, IH, J= 8.0 Hz), 7.43 (d, IH, J=8.0 Hz), 7.34 (s, IH), 7.12 (m, IH), 6.87 (m, 2H), 4.65 (d, IH, J=7.6 Hz), 4.55 (d, IH, J=7.6 Hz), 4.10 (t, 2H, J=6.0 Hz), 2.90 (t, 2H, J=6.0), 2.12 (t, 2H, J=6.0 Hz).
Example 49. Preparation of f±)-Trans-3-f5.6-dihydro-4H-pyrrolo [3,2.1-ζϊΙ quinolin-lvI)-4-phenyl-pyrrolidine-2. 5-dione (+)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-lyl)-4-phenyl-pyrrolidine-2, 5-dione was prepared according to the Example 40 replacing 2-chloro-4-fluorophenylacetamide with phenylacetamide. Ή NMR (DMSO-d6) 400 MHz δ: 11.511(s, IH), 7.24-7.36(m, 6H), 7.13(d, IH, J=7.2), 6.8-6.88(m, 2H), 4.49(d, IH, J=8.0 Hz), 4.3 (d, IH, J=7.6 Hz), 4.08(m, 2H), 2.88 (m, 2H), 2.088(m, 2H).
Example 50. Preparation of f±)-Trans-3-(5,6-dihydro-4H-pyrrolo [3.2J-z7'1 quinolin-lyl)-4-(2-chlorophenyl)-pyrrolidine-2. 5-dione (+)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-lyl)-4-(2-chlorophenyl)-pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with 2-chlorophenylacetamide. Ή NMR (DMSO-d6) 400 MHz δ: 11.655(s, IH), 7.41-7.48(m, 2H), 7.27-7.35(m, 3H, J=7.2), 7.87(d, IH, J=7.6), 6.81-6.88(m, 2H), 4.632 (d, IH, J=7.6 Hz), 4.494(d, IH, J=7.2), 4.07-4.10 (m, 2H), 2.884(m, 2H), 2.09(m, 2H).
Example 51. Preparation of f±)-Trans-3-f5.6-dihydro-4H-pyrrolo [3.2,l-z'/1 quinolin-lyl -4-(N-methylindol-3-yl) pyrrolidine-2, 5-dione (+)-Trans-3-(5,6-dihydro-4H-pyrrolo [352,1-ζ)'] quinolin-lyl)-4-(N-methylindol-3-yl) pyrrolidine-2, 5-dione was prepared according to Example 40 replacing 2-chloro-4-fluorophenylacetamide with N-methylindol-3-ylacetamide. ]H NMR (DMSO-d6) 400 MHz δ: 11.55(s, IH), 7.44-7.34(m, 4H), 7.2-7.18 (m, 2H), 7.01(t, IH), 6.82-6.89(m, 2H), 4.49 (dd, 2H), 4.093 (t, 2H):, 4.093 (t, 2H), 3.73 (s, 3H), 2.89 (t, 2H), 2.07 (m, 2H). 69 Example 52. Preparation of f±VCis-3-(S,6-dihvdro-4H-pyrrolo [3.2.1-//1 quinolm-lylV^^-methoxyphenvD-pyrrolidine-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4(4-methoxy-phenyl)-pyrrole-2, 5-dione, prepared as in Example 10 and was reduced by employing the method of Example 2, Protocol B, to yield (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-lyl)-4-(4-methoxyphenyl)-pyrrolidine-2, 5-dione. ¾ MR (CDC13) 400 MHz 5: 8.62(s, 1H), 7.15(d, 1H, J=7.6 Hz), 6.8-6.93(m, 4H), 6.7(s, 1H), 6.55(d, 2H, J=8.4 Hz), 4.8(d, 1H, J=8.8 Hz), 4.48(d, 1H, J=8.8 Hz), 3.96(m, 2H), 3.63(s, 3H), 2.87(t, 2H, J=6 Hz), 2.10(m, 2H).
Example 53. Preparation of f+VCis-S-rS^-dihvdro^H-oyrrolo Γ3.2.1-7>Ί qumo\w-M)-4-(2.5-dimethoxyphenyI)-pyrrolidine-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl)-4-(2,5-dimethoxy-phenyl)-pyrrole-2, 5-dione, prepared as in Example 17, was reduced by employing the method of Example 2, Protocol B, to yield (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1- ] quinolin-lyl)-4-(2,5-dimethoxyphenyl)-pyrrolidine-2, 5-dione. ¾ NMR (CDC13) 400 MHz δ: 8.0(s, 1H), 7.19(d, 1H, J=7.6 Hz), 6.89(t, 1H, J=7.2 Hz), 6.77(d, 2H, J=7.2 Hz), 6.44-6.51(m, 3H), 4.84(d, 2H, J=9.6 Hz), 3.88-4.00(m, 2H), 3.6(s, 3H), 3.49(s, 3H), 2.8(m, 2H), 2.05(m, 2H).
Example 54. Preparation of (+)-Cis-3-C5,6-dihydro-4H-pyrrolo [3.2.1-//] quinolin-lvD^-Q-chloro^-fluoro-phenyl)-pyrrolidine-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-z)'] quinolin-l-yl)-4-(2-chloro-4-fluoro-phenyl)-pyrrole-2, 5-dione, prepared as in Example 18, was reduced by employing the method of Example 2, Protocol B, to yield (+)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z)'] quinolin-lyl)-4-(2-chloro-4-fluoro-phenyl)-pyrrolidine-2, 5-dione. 'HNMR (DMSO-d6) 400 MHz δ: 11.82(s, 1H), 7.02-7.18(m, 4H), 6.7-6.85(m, 3H), 5.01(d, 1H, J=9.2 Hz), 4.79(d, 2H, J=9.6 Hz), 3.96(m, 2H), 2.79(m, 2H), 1.97(m, 2H).
Example 55. Preparation of (+)-Cis-3-f5.6-dihvdro-4H-pyrrolo [3.2.1-//1 quinolin-lyl)-4-("3-chlorophenyl -pyrrolidine-2. 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1-ζ)'] quinolin-l-yl)-4-(3-chloro-phenyl)-pyrrole-2, 5-dione, prepwered as in Example 15, was reduced by employing the method of Example 2, Procedure B, to yield (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinoIin-lyl)-4-(3-chlorophenyl)-pyrrolidine-2, 5-dione. ¾ NMR (DMSO-d6) 400 MHz δ: 11.66(s, lH), 7.13(d, 1H, J=8 Hz), 6.95-7.02(m, 5H), 6.78(t, 1H, J=7.6 Hz), 6.7(d, 1H, J=7.2 Hz), 4.84(d, 1H, J=9.2 Hz), 4.65(d, 2H, J=8.8 Hz), 3.9-4.03(m, 2H), 2.79(t, 2H, J=5.6 Hz), 1.97(m, 2H). 70 Example 56. Preparation of (+ -Phosphoric acid mono-rtrans-3- 5.6-dihydro-4H-pyrrolor3.2.1-f lquinolin-l-vD-4-ilH-indol-3-vn-2.5-dioxo-pyrrolidin-l-ylmethyl1 ester (±)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-/;] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (3.0 g, 8.13 mmol, prepared as in Example 2, Procedure C) and formaldehyde (30 ml, 37% in water) in tetrahydrofuran (30 ml) were stirred for 14-16 hours at room temperature. The mixture was then taken up in ethyl acetate (50 ml) and water (50 ml). The organic layer was washed with brine and dried over sodium sulfate. Solvent was removed under reduced pressure and residue was purified using a silica gel chromatography column eluted with EtOAc/Hexane 1:1 to yield 2.5 g, 77%, of (±)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,l-i) quinolm^ pyrrolidine-2,5-dione an orange foamy solid (2.5 g, 77%).
(+)-Trans-3 -(5 ,6-Dihy dro-4H-pyrro lo [3 ,2, l-ij] quinolin- 1 -y 1)- 1 -hydroxymethy l-4-( lH-indol-3 -yl)-pyrrolidine-2,5-dione (0.06 g) in anhydrous tetrahydrofuran (5 ml) was treated with dibenzylphosphoramidate (0.156 ml, 3.5 equivalents) followed by the addition of tetrazole (3% solution in acetonitrile, 2 ml). The reaction mixture was stirred at room temperature for 20 min and cooled to -78° C. A solution of m-chloroperbenzoic acid (70%, 0.162 g) in dichloromethane (2 ml) was added at -78° C. After 5 min at -78° C, the reaction was brought to room temperature and stirred for 5 min. Solvents were removed under reduced pressure and the residue was purified by flash chromatography on a silica column, eluted with ethyl acetate, hexane to give phosphoric acid diben2yl ester trans-3-(5,6-dihydro-4H-pyrrolo[3,2,l-zy]quinolin-l-yI)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin- 71 1-ylmetbyl ester as a solid (70 mg). !H NMR (DMSO-d6) 400 MHz δ: 11.10 (s, 1H), 7.32-7.39 (m, 12H), 6.84-7.24 (m, 2H), 5.49 (brs, 2H), 5.03 (m, 4H), 4.61(dd, 2H), 4.06 (brs, 2H), 2.87(brs, 2H), 2.07(brs, 2H).
The phosphoric acid dibenzyl ester of (+)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,l-zy]quinolin-l-yl)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-l-yl-methyl ester (0.160 g) in methanol (2 ml) and Pd/C (10%, 20 mg) was stirred at room temperature under 1 atmosphere of hydrogen for two hours. The mixture was filtered over Celite and the solvent removed to give (i)-phosphoric acid mono-[trans-3-(5,6-dihydro-4H-pyn lo[3,2,l-y]qumolin-l-^^ ester (0.110 g).
Example 57. Preparation of (+Vtrans-2-Amino-propionic acid-3-(5,6-dihvdro-4H-pyrrolof3.2.1-zY1qumolin-l-vn-4-riH-indol-3-vn-2.5-dioxo-pyrrolidin-l-yl methyl ester To a solution of (±)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,l-/ ]quinolin-l-yl)-l-hydroxymeth3d-4-(lH-indol-3-yl)-pyrrolidine-2,5-dione (0.5 mmol) in tetrahydrofuran (8 ml) was added N-carbobenzyloxy alanine (1.1 equivalents) followed by the addition of HBTU (1.5 equivalents) and DIPEA (2.2 equivalents). The mixture was stirred at room temperature for 15h. The solvents were 72 removed under reduced pressure and the residue was taken up in ethyl acetate and water (1 :1, 15 ml). The organic layer was separated and dried. The residue was purified by silica gel chromatography to provide the N-carbobenzyloxy protected product.
A solution of the N-carbobenzyloxy protected product from Step 1 (0.5 mmol) in methanol (8 ml) and a few drops of 4 M HC1 in ethyl acetate and 10% Pd/C (10% w/w) were stirred at room temperature under 1 atmosphere of hydrogen for 2 hours. The mixture was then filtered over celite and the solvent removed to provide final product (±)-trans-2 -amino-propionic acid-3-(5,6-dihydro-4H-pyrrolo[352,l-z;]quinolin-l-yl)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-l-ylmethyl ester. !H NMR (DMSO-de) 400 MHz δ: 11.10 (s, lH), 8.57(s, 2H), 6.84-7.41(m, 9H), 5.61 (m, 2H), 4.62(dd, 2H), 4.07 (brs, 2H), 3,72 (brm, 1H), 2.87(brs, 2H), 2.23 (s, 6H), 2.08(brs, 2H), 1.40 (d, J = 6.4 Hz, 3H).
Example 58. Preparation of (+Vtrans-2-Amino-acetic acid-3-('5.6-dihvdro-4H-pyrrolor3.2.1-z'/1qumolin- 1 -yl)-4-( 1 H-indol-3 -yl -2.5-dioxo-pyrrolidin- 1 -y 1 methyl ester (±)-trans-2-Amino-acetic acid-3-(5,6-dihydro-4H-pyrrolo[352,l-z)]quinolin-l-yl)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-l-ylmetbyl ester was prepared as in Example 57 by replacing N-carbobenzyloxy alanine with N-carbobenzyloxy glycine. !H NMR (DMSO-d6) 400 MHz δ: 11.19 (s, lH), 8.46 (s, 2H), 6.82-7.43(m, 9H), 5.61 (s, 2H), 4.65(dd, 2H), 4.08 (brt, J = 5.6 Hz, 2H), 3.88 (brs, 2H), 2.87(t, J = 5.6 Hz, 2H), 2.48 (s, 2H), 2.08(t, J = 4.8 Hz, 2H).
Example 59. Preparation of (+)-trans-2-dimethylamino-acetic acid-3-(5.6-dihydro-4H-pyrrolo 3,2,l-z/lquinolin-l -ylV4-f lH-indol-3-yiy2,5-dioxo-pyrrolidm-l -ylmethyl ester.
To a solution of (±)-trans-3-(5,6-Dihydro-4H-pyrrolo[3,2,l-zy]quinolin-l-yI)-l-hydroxymethyl-4-(lH-indol-3-yl)-pyrrolidine-2,5-dione (0.5 mmol) in tetrahydrofuran ( 8 ml) was added N,N- dimethylglycine (1.1 equivalents) followed by the addition of HBTU (1.5 equivalents) and DIPEA (N,N-diisopropylethylamine, 2.2 equivalents). The mixture was stirred at room temperature for 15 hours. The solvents were removed under reduced pressure and the residue was taken up in ethyl acetate and water (1 :1, 15 ml). The organic layer was separated and dried to yield a residue. The 73 residue was purified by chromatography on a silica gel column eluted with ethyl acetate hexanes to yield (±)-trans-2-dimethylamino-acetic acid-3-(5,6-dihydro-4H-pyrrolo[3,2,l-z ]quinolin-l-yl)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-l-yl methyl ester. ¾ NMR (DMSO-d6) 400 MHz δ: 11.10 (s, IH), 6.82-7.41(m, 9H), 5.70 (m, 2H), 4.62(dd, 2H), 4.07 (brs, 2H), 3.23 (s, 2H), 2.87(brs, 2H), 2.23 (s, 6H), 2.08(brs, 2H).
Example 60. Preparation of f+Vtrans-Isonicotinic acid-3-("5,6-dihvdro-4H-pyrrolo[3.2.1-f lquinolin-l-vn-4-(lH-indol-3-ylV2.5-dioxo-pyrrolidin-l-ylmethyl ester (+)-trans-Isonicotinic acid 3 -(5 ,6-dihydro-4H-pyrrolo [3 ,2, 1 -ij] quinolin- 1 -y l)-4-( 1 H-indol-3 -yI)-2,5-dioxo-pyrrolidin-l-yImethyl ester was prepared as in Example 59 by replacing N,N-dimethylglycine with 4-carboxypyridine. !H MR (DMSO-d6) 400 MHz δ: 11.19 (s, IH), 8.83 (d, 2H), 7.83 (d, 2H), 6.83-7.42 (m, 9H), 5.88 (s, 2H), 4.65(dd, 2H), 4.05 (brt, 2H), 2.86(brs, 2H), 2.08(brs, 2H).
Example 61. Preparation of 3-f5,6-dihvdro-4H-pyrrolo [3,2,1-771 quinolin-l-ylV4(l-methylindol-3-yl)-l-methyl pyrrole-2. 5-dione and f+)-cis-3-f5.6-dihydro-4H-pyrrolo [3.2.1-z71 quinolin-l-yl fl-methylindol-3-yl -l -methyl pyrrolidine-2, 5-dione.
Step 1: To a solution of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-z*/] quinolin-l-yl)-4(lH-indol-3-yl) pyrrole-2, 5-dione (100 mg, see Example 1) in anhydrous dimethylformamide (5 ml) was added potassium carbonate (0.5 g) and methyl iodide (0.1 ml). The mixture was stirred at room temperature for 48 hours then poured into ethyl acetate (100 ml), washed with water (100 ml), dried over anhydrous sodium sulfate and evaporated to give 3-(5,6-dihydro-4H-pyrrolo [3,2, 1-z)'] quinolin- l-yl)-4(l -methylindol-3-yl)-l-methyl pyrrole-2, 5-dione as a red solid (93 mg).
Step 2: To a solution of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-?;] quinolin- l-yl) (l-methylindol-3-yl)-l -methyl pyrrole-2, 5-dione (93 mg) in methanol (5 ml) and ethylacetate (5 ml) was added 10% Pd-C (50 mg) and the mixture stirred at room temperature under 1 atmosphere of hydrogen for 48 hours. Toluene (50 ml) was added and the mixture again stirred at room temperature under 1 atmosphere of hydrogen for 2 hours. The mixture was then filtered through a pad of celite and evaporated to dryness to yield a residue. The residue was purified using silica gel chromatography eluting with 35-40% ethylacetate in hexanes to give (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl)-4(l-methylindol-3-yl)-l -methyl pyrrolidine-2, 5-dione as a pale yellow solid (53 mg). !H NMR (CDCI3) 400 MHz δ: 7.23 (s, IH), 7.05-7.07 (m, 2H), 7.01 (d, IH, J=7.2 Hz), 6.92-6.97 (m, IH), 6.85 (t, IH, J=7.2 Hz), 6.74 (d, IH, J=6.8 Hz), 6.64 (d, 2H, J=6.4 Hz), 4.78 (m, 2H), 3.75-3.84 (m, 2H), 3.45 (s, 3H), 3.27 (s, 3H), 2.79 (t, 2H, J=5.6 Hz), 1.98 (m, 2H). 74 Example 62. Preparation of flVTrans-S-fS^-dihvdro^H-pyrrolo Γ3.2.1-ζΤ| qu olin-l-ylV4(!H-indol-3-vD pyrrolidine-2. 5-dione (±)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione may be prepared by reacting lH-indole and 3, 4-dibromo-l-phenyl-pyrrole-2, 5-dione in the presence of methyl magnesium bromide to yield 3-bromo-4-(lH-indol-3-yl)-l-phenyl-pyrrole-2,5-dione. The 3-bromo-4-(lH-indol-3-yl)-l-phenyl-pyrrole-2,5-dione is subsequently reacted with 5,6-dihydro-4H-pyrrolo[3,2,l-z ]quinoline and LiHMDS (lithium hexamethyldisilane) in toluene or (5,6-dihydro-4H-pyrrolo[3,2,l-z ]quinolin-l-yl)-boranediol and Pd(PPh3)4 (tetrakis(triphenylphosphine)palladium) to yield 3-(5,6-dihydro-4H-pyrrolo[3,2,l-z ]quinolin-l-yl)-4-(lH-indol-3-yl)-l-phenyl-pyrrole-2,5-dione, which is reduced and deprotected by treatment with Mg in methanol, as in Example 2 procedure C, followed by catalytic hydrogenation over palladium on carbon to yield (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione. Bnz is benzyl.
Example 63. Preparation of ±VTrans-3-C5.6-dihvdro-4H-pyrrolo Γ3.2.1-//1 quinolin-l-yl)-4 iH-indol-3-vD pyrrolidine-2. 5-dione (+)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione may be prepared by reacting l-aIIyI-7-bromo-lH-indole with (COCI)2 (oxalyl chloride) and sodium methoxide in a polar aprotic solvent such as dichloromethane to yield (l-allyl-7-bromo-lH- 75 indol-3-yl)-oxo-acetic acid methyl ester, which is subsequently reacted with 2-(lH-indol-3-yl)-acetamide and tBuOK (potassium tert-butoxide) in THF to yield 3-(l-allyl-7-bromo-lH-indol-3-yl)-4-(lH-indol-3-yl)-pyrrole-2,5-dione. Reduction of the 3-(l-allyl-7-bromo-lH-indol-3-yl)-4-(lH-indol-3-yl)-pyrrole-2,5-dione by Mg in refluxing methanol, as in Example 2 procedure C, yields 3-(l-allyl-7-bromo-lH-indol-3-yl)-4-(lH-indol-3-yl)-pyrrolidine-2,5-dione, which is treated with 9-BBN (9-borabicyclo[3.3.1]nonane)and Pd(PPh3)4 (tetrakis(triphenylphosphine)palladium) to yield (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione.
(COCi NaOMe CH2CI2 Example 64. Preparation of (+)-Cis-3-(5,6-dihvdro-4H-pyrrolo |"3.2.1-z' 1 quinolfa-l-ylV4f lH-indol-3--yl) pyrrolidine-2. 5-dione and f+VTrans-S-fS^-dihvdro^H-pyrrolo Γ3.2.1-//Ί quinolin-l-yl OH-indol-3-yl pyrrolidine-2. 5-dione The cis and trans isomers of 3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione may be prepared beginning with the reaction of (lH-indol-3-yl)-oxo-acetic acid methyl ester and (5,6-dihydro-4H-pyrrolo[3,2,l-z/]quinolin-l-yl)-acetic acid methyl ester in the presence of a base such as LDA (lithium diisopropylamide) in a polar aprotic solvent such as THF to 76 yield 2-(5,6-dihydro-4H-pyrrolo[352,l-z ]quinolin-l-yl)-3-(lH-indol-3-yl)-but-2-enedioic acid dimethyl ester. Alternatively, 2-(5 ,6-dihy dro-4H-pyrrolo [3 ,2, 1 -ij] quinolin- 1 -y l)-3 -( lH-indol-3 -yl)-but-2-enedioic acid dimethyl ester may be prepared by reaction of (lH-indol-3-yl)-acetic acid methyl ester and (5,6-dihydro-4H-pyrrolo[3,2,l-z)']quinolin-l-yI)-oxo-acetic acid methyl ester in the presence of a base (e.g., LDA) in THF. The 2-(5,6-dihydro-4H-pyrrolo [3,2,l-z ]quinolin-l-yl)-3-(lH-indol-3-yl)-but-2-enedioic acid dimethyl ester is reduced by catalytic hydrogenation over a noble metal catalyst (e.g., Pd on charcoal) to give 2-(5,6-dihydro-4H-pyrrolo[3,2,l-z)']quinolin-l-yl)-3-(lH-indol-3-yl)-succinic acid dimethyl ester, which is reacted with benzylamine (PhCH2NH2) to yield a mixture of cis and trans 3-(5,6-dihydro-4H-pyrrolo[3,2,l-y]quinolin-l-yl)-4-(lH-indol-3-yI)-l-phenyl-pyrrolidine-2,5-dione. The mixture of cis and trans isomers may be deprotected by catalytic hydrogenation over Pd on charcoal (Pd-C) to give rise to a mixture of cis and trans 3-(5,6-dihydro-4H-pyrrolo[3,2,l-zy]quinolm-l-yl)-4-(lH-indol-3-yl)-pyrrolidine-2,5-dione. The cis and trans isomers may be separated to give all four cis and trans isomers (e.g., by chromatography as in Examples 4 and 5). The deprotected mixture of cis and trans isomers may be treated with potassium tert-butoxide in tert-butanol (as in Example 3) or a mixture of THF and tert-butanol at 50° C to yield a mixture with a predominance of the trans isomers. Alternatively, the 2-(5,6-dihydro-4H-pyrrolo[3,2,l-zy]quinolin-l-yl)-3-(lH-indol-3-yl)-succinic acid dimethyl ester can be reacted with ammonia in methanol at elevated termperatures to yield predominatntly the cis isomers of 3-(5,6-dihydro-4H-pyrrolo[3,2,l-zj]qumolin-l-yl)-4-(lH-indol-3-yl)-pyrrolidine-2,5-dione, which may be isomerized to yield predominately the trans isomers of 3-(5,6-dihydro-4H-pyrrolo[3,2,l-zy]quinolin-l-yl)-4-(lH-indol-3-yl)-pyrrolidine-2,5-dione with potassium tert-butoxide in tert-butanol (as in Example 3) or a mixture of THF and tert-butanol at 50° C. 77 Example 65. Preparation of 3- 5.6-dihydro-4H-pyrrolo[3 ,2, 1 -iil quinolin- 1 -yD-4-(3-methoxyphenylV lH-pyrrole-2,5-dione To a mixture of 5, 6 -dihydro-4H-pyrrolo [3,2, 1-z)'] quinolin-l-yl) oxoacetic acid methyl ester (0.50 g, 2.05 mmol) and 2-(3-methoxyphenyl)acetamide (0.37 g, 2.26 mmol) in anhydrous tetrahydrofuran (5 mL) was added potassium rert-butoxide (1.0 M in tetrahydrofuran, 6.17 mL, 6.17 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 3 hours then concentrated hydrochloric acid (1.5 mL) was added at 0 °C. The resulting mixture was stirred for 1 hour, diluted with ethyl acetate (150 mL), washed with water (2x50 mL), dried over anhydrous sodium sulfate and concentrated to give 0.91 g of an orange solid. The residue was purified by column chromatography eluting with 20-40% ethyl acetate in hexane to give 3-(5,6-dihydro-4H-pyrrolo[3,2,l-ij]quinolin-l-yl)- 78 4-(3-methoxyphenyl)-lH-pyrrole-2,5-dione. Mp 99-101 °C; 'H NMR CCDCls) 400 MHz 5: 8.01 (s, 1 H), 7.81 (bs, 1 H), 7.20-7.25 (m, 1 H), 7.06-7.08 (m, 2 H), 6.85-6.91 (m, 2 H), 7.25 (t, 1 H), 6.13 (d, J = 8.0 Hz, 1 H), 4.24 (t, 2 H), 3.66 (s, 3 H), 2.97 (t, J = 6.0 Hz, 2 H), 2.22-2.26 (m, 2 H).
Example 66. Preparation of 3-[4-f benzyloxy phenyl]-4-f 5,6-d ydro-4H-pyrrolor3,2, 1 -iilquinolin-1 -vD-lH-pyrrole-2,5-dione. 3 -[4-(benzyloxy )phenyl] -4-(5 ,6-dihy dro-4H-pyrrolo [3 ,2, 1 -ij] quinolin- 1 -yl)- 1 H-pyrrole-2, 5 -dione was prepared according to Example 65, employing 2-(4-(benzyloxy)phenyl)acetamide in place of 2-(3-methoxyphenyl)acetamide. Mp 262-265 °C; H NMR (DMSO-d6) 400 MHz 8: 10.96 (s. 1 H), 8.01 (d, 1 H), 7.33-7.45 (m, 7 H), 6.99 (d, J= 6.8 Hz, 2 H), 6.83 (d, J= 7.2 Hz, 1 H), 6.63 (t, 1 H), 6.09 (d, J= 8.4 Hz, 1 H), 5.13 (s, 2 H), 4.27 (m, 2 H), 2.92 (m, 2 H), 2.15 (m, 2 H).
Example 67. Preparation of 3-f5,6-dihvdro-4H-pyrrolor3.2.1-i¾lquinolin-l-yl')-4-('4-fluorophenvn-lH-pyrroIe-2.5-dione. 3-(5,6-dmy
Example 68. Preparation of (+ -Trans-3-(5.6-dihvdro-4H-pyrrolo 3.2.1-ii1quinolin-l-yl')-4-(3-methoxyphenyl')pyrrolidine-2.5-dione.
A mixture of 3-(5,6-dihydro-4H-pyrrolo[3,2,l-ij]quinolin-l-yl)-4-(3-methoxyphenyl)-lH-pyrrole-2,5-dione (0.73 g, 2.04 mmol), magnesium (0.89 g, 36.7 mmol) in anhydrous methanol was heated to reflux for 1.5 h. After cooling to room temperature, the light yellow solution was diluted with ethyl acetate (200 mL), washed with 1.0 M hydrochloric acid (2x50 mL), water (100 mL), dried over sodium sulfate and concentrated to provide a light brown solid. The residue was purified by column chromatography on silica gel eluting with 40-50% ethyl acetate in hexane to yield (+)-trans-3--(5,6-dihydro-4H-pyrrolo[3,2,l-ij]quinolin-l-yl)-4-(3-methoxyphenyI)pyrrolidine-2,5-dione as a light yellow solid. Mp 87-91 °C; Ή NMR (CDC13) 400 MHz δ: 8.73 (s. 1 H), 7.25-7.30 (m, 1 H), 7.14 (d, J = 7.6 Hz, 1 H), 6.93-7.01 (m, 3 H), 6.77-6.86 (m, 3 H), 4.36 (d, J= 6.4 Hz, 1 H), 4.24 (d, J= 6.4 Hz, 1 H), 4.18 (t J= 5.5 Hz, 2 H), 3.78 (s, 3 H), 2.97 (t, J= 5.6 Hz, 2 H), 2.19-2.24 (m, 2 H). 79 Example 69. Preparation of r±VTrans-3-i5,6-dihvdro-4H-pyrroloi3.2.1-ii1quinolin-l-yl)-4-f3-hvdroxyphenyl pyrrolidine-2,5-dione.
To a solution of (±)-trans-3-(5,6-dihydro-4H-pyrrolo[352,l-ij]quinolin-l-yl)-4-(3-methoxyphenyl)pyrrolidine-2,5-dione in dichloromethane (10 mL) at -78° C under an atmosphere of nitrogen was slowly added boron tribromide (1.0 M in dichloromethane) (5.2 mL). The resulting mixture was stirred at -78° C for 30 minutes and at room temperature for 3 hours. The reaction mixture was cooled to -78° C then quenched by the addition of methanol (5 mL). The mixture was allowed to warm to room temperature and maintained at room temperature for 30 minutes. The reaction mixture was diluted with dichloromethane (80 mL), washed with saturated aqueous sodium bicarbonate (15 mL), water (15 mL) and saturated sodium chloride (15 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to dryness. The residue was purified by flash chromatography on silica gel eluting with ethyl acetate:hexane:dichloromethane (5:5:1, v/v) to give (±)-1rans-3-(5,6-dihydro-4H-pyrrolo[3,2,l-ij]quinolm-l-yl)-4-(3-hydroxyphenyl)pyrrolidine-2,5-dione as a brown solid (1.15 g, 63 %); Mp 108-110° C. IHNMR (CDC13) 400 MHz δ: 8.69 (s, 1H), 7.18 (t, 1H, J=8.0 Hz), 7.12 (d, 1H, J=8.0 Hz), 6.99 (d, 1H, J=6.8 Hz), 6.97 (d, 1H, J=2.0 Hz), 6.93 (d, 1H, J= 6.4 Hz), 6.76 (m, 1H), 6.69 (d, 1H, J=1.6 Hz), 5.67 (brs, IH), 4.32 (d, 1H, J=6.0 Hz), 4.20 (d, 1H, J=6.0 Hz), 4.07 (t, 2H, J=5.6 Hz), 2.96 (t, 2H, J=6.0 Hz), 2.19 (m, 2H), LC/MS: 347.3 [M+H].
Example 70. Preparation of f±)-Trans-3-(5.6-dihydro-4H-pyrrolo[3,2.1-ii]quinolin-l-yl)-4-f4-fluorophenyl)pyrrolidine-2.5-dione. 3-(5,6-dihydro-4H-pyrrolo[3,2,l-ij]quinolin-l-yl)-4-(4-fluorophenyl)-lH-pyrrole-2,5-dione prepared according to Example 67, was reduced by employing the method of Example 68 to yield (+)·· trans-3-(5,6-dihydro-4H-pyrrolo[3,2,l-ij]qumolm-l-yl)-4-(4-fluorophenyl)pyrrolidine-2,5-dione 1-ij]quinolin-l-yl)-4-(4-fluorophenyl)-lH-pyrrole-2,5-dione. Mp 208-210 °C; JH MR (DMSO-d6) 400 MHz δ: 11.52 (s. 1 H), 7.40-7.43 (m, 2 H), 7.32 (m, 1 H), 7.13-7.17 (m, 3 H), 6.82-6.89 (m, 2 H), 4.53 (m, 1 H), 4.36 (m, 1 H), 4.09 (t, J= 5.2 Hz, 2 H), 2.89 (t, J= 6.0 Hz, 2 H), 2.09-2.11 (m, 2 H).
Example 71. Preparation of (+)-Trans-3-|"4- benzyloxy)phenyl1-4-(5.6-dihydro-4H-pyrrolo 3.2.1-ii1quinolin-l-yl)pyrrolidine-2.5-dione 3 -[4-(benzy loxy)pheny 1] -4-(5 ,6-dihydro-4H-pyrrolo [3,2,1 -ij ]quinolin- 1 -y I)- 1 H-pyrrole-2, 5 -dione prepared according to Example 66, was reduced by employing the method of Example 68 to yield (±)-trans 3-[4-(benzyloxy)phenyl]-4-(5,6-dihydro-4H-pyrrolo[3,2,l-ij]quinolin-l-yl)pyrrolidine-2,5-dione. Mp 91-93 °C; Ή NMR (DMSO-d6) 400 MHz δ: 11.47 (s. 1 H), 7.25-7.43 (m, 8 H), 7.15 (d, J= 7.6 Hz, 2 H), 6.82-6.96 (m, 4 H), 5.07 (s, 2 H), 4.45 (d, J= 7.6 Hz, 1 H), 4.24 (d, J= 7.6 Hz, 1 H):, 4.07-4.10 (m, 2 H), 2.87-2.90 (m, 2 H), 2.09-2.10 (m, 2 H). 80 Example 72. Preparation of r+VTrans-3-r5.6-dihvdro-4H-pyrrolor3.2.1-ii1auinolin-l-ylV4-f4-hydroxyphenyDpyrrolidine-2.5-dione.
A mixture of (±)-trans-3-[4-(benzyloxy)phenyl]-4-(5,6-dmydro-4H-pyrrolo[3,2,l-ij]quinolin-l-yl)pyrrolidine-2,5-dione (0.2 g) and Pd/C (10% w/w, 0.076 g) was stirred under 1 atmosphere of hydrogen gas overnight. The catalyst was filtered off through a pad of celite and concentrated. The residue was purified by column chromatography on silica gel eluting with 30-40% ethyl acetate in hexane to provide (+) rans-3-(5,6-dihydro-4H-pyn,olo[3,2,l-ij]quinolin-l-yl)-4-(4-hydroxyphenyl)pyrrolidine-2,5-dione 0.07 g as a light yellow solid. Mp 105-107 °C; !H NMR (acetone-d6) 400 MHz δ: 10.27 (s. 1 H), 8.34 (s, 1 H), 7.17-7.21 (m, 4 H), 6.80-6.91 (m, 4 H), 4.39 (d, J= 7.0 Hz, 1 H), 4.22 (d, J= 7.0 Hz, 1 H), 4.13 (d, J= 5.6 Hz, 2 H), 2.92 (d, J= 5.2 Hz, 2 H), 2.15-2.19 (m, 2 H).
Example 73. Preparation of 7-r4- H-indol-3-ylV2.5-dioxo-2.5-dihvdro-lH-pyrrol-3-yl1-3.4-dihvdro-lH-[1.41diazepinor6,7J-/77lindole-2-carboxylic acid benzyl ester To a solution of 7-formyl indole (2.4 g, 16.6 mmol) in 1,2-dichloroethane (60 mL) was added aminoethanol (1.2 mL, 19.8 mmol) followed by glacial acetic acid (2.0 mL) and sodium triacetoxyborohydride (3.5 g, 16.6 mmol). The reaction mixture was allowed to stir at room temperature for 16 hours. The reaction mixture was quenched by addition of water (10 mL) and 1.0 sodium hydroxide (10 mL). The organic layer was then separated and the aqueous layer extracted with 1,2-dichloroethane (40 mL). The combined organic extracts were washed with saturated sodium bicarbonate (2 x 30 mL), water (2 x 50 mL), dried over anhydrous sodium sulfate and evaporated to dryness. 2-[(lH-indol-7-ylmethyl)-amino]-ethanol (4.4 g) was obtained as an oil LCMS (M+H) = 189. 81 Step 2 To a solution of 2-[(lH-indol-7-ylmethyl)-amino]-ethanol (4.4 g) in 1,2-dichloroethane (40 mL) was added triethylamine (4.85 mL, 34.6 mmol) followed by benzyl chloroformate (3.57 mL, 25.34 mmol). The mixture was allowed to stir at room temperature for 2 hours. The mixture was quenched by addition of water (20 mL), and 1.0 M sodium hydroxide (10 mL). The organic layer was separated and the aqueous layer extracted with 1,2-dichloroethane (20 mL). The combined organic extracts were washed with 1.0 M hydrochloric acid (20 mL), water (20 mL), dried over anhydrous sodium sulfate and evaporated to dryness. The residue was purified by silica gel chromatography, eluting with 20% ethyl acetate in hexanes to 40% ethyl acetate in hexanes to afford (2-hydroxy-ethyl)-(lH-indol-7-ylmethyl)-carbamic acid benzyl ester (2.79 g, 52% combined yield for two steps) as a colorless oil. l NMR (CDC13) 400 MHz δ: 9.97 (br s, IH), 7.75-6.9 (m, 8H), 6.54 (br s, IH), 5.21 (s;) 2H), 4.9-4.6 (m, 3H), 3.85-3.57 (m, 2H), 3.55-3.23 (m, 3H); LCMS M+H = 325.
Step3 To a solution of (2-hydroxy-ethyl)-(lH-indol-7-ylmethyl)-carbamic acid benzyl ester (2.79 g, 8.61 mmol) in dicliloromethane (50 mL) was added triethylamine (1.56 mL, 11.2 mmol). The mixture was cooled to 0 °C and methanesulfonyl chloride (0.74 mL, 9.47 mmol) added in a dropwise manner. The mixture was warmed to room temperature and allowed to stir for 2 hours. The mixture was then quenched with water (30 mL) and 1.0 M sodium hydroxide (10 mL). The organic layer was separated and the aqueous layer extracted with dichloromethane (20 mL). The combined extracts were washed with 1.0 M hydrochloric acid (20 mL), water (30 mL), dried over anhydrous sodium sulfate and evaporated to dryness. Methanesulfonic acid 2-[benzyloxycarbonyl-(lH-indol-7-ylmethyl)-amino]-ethyl ester (3.46 g) was obtained as an oil 82 Step 4 To a solution of methanesulfonic acid 2-[benzyloxycarbonyl-(lH-indol-7-ylmethyl)-amino]-ethyl ester (3.46 g, 8.61 mmol) in dimethylformamide (20 mL), which has been cooled to 0 °C was added sodium hydride (60%) in mineral oil. The reaction mixture was allowed to stir at 0 °C for 1 hour and then quenched by the addition of water (40 mL). The aqueous layer was extracted with ethyl acetate (4 x 20 mL). The combined organic extracts were washed with water (3 x 30 mL), dried over anhydrous sodium sulfate and evaporated to dryness. The residue was purified by silica gel chromatography, eluting with dichloromethane to afford 3,4-dihydro-lH-[l,4]dia2epino[6,7,l-/zz']indole-2-carboxylic acid benzyl ester (1.95 g, 74% combined yield for two steps) as a colorless oil. Ή NMR (CDCL3) 400 MHz δ: 7.6-7.45 (m, lH), 7.4-7.2 (m, 5H), 7.17-6.9 (m, 3H), 6.6-6.48 (m, 1H), 5.2-5.05 (m, 2H), 5.0-4.82 (m, 2H), 4.4-4.2 (m, 2H), 4.1-3.95 (m, 2H); LCMS (M+H) = 307.
To a solution of 3,4-dihydro-lH-[l,4]diazepino[6,7,l-/??']indole-2-carboxylic acid benzyl ester (557 mg, 1.8 mmol), in anhydrous tetrahydrofuran (10 ml) at 0°C, was added oxalyl chloride (238 μΐ, 2.7 mmol) followed by a further portion of oxalyl chloride (340 μΐ, 3.85 mmol). The mixture was stirred at 0° C until all the starting material has been consumed before being cooled to -78° C. Sodium methoxide in methanol (0.5M) (10 ml) was then added slowly and the mixture allowed to warm to room temperature. After 1 hour at room temperature the mixture was then diluted with ethyl acetate (200 ml) and washed with water (300 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was purified by silica gel chromatography, eluting with a ethyl acetate/hexanes (1 :1) to afford 7-methoxyoxalyl-3,4-dihydro-lH-[l,4]diazepino[6,7,l-/?z]indole-2-carboxylic acid benzyl ester as a pale yellow solid (481 mg, 67 %). ¾NMR (CDC13) 400 MHz δ: 83 8.26-8.36(m, 2H), 7.22-7.37(m, 6H), 7.10(dd, 1H, J=32.8 and 7.2 Hz), 5.1 l(d, 2H, J=8.0 Hz), 4.94(d, 2H, J=22.4 Hz), 4.41-4.48(m, 2H), 4.01-4.05(m, 2H), 3.93(m, 3H).
To a solution of 7-methoxyoxalyl-3,4-dmydro-lH-[l,4]diazepino[6,7,l-/7z']indole-2-carboxylic acid benzyl ester (481 mg, 1.22 mmol) and indole-3-acetamide (234 mg, 1.34 mmol) in anhydrous tetrahydrofuran (14 ml) at 0° C was added potassium t-butoxide (412 mg, 3.67 mmol). The mixture was stirred at 0° C for 2 hours. Concentrated hydrochloric acid (5 ml) was then added and the mixture stirred for 2 hours at room temperature. The mixture was then diluted with ethyl acetate (300 ml), washed with water (500 ml), and the organic layer dried over anhydrous sodium sulfate. The residue was purified by silica gel chromatography, eluting with a ethyl acetate/hexanes (1:1) to afford 7-[4-(lH-indoI-3-yl)-2,5-dioxo-2,5-dihydro-m-pyrrol-3-ylj-3,4-dmydro-m-[l,4]diazepino[6,7,l-/i ]indole-2-carboxylic acid benzyl ester as a bright orange/red solid (1.2 g, 80 %). ¾NMR (DMSO-d6) 400 MHz δ: 11.66(d, 1H, J=2.4 Hz), 10.94(s,lH), 7.69-7.75(m, 2H), 7.19-7.38(m, 6H), 6.98 (t, 1H, J=7.2 Hz), 6.73-6.89(m, 3H), 6.60-6.66(m, 2H), 4.90-5.08(m, 2H), 4.50(m, 2H), 3.95(m, 2H).
Example 74. Preparation of (+)-Trans-7-[4-(lH-indol-3-yl)-2.5-dioxo-pyrrolidin-3-vn-3,4-dihydro- Magnesium turnings (195 mg, 8.0 mmol) were added to a solution of 7-[4-(lH-indol-3-yl)-2,5-dioxo-2,5-dihydro-lH-pyrrol-3-yl]-3,4-dihydro-lH-[l,4]diazepino[6,7,l-/7z']indole-2-carboxylic acid benzyl ester (230 mg, 0.44 mmol) in anhydrous methanol (20 ml) and heated to reflux under an atmosphere of nitrogen for 1.5 hours. After cooling to room temperature the mixture was poured into ethyl acetate (200 ml) and washed with 1 M hydrochloric acid (100 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was then purified by silica gel 84 chromatography using 50-60% ethyl acetate in hexanes to yield (±)-trans-7-[4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-3 -yl]-3 ,4-dihydro- 1 H-[ 1 ,4]diazepino [6,7, 1 -fo]indole-2-carboxylic acid benzyl ester as an off white solid (205 mg). ]H MR (DMSO-d6) 400 MHz δ: 11.56(s, 1H), 11.03(d, 1H, J=2 Hz), 7.21-7.43(m, lOH), 7.09(t, 1H, J=7.2 Hz), 6.92-7.00(m, 2H), 6.82-6.89(m, 3H), 5.04(s, 2H), 4.87(d, 2H, J=7.6 Hz), 4.54(dd, 2H, J=7.6 and 28.8 Hz), 4.30(m, 2H), 3.92(m, 2H).
Example 75. Preparation of r+VTrans-3-(lH-indol-3-vn-4-ri.2.3.4-tetrahvdro-ri.41diazeDinor6.7.1- (±)-Trans-7-[4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-3-yl]-3,4-dihydro-lH-[l,4]diazepino[6,7,l-/«']indole-2-carboxylic acid benzyl ester (161 mg, 0.31 mmol) and 10% palladium on carbon (100 mg) in anhydrous methanol (15 ml) were stirred under 1 atmosphere of hydrogen for 16 hours. The catalyst was then filtered through a bed of Celite and the filtrate evaporated to dryness to yield (+)-trans-3-(lH-indol-3-yl)-4-(l,2,3,4-tetrahydro-[l,4]diazepino[6,7,l-/i/]indol-7-yl)-pyrrolidine-2,5-dione as an off white solid (95 mg). Ή NMR (DMSO-d6) 400 MHz δ: 11.04(d, 1H, J=1.6 Hz), 7.35-7.42(m, 4H), 7.24(dd, 1H, J=2.8 and 5.6 Hz), 7.09(t, 1H, J=7.2 Hz), 6.89-6.98(m, 3H), 4.52(dd, 2H, J=7.2 and 24.8 Hz), 4.11(s, 2H), 4.07-4.10(m, 2H), 3.14-3.17(m, 2H).
Example 76.
Cell viability was determined by measuring the activity of dehydrogenase enzymes in metabolically active cells using a tetrazolium compound, MTS. The assay was performed as described in Promega Technical Bulletin No. 1 9 (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay). Thirteen human cancer cell lines were assayed {see, e.g., Table 1). Cells were maintained at 37° C, 5% C02. Adherent cells were maintained DMEM media (4.5 g/L glucose) supplemented with 15% heat-inactivated FBS, 10 mM L-glutamine, and 10 mM Hepes pH 7.5. Suspension cells were maintained in RPMI 1640 media, supplemented with 10% heat-inactivated FBS and 10 mM Hepes pH 7.5. Briefly, cells were seeded in 96-well plates as set forth in Table 1 and incubated for 16-24 hours. Candidate compounds were serially diluted in DMSO, further diluted in cell culture media, and then added to cells (final DMSO concentration of 0.33%). Cells were incubated in the presence of candidate compound for 72 hours. MTS stock solution (MTS 2 gm/L, PMS 46.6 mg/ml in PBS) was added to the cells (final concentration MTS 2 gm/L and PMS 7.67 mg/L) and incubated for 4 hours. SDS was added to a final concentration of 1.4% and absorbance at 490 nM was measured within two 85 hours using a platereader. The IC50 was defined as the concentration of compound that results in a 50% reduction in the number of viable cells as compwered to control wells treated with DMSO only (0.33%) and was calculated using non-linear regression analyswas. IC50 values were given in Table 2 for the compounds listed.
Table 1 86 . .
Table 2 Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- NCI- Number 145 Η69 116 MB- H446 231 (±)-Cis-3-(5,6-dihydro-4H-pyrrolo 2 2.89 4.04 [3,2,1- ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H- 2, 3 10.7 9.61 1.82 4.55 0.424 >100 3.34 pyrrolo [3,2,1- ] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione 3(R),4(S)-3-(5,6-Dihydro-4H- 4 1.85 5.5 3.69 1.27 pyrrolo [3,2,1-y] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (faster eluting peak in supercritical chromatography) Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- NC Number 145 Η69 116 MB- H4 231 3(S),4(R)-3-(5,6-Dihydro-4H- 4 2.07 9.71 5.17 1.4 pyrrolo [3,2,1-y] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (slower eluting peak in supercritical chromatography) (-)-Trans-3-(5,6-dihydro-4H- 5 5.8 4 1.04 0.812 1.95 0.294 >100 2.19 0.5 pyrrolo [3,2,1- /] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (faster eluting peak in supercritical chromatography) (+)-Trans-3-(5,6-dihydro-4H- 5 27.9 10.5 14.4 30.13 4.52 >100 26.83 8.5 pyrrolo [3,2,1-//] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (slower eluting peak in supercritical chromatography) Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- N Number 145 Η69 116 MB- H4 231 3-(5,6-Dihydro-4H-pyrrolo [3,2,1- 12 66.5 81.6 y] quinolin- 1 -yl)-4-phenyl-pyrrole-2, 5-dione 3-Benzo[b]thiophen-2-yl-4-(5,6- 13 >100 78.8 dihydro-4H-pyrrolo [3,2, l-ij] quinolin- l-yl)-pyrrole-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1- 14 71.6 98.2 ij] quinolin- l-yl)-— (3 -phenoxy-phenyl)-pyrrole-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1- 15 75.8 43.6 ij] quinolin- l-yl)-4— (3 -chloro-phenyl)-pyrrole-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1- 16 40.9 21.5 ij] quinolin- l-yl)-4-(2-chloro-phenyl)-pyrrole-2, 5-dione Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- N Number 145 Η69 116 MB- H4 231 3-(5,6-Dihydro-4H-pyrrolo [3,2,1- 22 >100 59.4 ij] quinolin- l-yl)-4-indol-l-yl-pyrroIe-2, 5-dione 3-(5,6-Dihydro-4H-pyrrolo [3,2,1- 23 76.8 28.7 if] quinolin- 1 -y l)-4~pyridine-3 -yl-pyrrole-2, 5-dione 3-(4-Benzoyloxy-phenyl)-4-(5,6- 29 >100 >100 di ydro-4H-pyrrolo [3,2,1-i ] quinolin- l-yl)-pyrrole-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H- 37 37.4 43.4 pyrrolo [3,2,1-zy] quinolin- lyl)-4-(5-(l-naphthyl)-lH-indol-3-yl) pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H- 38 10.6 13.1 pyrrolo [3,2,1-//] quinolin-lyl)-4-(5-(4-raethoxyphenyl)-lH-indol-3-yl) pyrrolidine-2, 5-dione Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- NC Number 145 Η69 116 MB- H4 231 (±)-Trans-3-(5,6-dihydro-4H- 39 10.5 11.2 pyrrolo [3,2, l-ij] quinolin-lyl)-4-(5-(3-methyIphenyl)-lH-indoI-3-yl) pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H- 40 10.5 10.7 pyrrolo [3,2,1-/ ] quinolin-lyl)-4-(2-chloro-4-fluorophenyl) pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro4H- 41 4.65 7.63 pyrrolo [3,2,1- ] quinolin-lyl)-4-(2,6-dichlorophenyl) pyrrolidine-2, -dione (±)-Trans-3-(5,6-dihydro-4H- 42 44.1 49.6 pyrrolo [3,2,1-//] quinolin-lyl)-4-(4-bromophenyl) pyrrolidine-2, 5-dione Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- NC Number 145 Η69 116 MB- H4 231 (±)-Trans-3-(5,6-dihydro-4H- 43 48.7 54.5 pyrrolo [3,2,1-y] quinolin-lyl)-4-(4-chlorophenyl) pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H- 44 12.5 14.1 pyrrolo [3,2,1-y] quinolin-lyl)-4-(4-trifluoromethoxyphenyl) pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H- 45 27.6 42.7 pyrrolo [3,2,1-y] quinolin-lyl)-4-(thiophen-3-yl) pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H- 46 4.76 >100 pyrrolo [3,2,1-//] quinolin-lyl)-4-(2-fluorophenyl) pyrrolidine-2, 5-dione Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- N Number 145 Η69 116 MB- H4 231 (±)-Trans-3-(5,6-dihydro-4H- 47 4.45 18.3 19.87 9. pyrrolo [3,2,1-y] quinolin-lyl)-4-(2-thiophen-2-yl) pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H- 48 8.39 14.8 pyrrolo [3,2,1-zy] quinolin-lyl)-4-(2,4-dichlorophenyl) pyrrolidine-2, -dione (±)-Trans-3-(5,6-dihydro-4H- 49 14.6 12 pyrrolo [3,2,1-zy] quinolin-lyl)-4-phenyl-pyrrolidine-2, 5-dione (±)-Trans-3-(5,6-dihydro-4H- 50 5.41 8.51 4.56 4. pyrrolo [3,2,1-/7] quinoIin-lyl)-4-(2-chlorophenyl)-pyrrolidine-2, 5-dione Compound Example A549 DU- NCI- HCT- HT29 562 MCF7 MDA- NC Number 145 Η69 116 MB- H4 231 (±)-Trans-3-(5,6-dihydro-4H- 51 37.7 66.75 67.3 65. pyrrolo [3,2,1-//] quinolin-lyl)-4-(N-methylindol-3-yl) pyrrolidine-2, -dione (±)-Cis-3-(5,6-dihydro-4H-pyrrolo 53 >100 >100 >100 >100 36.3 >100 >100 [3,2,1-//·] quinolin-lyl)-4-(2,5-dimethoxyphenyl)-pyrrolidine-2, 5-dione (±)-Cis-3-(5,6-dihydro-4H-pyrrolo 54 22.1 21.1 7.63 8.78 3.37 >100 9.3 [3,2,1-//] quinolin-lyl)-4-(2-chloro-4-fluoro-phenyl)-pyrrolidine-2, 5-dione (±)-Cis-3-(5,6-di ydro-4H-pyrrolo 55 13.1 35.7 12.1 13.1 3.47 >100 15.54 [3,2,1-zy] quinolin-lyl)-4-(3-chlorophenyl)-pyrrolidine-2, 5-dione Docket No.: AQOlllPCT/16887.142 Compouad Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- Number 145 Η69 116 MB- 231 Phosphoric acid dibenzyl ester 56 22.6 >100 trans-3-(5,6-dihydro-4H-pyrrolo[3,2, 1 -z/Jquinolin-1 -yl)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-l-ylmethyl ester (±)-Phosphoric acid mono-[trans-3- 56 4.45 5.89 (5,6-dihydro-4H-pyrrolo[3,2,l-zj'jquinolin- 1 -yl)-4-( lH-indol-3 -yl)-2,5-dioxo-pyrrolidin- l-ylmethyl] ester (±)-trans-2-Amino-propionic acid - 57 2.9 3.14 3-(5,6-dihydro-4H-pyrrolo[3,2, 1-zy]quinolin- 1 -yl)-4-( lH-indol-3 -yl)-2,5-dioxo-pyrrolidin-l-yl methyl ester Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- NC Number 145 He 116 MB- H44 231 (±)-trans-Amino-acetic acid-3-(5,6- 58 2.77 3.45 dihydro-4H-pyrrolo[3,2, 1-z7]qumolk-l-yl)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-l-yl methyl ester (±)-trans-dimethylarnino-acetic 59 3.74 4.47 acid-3-(5,6-dihydro-4H-pyrrolo[3,2,l-z']quinolin-l-yl)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin-1 -ylmethyl ester (±)-trans-Isonicotinic acid-3-(5,6- 60 3.59 3.55 dihydro-4H-pyrrolo[3,2, 1 -i ]quinolin-l-yl)-4-(lH-indol-3-yl)-2,5-dioxo-pyrrolidin- 1 -ylmethyl ester Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- NC Number 145 He 116 MB- H44 231 (±)-cis-3-(5,6-dihydro-4H-pyrrolo 61 78.9 >100 96.2 >100 18.7 >100 >100 [3,2,1-zy] quinolin-l-yl)-4(l-methylindol-3-yl)-l -methyl pyrrolidine-2, 5-dione Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- NC Number 145 H69 116 MB- H4 231 (+)-Trans-3-(5,6-dihydro-4H- 69 55.4 65.9 pyrrolo[3,2, l-ij]quinolin-l -yl)-4-(3-hydroxyphenyl)pyrrolidine-2,5-dione (+)-Trans-3-(5,6-dihydro-4H- 70 26.2 49.2 pyrrolo[3,2,l-ij]quinolin-l-yl)-4-(4-fluorophenyl)pyrrolidine-2,5-dione (±)-Trans-3-[4- 71 48.7 97.5 (benzyloxy)phenyI]-4-(5,6-dihydro-4H-pyrrolo[3,2,l-ij]quinolin-l-yl)pyrrolidine-2,5-dione (±)-Trans-3-(5,6-dihydro-4H- 72 >100 >100 pyrrolo[3,2,l -ij]quinolin-l -yl)-4-(4-hydroxyphenyl)pyrrolidine-2,5-dione Compound Example A549 DU- NCI- HCT- HT29 K562 MCF7 MDA- NC Number 145 H69 116 MB- H4 231 7-[4-(lH-indol-3-yl)-2,5-dioxo- 73 >100 >100 2,5-dihydro-lH-pyrrol-3-yl]-3,4-dihydro-lH-[l,4]diazepino[6,7, 1-&z]indole-2-carboxylic acid benzyl ester (+)-Trans-7-[4-(lH-indol-3-yl 74 90.7 >100 2,5-dioxo-pyrrolidin-3-yl]-3,4-dihydro- lH-[l,4]diazepino[6,7, 1-A/]indole-2-carboxylic acid benzyl ester (+)-Trans-3-(lH-indol-3-yl)-4- 75 >10C >100 (1,2,3,4-tetrahydro-[l,4]diazepino[6,7,l- 2z']indol-7-yl) pyrrolidine-2,5-dione Example 77.
Exponentially growing MDA-MB-231 cells or Paca-2 cells were seeded at 1,000 cells per well in six-well plates and allowed to attach for 24 hours. MDA-MB-231 and Paca-2 cells were cultured in DMEM supplemented with 10% (v/v) fetal calf serum (FCS) and 5 ml Penicillin/Streptomycin at 37°C in 5% C02. MDA-MB-231 and Paca-2 were established estrogen receptor negative human breast cancer and pancreatic carcinoma cell lines, respectively. (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zyJ quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione were each dissolved at a concentration of 10 mM in DMSO, and separately added to cells at a concentration of 0.1, 0.25, 0.5, 1 or 2 μΜ. Control plates received DMSO alone, at the same percentage of total culture volume as that administered in conjunction with the highest concentration of drug. Cell cultures were observed daily for 10-15 days, then fixed and stained with modified Wright-Giemsa stain (Sigma). Treatment with (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-lyl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione or (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione results in cell death of MDA-MB-231 cells or Paca-2 cells. See, e.g., Figure 2. The ICS0 for (+)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-/ ] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione was found to be 0.5 μΜ. The IC50 for (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione was found to be 0.5 μΜ.
Example 78.
MDA-MB-231 cells (ATCC# ΗΤΒ-26), grown in DMEM plus 15% heat inactivated fetal bovine serum plus 10 mM HEPES pH 7.5, were plated in 60 mm plates (2 x 105 cells per plate). After two days candidate compounds in DMSO at various concentrations were diluted in media and added to individual plates such that the final DMSO concentration in the cell culture media was 0.1%. After two days incubation the culture was trypsinized, cells were washed with media, counted using a hemocytometer and 500 cells, including cell bodies, were plated in 100 mM plates in media. Two weeks later the media was removed and the cell colonies were fixed with methanol for 10 minutes, stained with 1% crystal violet 10 minutes, washed with water and airdried. Cell colonies were visually counted when there were greater then 50 cells present per colony. Plating efficiency was defined as the average number of colonies formed divided by 500. The surviving fraction was defined as the plating efficiency of a candidate compound divided by the plating efficiency of DMSO multiplied by 100. For candidate compound titrations, the IC50 concentration was determined by fitting the equation y=AeBx to the data points and extrapolating the concentration where surviving fraction equaled 50. Treatment with (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indoI-3-yl) pyrrolidine-2, 5-dione or (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione results in cell death of MDA-MB-231 cells. See, e.g., Figure 3. The IC50 for (-)-trans-3-(5,6-dihydro-4H- 103 pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione was found to be 0.62 μΜ. The IC50 for (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione was found to be 4.1 μΜ.
Example 79.
Recombinant Protein Kinase C (Calbiochem) (100 ng) was incubated with (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione at 0.05, 0.5, or 10 μΜ for 15 minutes at room temperature. Subsequently, a radioactive labeling mix in kinase buffer (20 mM Tris-HCl pH 7.5, 10 mM MgCl2) containing 20 μΜ ATP, 0.2 μθ/μΐ γ32Ρ-ATP, 0.2μ§/μ1 Histone HI (Upstate) was added to each sample. The kinase reaction was carried out for 5 minutes at room temperature. Reaction products were analyzed by 12% SDS-PAGE and autoradiography.
Treatment of recombinant Protein Kinase C for 15 minutes at room temperature with (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione at the tested concentrations did not reduce kinase activity in comparison to treatment with carrier alone. See, e.g., Figure 4.
Example 80.
MDA-MB-231 cells were serum-deprived overnight (16 hours) in the absence or in the presence of the indicated concentrations of the separate enantiomers (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione and (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione. Cells were treated with 100 ng/ml recombinant human Hepatocyte Growth Factor/Scatter Factor (HGF/SF) (R&D Systems #294-HG) for 10 minutes. Whole cell extracts were prepared in lysis buffer (20 mM Trwas-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3V04, 1 μg ml leupeptin, 1 mM phenylmethylsulfonyl fluoride) and sonicated. Protein concentration was measured by Bradford assay using the BioRad reagent (BioRad, Hercules, CA), according to the manufacturer's directions. Samples (50 μg of protein) were resolved by 8% SDS-PAGE under reducing conditions, and transferred onto a PVDF membrane (BioRad). The membrane was incubated 1 hour in TBS-T (50 mM Trwas-HCl pH 7.6, 200 mM aCl, 0.05% Tween 20) with 5% milk. Proteins were detected by incubation overnight at 4°C in TBS-T with 5% milk and either a polyclonal antibody against phosphorylated c-Met (#3121), phosphorylated Erkl/2 (#9101), total Erkl/2 protein (#9102) (Cell Signaling Technology); or a monoclonal antibody against β-actin (A-5441) (Sigma), which was used as a control for total protein loading. After extensive washing in TBS-T, a horseradish peroxidase-conjugated anti-rabbit IgG (1 :5000) or anti-mouse IgG (1 :2000) 104 (Amersham Biosciences) was added for 1 hour, and specific protein bands visualized using an enhanced chemiluminescence detection system (Amersham Biosciences), according to the manufacturer's instructions. See, e.g., Figure 5.
Treatment with (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione inhibits both basal and HGF-induced autophosphorylation of c-Met at a concentration of at least 500 nM. (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-z/] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione has a partial inhibitory effect on c-Met phosphorylation at greater concentrations (10 to 20 μΜ). Additionally, (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zj] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione decreases the phosphorylation of ERK1/2; a well-known downstream target in the signaling of the c-Met tyrosine kinase receptor. See, e.g., Figure 5.
Example 81.
Athymic female nude mice (CRL: U/NU-7ZMBR) were injected subcutaneously in the flank with MDA-MB-231 human breast cancer cells (8 x 10s cells/mouse). Prior to injection, MDA-MB-231 cells were cultured in DMEM (Invitrogen #11965-092) supplemented with 10% (v/v) heat inactivated fetal bovine serum (FBS), 1% Hepes buffer solution (Invitrogen #15630-080) and 1% Penicillin/Streptomycin (Invitrogen #15140-122) at 37°C in 5% C02. Tumors were allowed to grow to approximately 50 mm3 in size. Animals were randomized into three groups of five animals per group. At day ten post injection, mice with established tumors were treated intraperitoneally with (+)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (160 mg/kg), (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-zy] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (160 mg/kg) administered in iodinated poppy seed oil (lipiodol) as the vehicle at 10 mg/ml, or vehicle control. Drug or vehicle was administered every three days for a total of ten doses (q3dxl0). Tumor size was evaluated periodically during the study. For each subject, tumor volume was calculated using the formula (L x W2)/2 where L and W were the length and width of the tumor, respectively. The arithmetic mean tumor volume was calculated for each treatment group +/- standard error of the mean (SEM). The means for each group were normalized with respect to the mean starting tumor volume in order to determine fold increase in tumor volume. See, e.g., Figure 6.
Treatment with (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-y'] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione at 160 mg/kg reduced the normalized mean tumor volume of human breast cancer xenograft by 80.5% (p = 0.0037) and 43.5% (p = 0.133), respectively, compared to vehicle treated control. See, e.g., Fig. 6. 105 Example 82.
Athymic female nude mice (C L: U/NU-?ZMBR) were injected subcutaneously in the flank with MDA-MB-231 human breast cancer cells (8 x 106 cells/mouse). Prior to injection, MDA-MB-231 cells were cultured in DMEM (Invitrogen #11965-092) supplemented with 10% (v/v) heat inactivated fetal bovine serum (FBS), 1% Hepes buffer solution (Invitrogen #15630-080) and 1% Penicillin/Streptomycin (Invitrogen #15140-122) at 37°C in 5% C02. Tumors were allowed to grow to approximately 50 mm3 in size. Animals were randomized into three groups of eight animals per group. At day four post injection, mice with established tumors were treated intraperitoneally with (±)-Cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (80 mg kg), (±)-Trans-3-(5,6-dihydro-4H-pyrrolo [3,2, 1-y] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione (80 mg kg) administered in DMA/PEG 400 (1 :4 v/v) as the vehicle at 50 mg/ml, or vehicle control intraperitoneally. Drug or vehicle was administered once per day for five consecutive days followed by two consecutive days of no treatment (one cycle of dose administration). A total of four cycles of treatment were administered. Tumor size was evaluated periodically during the study. For each subject, tumor volume was calculated using the formula (L x W2)/2 where L and W were the length and width of the tumor, respectively. The arithmetic mean tumor volume was calculated for each treatment group +/- standard error of the mean (SEM). Each data point in Figure 6 represents the arithmetic mean +/- standard error of the mean (SEM) of eight tumors.
Treatment with (±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1- ] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or (±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione at 80 mg/kg reduced the mean tumor volume of human breast cancer xenograft by 73.4% (p = 0.04) and 69.4% (p = 0. 075), respectively, compared to vehicle treated control.. See, e.g., Fig. 7. 106 Example 83. C-Vtrans-3-(5,6-dihvdro-4H-pyrrolo f3.2.1-ii1 guinolin-l-ylV4riH-indol-3-yl pyrrolidine-2, 5-dione Induces Cell Death of a Wide Range of Tumor Cells. Which Correlates with its Ability of Inhibiting c-Met Phosphorylation CFA = Colony Formation Assay na = Not Applicable To determine c-met inhibition, exponentially growing MCF-7 and MDA-MB-231 human breast cancer cells, DLD1 and HT29 human colon cancer cells, PACA2 and PANC-1 human pancreatic cancer cells and NCI-H441 human non-small cell lung cancer cells (H441) were serum starved in 0.5% FBS and treated with increasing amounts of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yI)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione for 24 hours as indicated. Cells were then left unstimulated or stimulated with 100 ng/mL HGF for 10 minutes and whole cell extracts were prepared. Whole cell lysates (50 μg) were resolved by SDS-PAGE, transferred onto a PVDF membrane, and an enhanced chemiluminescence assay system (ECL) was used to determine the phosphorylation status of c-Met. A polyclonal antibody against phospho (Y1349) c-Met (phospho-c-Met) was obtained from Biosource International and a monoclonal antibody against β-actin was purchased from Invitrogen. Percent inhibition was determined by densitometry using the Scion Image For colony formation assays (CFA), exponentially growing cells were seeded at 2,000 cells per well in 6-well plates and allowed to attach for 24 hours. Increasing concentrations of (-)- trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-mdol-3-yl) pyrrolidine-2, 5-dione (from 0.01 to 30 μΜ) were then added to the media for another 24 hours. After 24 hours exposure., the drug was removed and fresh media was added for the next 14-21 days, allowing for colony formation. Cells were fixed and stained with GEMSA (Gibco BRL). Colonies of greater than 50 cells were scored as survivors and percentage of cell survival was plotted to determine the IC50. (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine- 2, 5-dione was found to potently inhibit growth and induce apoptosis across a wide range of human tumor cell lines. The IC50 of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)- 107 4(lH-indol-3-yl) pyrrolidine-2, 5-dione for c-Met expressing solid tumor types is in the 0.1 -0.7 μΜ range following exposure to (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione for 24 hours, as determined by colony formation assay (CFA). More notably cells lacking c-Met such as NCI-H661 (human non-small cells lung cancer cells) and NCI-H446 (human small lung cancer cells) yielded IC50s approximately 10-fold higher for (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, strongly indicating a correlation between the presence of c-Met and the cytotoxic sensitivity of the cells towards (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione. It should be noted that the IC50 of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione on c-Met inhibition and cellular cytotoxicity after 24 hours treatment are highly comparable in c-Met expressing cancer cells.
Example 84. (-,)-trans-3-f5.6-dihvdro-4H-pyrrolo [3.2,1-iil quinolin-l-vn-4(lH-indol-3-yl) pyrrolidine-2. 5-dione Induces Apoptosis in Cancer Cells A549 human lung cancer cells in a 96-well plate (Costar 3603, 5,000/well) were treated with either A) DMSO as a control; B) 1.2 μΜ (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione for 38 hours before addition of 1:200 fluorescent Annexin V (green) and 1:500 Propidium iodide (magenta, final concentration of 1 μg/mL). The labeling procedure was allowed to process at 37°C for 20 minutes followed by image acquisition and analysis using an ICIOO Image Cytometer (Beckman Coulter, Inc) with 10X amplification.
To determine whether (-)-trans-3 -(5, 6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione works primarily through a cytostatic or apoptotic mechanism, cancer cells exposed to (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione were stained with fluorescently labeled Annexin V (green fluorescence) and propidium iodide (bright magenta fluorescence). Annexin V is a well- validated reagent that specifically binds with high affinity to externalized membrane phosphatidylserine, an early marker of the onset of apoptosis, while propidium iodide is a marker for dead cells. Incubation of human lung cancer cells (A549) with 1.2 μΜ (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione for 38 hours induced cells to undergo apoptosis as evidenced by strong Annexin V staining. A small percentage of cells (~ 10-20%) co-stain with both Annexin V and propidium iodide, indicating that a sub-population of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione treated cells were already dead within 38 hours. These data are consistent with (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione inducing cell death largely through activation of apoptotic mechanisms. (See Figure 8) 108 Example 85. f-Vtrans-3-(5.6-dihvdro-4H-Pyrrolo [3.2. -iil quinolin-l-ylV4flH-indol-3-vn pyrrolidine-2. 5-dione Inhibits Metastatic Cancer Cell Invasion MDA-MB-231 cells were pretreated with indicated concentrations of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione for 24 hours. 300 μΐ of each cell suspension (at a concentration 0.5 x 106 cells/mL in serum free medium) was placed in individual inserts and incubated for 24 hours at 37°C. The bottom wells housing the inserts contained 500 μΐ of 10% FBS medium. At 24 hours the media from the inserts was aspirated and cells that failed to invade were gently removed from the interior of the inserts with a cotton tipped swab. Each insert was then transferred to a clean well containing cell stain solution and incubated for 10 minutes at room temperature. The bottom of the insert was destained by incubating in extraction solution and OD was measured at 560 nM. (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-lryl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione inhibited the migration across interstices in confluent cultures of MDA-MB-231 cancer cells. The data represent the mean of two independent experiments. (See Figure 9) The morbidity and mortality resulting from most cancers is the result of local invasion and metastasis from the primary tumors to other tissues. This process mostly depends on the motility and growth of tumor cells. Activation of c-Met by HGF induces a variety of cellular responses including motility, invasion, wound healing and tissue regeneration. It has been established that aberrant activation of c-Met plays a critical role in the development and progression of primary tumors and secondary metastases. HGF has the ability to dissociate epithelial sheets, to stimulate cell motility and invasion through extracellular matrix substrates and HGF production correlates with tumor metastasis in vivo.
. As shown above, (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione inhibited the invasive phenotype of MDA-MB-231 breast cancer cells with an estimated IC50 of approximately 500 nM. Similar results were seen with brain and lung cancer cells (data not shown).
Example 86. Breast Cancer Xenograft Model (-)-trans-3-(5,6-dihydro-4H-pyrroIo [3,2,1-ij] quinolin-l-yl)-4(lH-indoI-3-yl) pyrrolidine-2, 5-dione shows efficacy in a human breast cancer xenograft. MDA-MB-231 human breast cancer cells were inoculated subcutaneously into female athymic nude mice (8.0x106 cells/mouse) and allowed to form palpable tumors. Once the tumors reached approximately 60 mm3, the animals were treated orally with (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione at 200 mg/kg or vehicle control daily (5 consecutive days, followed by a 2 day dosing holiday). (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione was formulated in PEG 400:20% Vitamin E TPGS (60:40). The animals received a total of 20 doses of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or vehicle control. Tumors were measured 109 throughout treatment and the post-treatment observation period. Each point represents the mean ± SEM of ten tumors. (See Figure 10) Treatment with (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione as monotherapy was effective at slowing tumor growth. Tumor growth inhibition of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione was calculated to be 79% and was statistically significant (p = 0.009). There was no significant change in body weight due to oral administration of the vehicle or (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yI) pyrrolidine-2, 5-dione at 200 mg/kg.
Example 87. Colon Cancer Xenograft Model In this human colon cancer xenograft model HT29 human colon cancer cells were inoculated subcutaneously into female athymic nude mice (5xl06 cells/mouse) and allowed to form palpable tumors. Once the tumors reached approximately 60 mm3, the animals were treated orally with either (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione at 200 mg kg or 300 mg/kg, or vehicle control daily (5 consecutive days, followed by a 2 day dosing holiday). (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione was formulated in PEG 400:20% Vitamin E TPGS (60:40). The animals received a total of 20 treatments of either (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or vehicle control.
Tumors were measured throughout treatment and the post-treatment observation period. Each point represents the mean ± SEM of ten tumors. (See Figure 11) In this highly aggressive colon xenograft model, animals dosed with either 200 mg/kg or 300 mg/kg as a monotherapy showed significant tumor growth inhibition, with 300 mg/kg being more efficacious than 200 mg/kg. (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione dosed at 200 mg/kg showed an optimal tumor growth inhibition of 39% (p = 0.006) while 300 mg/kg showed an optimal tumor growth inhibition of 55% (p = 0.00001). There was no significant change in body weight due to oral administration of either vehicle control or (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione at 200 mg/kg or 300 mg/kg.
Example 88. Pancreatic Cancer Xenograft Model (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione shows efficacy in a human pancreatic cancer xenograft model. PACA-2 human pancreatic cancer cells were inoculated subcutaneously into female athymic nude mice (5x106 cells/mouse) and allowed to form palpable tumors. Once the tumors reached approximately 60 mm3, the animals were treated orally with (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione at 200 mg/kg or 300 mg/kg or vehicle control daily 110 (5 consecutive days, followed by a 2 day dosing holiday). (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione was formulated in PEG 400:20% Vitamin E TPGS (60:40). The animals received a total of 20 doses of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione or vehicle control.
Tumors were measured throughout treatment and the post-treatment observation period. Each point represents the mean ± SEM often tumors. (See Figure 12) Treatment with (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione as a monotherapy at either 200 mg/kg or 300 mg/kg showed significant tumor growth inhibition, with 200 mg/kg and 300 mg/kg being equally effective. (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione dosed at 200 mg/kg showed an optimal tumor growth inhibition of 58% (p = 0.036) while 300 mg/kg showed an optimal tumor growth inhibition of 60% (p = 0.018). There was no significant change in body weight due to oral administration of either vehicle control or (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione at 200 mg/kg and 300 mg/kg.
Other embodiments were within the following claims. While several embodiments have been shown and described, various modifications may be made without departing from the spirit and scope of the present invention.
I l l
Claims (34)
1. A pyrroloquinolinyl-pyrrolidine-2,5-dione compound of formula IVa, IVb, Va, or Vb, or pharmaceutically acceptable salts thereof: R4 R4 where: Rl, R2 and R3 are independently selected from the group consisting of hydrogen, F, CI, Br, I, -NR5R6, -(C,-C6) alkyl, -(C,-C6) substituted alkyl, -(C3r-C9) cycloalkyl, — (C3— C9) substituted cycloalkyl, — O— (Q— C6) alkyl, — O— (C!— C6) substituted alkyl, — O— (C3— C9) cycloalkyl, and — 0— (C3— C ) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl; R4 is independently selected from the group consisting of hydrogen,— (Ci— C6) alkyl, -CH2R7; R5, R6 are independently selected from the group consisting of hydrogen, and -(C,-C6) alkyl; R7 is independently selected from the group consisting of — 0— P(-0)(OH)2; -0-P(=0)(-OH)(-0-(C,-C6) alkyl); -0-P(-0)(-0-(C,-C6) alkyl)2; 112 184951/2 -0-P(=0)(-OH) (-0-(CH2)-phenyl); -0-P(=0)(-0-(CH2)-phenyl)2; a carboxylic -acid group selected from a group consisting of— O— C(=0)— (C|— C6) alkyl,— O— C(=0)— (C3— C9) cycloalkyl, -0-C(=0)-heterocycle, alkyl-aryl, alkyl-heteroaryl, and alkyl— heterocycle, which may be substituted with one or more substituent independently selected from the group consisting of: F, CI, Br, I, -OH, -SH, -NR5'R6', -{Q-Ce) alkyl, -(C,-C6) substituted alkyl, — (C3— C9) cycloalkyl, -{C3— C9) substituted cycloalkyl, — O— (d— C6) alkyl, -0-(C,-C6) substituted alkyl, -S-CC-Q) alkyl, ~0-{C3-< 9) cycloalkyl, -0-(C3-C9) substituted cycloalkyl, — aryl, — O— aryl, — O— (Ci— C4) alkyl— aryl, heteroaryl, heterocyclyl, -C C1-C4) alkyl-heterocycle, - S(=0)2)-{C|-C6) alkyl, -NH-C(=NH)-NH2, -COOH, and — C(=0)— NR5'R6', where R5' and R6' are independently selected from the group consisting of hydrogen, and— (Ci— C6) alkyl; an amino acid or an imino acid linked through an ester linkage involving its carboxylic acid, selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; and a peptide being a dipeptide, a tripeptide, a tetrapeptide, or a pentapeptide, linked through an ester linkage involving its carboxylic acid, comprised of two to five imino or amino acids selected from the group consisting of: L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine; Q is selected from the group consisting of aryl, heteroaryl, — O— aryl, — S— aryl, —0— heteroaryl, and— S— heteroaryl; X is selected from the group consisting of— (CH2)— ,— (NR8)— , S, and 0; R8 is independently selected from the group consisting of hydrogen,— (Ci— C6) alkyl, — (Ci— C6) substituted alkyl, — (C3— C9) cycloalkyl, — (C3— C9) substituted cycloalkyl, and -0-(d-C6) alkyl, -C(=0)-0- (Ci-C6) alkyl and -C(=0)-0-(Ci-C6) substituted alkyl; Y is selected from the group consisting of— (CH2)— or a bond; wherein said aryl, heteroaryl, — O— aryl, — S— aryl, — O— heteroaryl, and — S— heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, CI, Br, I, — NR5R6,— (C\— C6) alkyl,— (C\— C6) substituted alkyl, — (C3— C9) cycloalkyl, — (C3— C9) substituted cycloalkyl, — O— (C\— C6) alkyl, — O— (Cj— C6) substituted alkyl, — 0— (C3— C9) cycloalkyl, — O— (C3— C9) substituted cycloalkyl, -aryl, -aryl-(C,-C6) alkyl, -aryl-0 -(C]-C6) alkyl, -0- aryl, -0-(C,-C4) 1 13 184951/2 alkyl— aryl, heteroaryl, heterocyclyl, — O— (Q— C4) alkyl— heterocycle, and -(S(=0)2)-(C)-C6) alkyl; and m is 1 or 2.
2. The compound of claim 1, where Q is an indolyl group or an indolyl group substituted with one or more substituents independently selected from the group consisting of: F, CI, Br, I, -(Ci-C6) alkyl, -(Ci-C6)fluoro-substituted alkyl, -(C3-C9) cycloalkyl, -(C3-C9) fluoro-substituted cycloalkyl, — O— (Ci— C6) alkyl, — O— (Q— C6) fluoro-substituted alkyl, — O— (C3— C9) cycloalkyl, and— O— (C3— C9) fluoro-substituted cycloalkyl,—aryl, — O— aryl, -O- (C1-C4) alkyl-aryl, -O- (C 1-C4) alkyl-heterocycle, and alkyl.
3. The compound of claim 1 , wherein R4 is hydrogen.
4. The compound of claim 1 , wherein R4 is ~CH2R7, and R7 is -0-P(=0)(OH)2, alkyl)2.
5. The compound of claim 1, wherein R4 is — CH2R7, and R7 is the carboxylic acid group as defined in claim 1.
6. The compound of claim i, wherein R4 is— CH2R7, and R7 is the amino acid or the imino acid as defined in claim 1.
7. The compound of claim 6, where R7 is L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, or L-valine.
8. The compound of claim 1 , wherein R4 is— CH2R7, and R7 is the peptide as defined in claim 1.
9. The compound of claim 1 , where X is selected from the group consisting of -(NR8)-, S, and 0.
10. The compound of claim 1 , where m is 2. 1 14 184951/2
11. 1 1. The compound of claim 1 is selected from the group consisting of (+)-cis-3-(5,6- dihydro-4H-pyrroio [3,2, 1- ] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, (-)-cis-3- (5,6-dihydro-4H-pyrrolo [3,2, 1 - /'] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1 -//'] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, and (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione.
12. The compound of claim 1 is (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-/ ] quinolin-1-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5rdione.
13. A pharmaceutical composition comprising a compound of formula IVa, IVb, Va, or Vb as defined in claim 1 or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or excipients.
14. The pharmaceutical composition of claim 13 wherein the compound is (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione.
15. The pharmaceutical composition of claim 13 further comprising a second chemotherapeutic agent.
16. The pharmaceutical composition of claim 15, wherein said second chemotherapeutic agent is selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, trastuzumab, imatanib, paclitaxel, cyclophosphamide, lovastatin, minosine, gemcitabine, araC, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristin, vinblastin, nocodazole, teniposide, etoposide, gemcitabine, epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin or idarubicin.
17. A pharmaceutical composition for use in treating a cell proliferative disorder, comprising a therapeutically effective amount of a compound of formula IVa, IVb, Va, or Vb as defined in claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier. 1 15 1 84951/2
18. The pharmaceutical composition of claim 17, wherein said cell proliferative disorder is a precancerous condition.
19. ' The pharmaceutical composition of claim 17, wherein said cell proliferative disorder is a cancer.
20. The pharmaceutical composition of claim 19, wherein said cancer is lung cancer, colon cancer, breast cancer, pancreatic cancer, prostate cancer, chronic myelogenous leukemia, melanoma, or ovarian cancer.
21. The pharmaceutical composition of claim 17, wherein said cell proliferative disorder is a cell proliferative disorder of the breast.
22. The pharmaceutical composition of claim 21, wherein said cell proliferative disorder of the breast is a precancerous condition of the breast.
23. The pharmaceutical composition of claim 22, wherein said precancerous condition of the breast is selected from the group consisting of atypical hyperplasia of the breast, ductal carcinoma in situ, and lobular carcinoma in situ.
24. The pharmaceutical composition of claim 21 , wherein said cell proliferative disorder of the breast is breast cancer.
25. The pharmaceutical composition of claim 24, wherein said breast cancer is an estrogen-receptor negative breast cancer.
26. The pharmaceutical composition of claim 17, further comprising a second chemotherapeutic agent.
27. The pharmaceutical composition of claim 26, wherein said second chemotherapeutic agent is selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, trastuzumab, imatanib, paclitaxel, cyclophosphamide, lovastatin, minosine, gemcitabine, araC, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristin, vinblastin, 1 16 184951/1 nocodazole, teniposide, etoposide, gemcitabine, epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin or idarubicin.
28. The pharmaceutical composition of claim 17, wherein said treating cancer comprises a reduction in tumor size.
29. The pharmaceutical composition of claim 19, wherein the cancer is metastatic cancer.
30. The pharmaceutical composition of claim 29, wherein said treating cancer comprises inhibition of metastatic cancer cell invasion.
31. The pharmaceutical composition of claim 17 wherein the compound is selected from the group consisting of (+)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-/ ] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, (-)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1 -//] quinolin-lyl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, (+)-trans-3-(5,6-dihydro-4H-pyrrolo [3 ,2, 1 - /'] quinolin-1-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione, and (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-//] quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione.
32. The pharmaceutical composition of claim 17 wherein the compound is (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2, quinolin-l-yl)-4(lH-indol-3-yl) pyrrolidine-2, 5-dione.
33. The pharmaceutical composition of claim 17 wherein the cells with proliferative disorder to be treated contains DNA encoding c-Met.
34. The pharmaceutical composition of claim 33 wherein the cells have a constitutively enhanced c-Met activity. For the Applicants, REINHOLD COHN AND PARTNERS 1 17
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65095105P | 2005-02-09 | 2005-02-09 | |
PCT/US2006/004456 WO2006086484A1 (en) | 2005-02-09 | 2006-02-09 | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
IL184951A0 IL184951A0 (en) | 2007-12-03 |
IL184951A true IL184951A (en) | 2011-11-30 |
Family
ID=36579999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL184951A IL184951A (en) | 2005-02-09 | 2007-07-31 | Maleimide derivatives and pharmaceutical compositions comprising them for treating cell proliferative disorder |
Country Status (26)
Country | Link |
---|---|
US (5) | US7713969B2 (en) |
EP (2) | EP1846406B9 (en) |
JP (1) | JP4171061B2 (en) |
KR (1) | KR100941205B1 (en) |
CN (2) | CN101133055B (en) |
AT (1) | ATE486872T1 (en) |
AU (1) | AU2006213890B2 (en) |
BR (1) | BRPI0607240A2 (en) |
CA (1) | CA2599611C (en) |
CY (1) | CY1111190T1 (en) |
DE (1) | DE602006017965D1 (en) |
DK (1) | DK1846406T5 (en) |
ES (1) | ES2354267T3 (en) |
HK (1) | HK1107816A1 (en) |
HR (1) | HRP20100650T2 (en) |
IL (1) | IL184951A (en) |
MX (1) | MX2007009649A (en) |
NO (1) | NO332635B1 (en) |
NZ (1) | NZ560225A (en) |
PL (1) | PL1846406T3 (en) |
PT (1) | PT1846406E (en) |
RS (1) | RS51826B (en) |
RU (3) | RU2409579C2 (en) |
SI (1) | SI1846406T1 (en) |
WO (1) | WO2006086484A1 (en) |
ZA (1) | ZA200706530B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
US7713969B2 (en) * | 2005-02-09 | 2010-05-11 | Arqule, Inc. | Compositions and methods for treatment of cancer |
US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
CA2662335A1 (en) * | 2006-09-05 | 2008-03-13 | Valeria Ossovskaya | Methods for designing parp inhibitors and uses thereof |
EP2094689B1 (en) | 2006-12-19 | 2013-04-03 | Novartis AG | Indolylmaleimide derivatives as kinase inhibitors |
JP2010530872A (en) * | 2007-06-22 | 2010-09-16 | サイドース・エルエルシー | Docetaxel solubilized preparation without TWEEN80 |
WO2009002808A2 (en) | 2007-06-22 | 2008-12-31 | Arqule, Inc. | Quinazolinone compounds and methods of use thereof |
US8304425B2 (en) * | 2007-06-22 | 2012-11-06 | Arqule, Inc. | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer |
CN101801969B (en) * | 2007-06-22 | 2014-10-29 | 艾科尔公司 | Indolyl pyrrolidines for the treatment of cancer |
US7960134B1 (en) | 2007-08-01 | 2011-06-14 | Arqule, Inc. | Kinase inhibition models and their uses |
CN105330743B (en) * | 2007-08-02 | 2019-05-28 | 吉利德生物制剂公司 | LOX and LOXL2 inhibitor and its application |
CN101903025A (en) * | 2007-10-19 | 2010-12-01 | 彼帕科学公司 | Utilize benzopyrone-type PARP inhibitor for treating method for cancer and compositions |
ES2554623T3 (en) | 2008-12-30 | 2015-12-22 | Arqule, Inc. | Compounds of substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine |
WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
EP2396003B1 (en) * | 2009-02-12 | 2013-04-17 | ArQule, Inc. | A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib |
JP2013502226A (en) | 2009-08-21 | 2013-01-24 | ギリアド バイオロジクス,インク. | Catalytic domain derived from lysyl oxidase and LOXL2 |
AU2010284000A1 (en) * | 2009-08-21 | 2012-03-22 | Gilead Biologics, Inc. | In vitro screening assays |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
AU2010336533B9 (en) * | 2009-12-23 | 2015-10-08 | Arqule, Inc. | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
US8563567B2 (en) | 2009-12-30 | 2013-10-22 | Arqule, Inc. | Substituted heterocyclic compounds |
CN105622757A (en) | 2010-02-04 | 2016-06-01 | 吉联亚生物科技有限公司 | Antibodies that bind to lysyl oxidase-like 2(LOXL2) and methods of use therefor |
WO2011109237A2 (en) * | 2010-03-02 | 2011-09-09 | Emory University | Uses of noscapine and derivatives in subjects diagnosed with fap |
US8580764B2 (en) | 2010-07-01 | 2013-11-12 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
WO2012030896A2 (en) | 2010-09-01 | 2012-03-08 | Arqule, Inc. | Methods for treatment of non-small cell lung cancer |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
TWI525091B (en) * | 2010-12-23 | 2016-03-11 | 亞闊股份有限公司 | Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
JP6073310B2 (en) * | 2011-07-07 | 2017-02-01 | アーキュール,インコーポレイティド | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for their preparation and use |
TW201350483A (en) * | 2012-04-23 | 2013-12-16 | Arqule Inc | Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same |
CN102757435B (en) * | 2012-06-21 | 2014-05-28 | 成都苑东药业有限公司 | Trans-3-indolyl-4-pyrroldiazepinecycloheptane-2,5-pyrrolidine-2,5-diketone compound and preparation method thereof |
WO2014098000A1 (en) * | 2012-12-17 | 2014-06-26 | Daiichi Sankyo Company, Limited | Process for preparation of a tricyclic heterocycle |
US20160137644A1 (en) * | 2013-06-26 | 2016-05-19 | Daiichi Sankyo Company, Limited | Method for producing tricyclic heterocyclic compound |
WO2015173764A1 (en) | 2014-05-15 | 2015-11-19 | Iteos Therapeutics | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors |
BR112017019699A2 (en) | 2015-03-17 | 2018-09-04 | Pfizer Inc. | 3-indole substituted derivatives, pharmaceutical compositions and methods for use |
EP3334733A1 (en) | 2015-08-10 | 2018-06-20 | Pfizer Inc | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
US10874130B2 (en) | 2015-08-18 | 2020-12-29 | PURE CIRCLE USA Inc. | Steviol glycoside solutions |
SG10201910821XA (en) * | 2016-12-30 | 2020-01-30 | Frequency Therapeutics Inc | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US650951A (en) | 1899-08-09 | 1900-06-05 | Fred Holmes Rees | Station-indicator. |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
SK75289A3 (en) * | 1988-02-10 | 1998-05-06 | Hoffmann La Roche | Substituted pyrroles, their use for producing a drug, and the drug on their base |
USRE36736E (en) * | 1989-02-06 | 2000-06-13 | Hoffman-La Roche Inc. | Substituted pyrroles |
MC2096A1 (en) | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | SUBSTITUTED PYRROLES |
GB8904161D0 (en) * | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
US5380746A (en) * | 1989-05-05 | 1995-01-10 | Goedecke Aktiengesellschaft | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
IL94274A0 (en) | 1989-05-05 | 1991-03-10 | Goedecke Ag | Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same |
DE4005970A1 (en) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | NEW TRISUBSTITUTED MALEINIMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE4005969A1 (en) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | NEW TRISUBSTITUTED PYRROLE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US5360811A (en) * | 1990-03-13 | 1994-11-01 | Hoechst-Roussel Pharmaceuticals Incorporated | 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents |
US5292747A (en) * | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
US5591842A (en) * | 1991-11-29 | 1997-01-07 | Banyu Pharmaceutical Co., Ltd. | Indolopyrrolocarbazole derivatives |
AU3761393A (en) | 1992-03-20 | 1993-10-21 | Wellcome Foundation Limited, The | Indole derivatives with antiviral activity |
US5721230A (en) * | 1993-05-10 | 1998-02-24 | Hoffmann-La Roche Inc. | Substituted pyrroles |
US5545636A (en) * | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
PT817627E (en) | 1993-12-23 | 2005-07-29 | Lilly Co Eli | PROTEIN INHIBITORS CINASE C |
US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
WO1995030682A1 (en) | 1994-05-09 | 1995-11-16 | Banyu Pharmaceutical Co., Ltd. | Antitumor indolopyprolocarbazole derivative |
US7501441B1 (en) * | 1994-09-20 | 2009-03-10 | Eli Lilly And Company | Naphthyl compounds, intermediates, processes, compositions, and methods |
US5591855A (en) * | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5559228A (en) * | 1995-03-30 | 1996-09-24 | Eli Lilly And Company | Synthesis of bisindolylmaleimides |
WO1997034890A1 (en) | 1996-03-20 | 1997-09-25 | Eli Lilly And Company | Synthesis of indolylmaleimides |
PE91698A1 (en) * | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | SUBSTITUTED PYRROLES |
PE91598A1 (en) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | SUBSTITUTED PYRROLES |
US5990319A (en) | 1996-08-23 | 1999-11-23 | Eli Lilly And Company | Synthesis of bisindolylmaleimides |
SE9603283D0 (en) * | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
US6153618A (en) | 1996-10-11 | 2000-11-28 | Chiron Corporation | Inhibitors of glycogen synthase 3 kinase |
US5859261A (en) * | 1997-03-20 | 1999-01-12 | Eli Lilly And Company | Synthesis of indolylmaleimides |
IL134590A0 (en) * | 1997-09-08 | 2001-04-30 | Univ Georgetown | Substituted 2-pyrrolidinone activators of pkc |
TW380295B (en) * | 1997-10-18 | 2000-01-21 | United Microelectronics Corp | Manufacturing method for DRAM capacitor dielectric |
CN1320123A (en) | 1998-07-30 | 2001-10-31 | 日本烟草产业株式会社 | Disubstituted maleimide compounds and medicinal utilization thereof |
US6589977B1 (en) | 1999-02-09 | 2003-07-08 | Sagami Chemical Research Center | Pyrrole derivatives and cell death inhibitors |
EP1242420A2 (en) | 1999-12-16 | 2002-09-25 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
DE60010934T2 (en) | 1999-12-16 | 2005-05-19 | Eli Lilly And Co., Indianapolis | Medicines suitable for the treatment of proliferative diseases |
US20030087949A1 (en) | 2000-03-30 | 2003-05-08 | Mikiko Sodeoka | Indolylpyrrole derivatives and cell death inhibitors |
EP1286964B1 (en) | 2000-05-11 | 2007-07-04 | Consejo Superior de Investigaciones Cientificas | Heterocyclic inhibitors of glycogen synthase kinase gsk-3 |
CA2452445C (en) | 2000-06-29 | 2011-02-15 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
WO2004022701A2 (en) | 2001-07-15 | 2004-03-18 | Keck Graduate Institute | Exponential amplification of nucleic acids using nicking agents |
WO2003066808A2 (en) | 2002-01-23 | 2003-08-14 | Texas Tech University | Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells |
AU2003215325B8 (en) | 2002-03-05 | 2008-10-09 | Eli Lilly And Company | Purine derivatives as kinase inhibitors |
CA2522299A1 (en) | 2003-04-15 | 2004-10-28 | Avalon Pharmaceuticals, Inc | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
CA2528343A1 (en) | 2003-06-06 | 2005-01-06 | Genentech, Inc. | Modulating the interaction between hgf beta chain and c-met |
DE602004024536D1 (en) | 2003-07-07 | 2010-01-21 | Van Andel Res Inst | INHIBITION OF TUMOR ANGIOGENESIS BY A COMBINATION OF THROMBOSPONDIN-1 AND INHIBITORS OF THE VASCULAR ENDOTHEL GROWTH FACTOR |
KR101195291B1 (en) | 2003-12-11 | 2012-10-26 | 제넨테크, 인크. | Methods and compositions for inhibiting C-MET dimerization and activation |
US7713969B2 (en) | 2005-02-09 | 2010-05-11 | Arqule, Inc. | Compositions and methods for treatment of cancer |
WO2006105511A1 (en) | 2005-03-31 | 2006-10-05 | The General Hospital Corporation | Monitoring and modulating hgf/hgfr activity |
AU2010336533B9 (en) * | 2009-12-23 | 2015-10-08 | Arqule, Inc. | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
JP6073310B2 (en) * | 2011-07-07 | 2017-02-01 | アーキュール,インコーポレイティド | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for their preparation and use |
-
2006
- 2006-02-09 US US11/350,335 patent/US7713969B2/en active Active
- 2006-02-09 ZA ZA200706530A patent/ZA200706530B/en unknown
- 2006-02-09 WO PCT/US2006/004456 patent/WO2006086484A1/en active Application Filing
- 2006-02-09 RS RS20110040A patent/RS51826B/en unknown
- 2006-02-09 KR KR1020077020005A patent/KR100941205B1/en active IP Right Grant
- 2006-02-09 CN CN200680006758XA patent/CN101133055B/en active Active
- 2006-02-09 RU RU2007131428/04A patent/RU2409579C2/en active
- 2006-02-09 SI SI200630867T patent/SI1846406T1/en unknown
- 2006-02-09 BR BRPI0607240-2A patent/BRPI0607240A2/en not_active IP Right Cessation
- 2006-02-09 EP EP06720509A patent/EP1846406B9/en active Active
- 2006-02-09 DE DE602006017965T patent/DE602006017965D1/en active Active
- 2006-02-09 JP JP2007554342A patent/JP4171061B2/en active Active
- 2006-02-09 RU RU2010135836/04A patent/RU2547148C2/en active
- 2006-02-09 CA CA2599611A patent/CA2599611C/en active Active
- 2006-02-09 AU AU2006213890A patent/AU2006213890B2/en active Active
- 2006-02-09 AT AT06720509T patent/ATE486872T1/en active
- 2006-02-09 CN CN2010102637660A patent/CN101941970B/en active Active
- 2006-02-09 EP EP10172543A patent/EP2289892B1/en active Active
- 2006-02-09 MX MX2007009649A patent/MX2007009649A/en active IP Right Grant
- 2006-02-09 PL PL06720509T patent/PL1846406T3/en unknown
- 2006-02-09 NZ NZ560225A patent/NZ560225A/en unknown
- 2006-02-09 DK DK06720509.6T patent/DK1846406T5/en active
- 2006-02-09 ES ES06720509T patent/ES2354267T3/en active Active
- 2006-02-09 PT PT06720509T patent/PT1846406E/en unknown
-
2007
- 2007-07-31 IL IL184951A patent/IL184951A/en active IP Right Grant
- 2007-08-06 NO NO20074044A patent/NO332635B1/en unknown
-
2008
- 2008-02-11 HK HK08101518.3A patent/HK1107816A1/en unknown
-
2010
- 2010-03-11 US US12/722,394 patent/US8377927B2/en active Active
- 2010-11-26 HR HR20100650T patent/HRP20100650T2/en unknown
-
2011
- 2011-01-04 CY CY20111100020T patent/CY1111190T1/en unknown
-
2013
- 2013-02-07 US US13/761,712 patent/US8754078B2/en active Active
-
2014
- 2014-03-17 US US14/215,852 patent/US9447088B2/en active Active
-
2015
- 2015-02-10 RU RU2015104346A patent/RU2015104346A/en not_active Application Discontinuation
-
2016
- 2016-08-19 US US15/241,240 patent/US20160355515A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2289892B1 (en) | Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer | |
US8304425B2 (en) | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | |
EP2396003A2 (en) | A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with a second anti-proliferative agent, | |
EP2392574B1 (en) | Indolyl pyrrolidines for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed |